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Abstract
Heparan sulfate (HS) proteoglycans are key components of the cell surface and pericellular space
in eumetazoans. Thanks to its structural diversity, HS interacts with a vast numberof extracel-
lular proteins including growth factors and structural components of the extracellular matrix.
By dynamically modulating the activity of its protein partners, HS participates in the regulation
of complex physiological and pathological processes such as development and cancer. Despite
the identification of more than 200 proteins being able to interact with HS, or the structurally
related heparin, it remains unclear what are the structural determinants that mediate the in-
teraction with these carbohydrates. In order to speed up this process, a new method for the
identification of heparin/HS-binding sites was developed. The new procedure, called the pro-
tect and label strategy, is based on the selective chemical labelling of residues involved in the
interaction with the sugar and their identification by mass spectrometry. The protect and label
strategy was validated using three well characterised heparin/HS-binding proteins (HBPs) and
applied to the structural comparison of the binding sites of three evolutionary distant members
of the fibroblast growth factor family. Furthermore, a workflow for the systematic analysis of the
heparin interactome was designed. First, an affinity proteomic strategy for the identification of
new HBPsfrom plasma membraneenriched fractions extracted from rat liver was implemented.
This approach led to the identification of 50 new and 12 previously described HBPs. The affin-
ity proteomic data were integrated with literature-derived data in order to build list of 373
HBPs. This dataset was then used to investigate the network properties, and functional and
structural features that characterise the heparin interactome. This analysis revealed that HBPs
form a highly modular network involved in the regulation of key physiological and pathologi-
cal processes characteristic of higher organisms. A strong correlation between the expansion of
the heparin interactome and heparin/HS biosynthetic machinery and organism complexity also
emerged from this analysis. This workflow exemplifies a new wayofinvestigating protein-glycan
interactions that has the potential for widespread application in the field of glycobiology.
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Chapter 1
Introduction
1.1 Heparin and heparan sulfate
Heparin and heparan sulfate (HS) are linear polysaccharides containing characteristic repeating
disaccharide units. They belong to the family of glycosaminoglycans (GAGs) together with
chondroitin sulfate (CS), dermatan sulfate (DS), hyaluronic acid and keratan sulfate. In com-
parison to other members, HS showsthe highest sequence variability deriving from modifications
of the sugar backbone, mainly by addition of sulfate groups. Heparin and HSshare the samere-
peating unit that consists of 1-4-linked pyranosyluronic acid and 2-amino-2-deoxyglucopyranose
(glucosamine) residues. The uronic acid may be either 3-D-glucuronic acid (GlcA) or its C-
5 epimer a-L-iduronic acid (IdoA). The $-D-glucosamine may be N-acetylated (GlcNAc), N-
sulfated (GIcNS)or, rarely, unsubstituted (GlcN). Further complexity derives from the variable
degree of O-sulfation that may occur at position 2 of the uronic acid and at positions 3 and 6
of the glucosamine [Fig. 1.1 A]. A broad spectrum of structural motifs may be generated by
combining these modification patterns along the sugar chain. Combiningall the possible modi-
fications, 48 different disaccharide units can be generated. Structures more complex than DNA
(4 units), proteins (20 units) or any other biopolymer foundin living cells could be potentially
assembled with these building blocks. However, restrictions in the biosynthetic pathway reduce
to 23 the numberof disaccharide units that have been identified to date in mature heparin/HS,
or as intermediates in biosynthesis [1].
Heparin has a more homogenousand extensively modified structure with an overall high level
of sulfation [Fig. 1.1 B], while HS presents higher structural diversity due to the arrangement
of sulfation patterns along the sugar chains [2-4]. These patterns are generated during the
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URONIC ACID
D-glucuronic acid (GIcA)
L-iduronic acid (IdoA)
D-GLUCOSAMINE
N-acetylglucosamine (GIcNA)
Re =-H, SOs
(Ry =-H, -SO;
Re = -H, SOs
N-sulfoglucosamine (GIcNS)
N-glucosamine (GIcN)
 
Heparin Vs HS
2.4 sulfates/unit Degree Sulfation 0.2-0.7 sulfates/unit
IdoA(2S)-GIcNS(6S) Predominant Unit GlcA-GIcNAc
5-40 kDa, average 5-50 kDa, average
Re = -H, -COCH3, -SO
Chain Length17.5 kDa 30 kDa    
Figure 1.1: Heparin and HS disaccharide unit and structural comparison. (A) The characteristic disaccharide
unit of heparin and HSconsists of an iduronic acid, GlcA or its C5-epimer IdoA, 1-4-linked with a glucosamine
residue. The glucosamine may be N-acetylated (Rl = COCHs), N-sulfated (R1 = SO3_ ) or, rarely, unsubstituted
(R1 = H). Further complexity derives from variable degree of O-sulfation that may occur at position 2 of the
uronic acid (R4) and at positions 3 (R3) and 6 (R2) of the glucosamine. (B) Comparative table of the chain
composition features of heparin and HS.
biosynthetic process and they are determined by the fact that modification reactions do not
go to completion. Therefore, HS chains have been described as possessing a domain structure
where highly sulfated regions resembling heparin (NS domain) are separated from an unmodified
one (NA domains) by stretches of partially sulfated disaccharides (NA/NS domains) [5,6]. The
number, length and arrangement of these domains contribute, together with the polydispersity
of the sugar chains, to the structural complexity of HS.
HS is biosynthesised as HS proteoglycans (HSPGs) by most mammalian cells and it repre-
sents one of the key components of the cell surface and pericellular space. One or more sugar
chains are attached to serine residues of core proteins through a linker tetrasaccharide. HS
core proteins include the transmembrane syndecans (four members in humans), the glypicans,
which are attached to the cell membrane by a glycosylphosphatidilinositol tail, (six members)
and extracellular matrix (ECM)proteins such as perlecan, agrin and collagen XVIII. In thefirst
two cases the polysaccharides are exposed at thecell surface, in the third they are localised in
the ECM (for reviews see [7], [8]). HS chains rarely occur as free entities and where they do so
this is the consequence of a post-synthesis cleavage by the extracellular enzyme heparanase [9].
Introduction
 
Heparin is also synthesised as a proteoglycan, but its expression is specific to connective-tissue
mast cells and oligodendrocyte-type-2 astrocyte progenitors [10]. Heparin proteoglycan consists
of a unique core protein (serglycin) with multiple heparin chains attached. In the mastcell the
sugar chains are then cleaved at random points along the chains, to give mixtures of smaller
heparin polysaccharides that are stored in the cytoplasmic secretory granules as non-covalent
complexes with basic proteases [11].
1.2 Biosynthesis
The complexity of heparin/HS derives from the characteristics of their biosynthesis. Heparin
and HS are assembled by a non template-driven process, in which a set of enzymes act on
the growing polysaccharide introducing modifications to the sugar backbone; these modification
reactions depend on the specificity of the enzymes and cell regulation mechanisms [1]. The
biosynthetic process begins in the lumen of the endoplasmic reticulum with the assembly of a
linker tetrasaccharide (3-GlcA-(1,3)-3-Gal-(1,3)-G-Gal-(1,4)-(G-Xyl-L-[ser]) attached to specific
serine residues of newly translated core proteins. This linker tetrasaccharide is common to hep-
arin, HS, CS and DS. The nature of the core protein specifically drives the synthesis towards
a specific GAG, probably by affecting the localisation of the growing proteoglycan in different
Golgi sub-compartments wheredifferent GAG biosynthetic machineries are assembled [12]. In
the case of heparin/HS, the biosynthesis proceeds by the addition of an a4-GlcNAcresidue that
initiates the polymerisation of the sugar chain. The polymerisation occurs through the alternate
transfer of UDP-GlcA(4 and UDP-GlcNAcad4to the non-reducing end of the growing polysac-
charide andit is catalysed by hetero-oligomeric complexes of members of the EXT gene family
(copolymerases), which possess both transferase activities [13]. The chain elongation proceeds
to variable extents generating polysaccharides ofdifferent length [1]. During the polymerisation,
the sugar chain is modified by a series of enzymes that include four classes of sulfotransferases,
responsible for the sulfation at different positions of the disaccharide unit [Fig. 1.1 A], and
an epimerase that converts GlcA in its C5 epimer IdoA. The modification reactions occur in
a ordered and regulated way and they are initiated by the de-acetylation and N-sulfation of
GlcNAc units catalysed by dual functional N-deacetylase/N-sulfotransferases (NDSTs). The
presence of N-sulfated glucosamine is a prerequisite for all other modifications to occur and
thus this step plays a key role in determining the patterns of sulfation on HS chains. Also the
subsequent reactions of epimerisation and O-sulfation are regulated, mainly by the specificity
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of the enzymes. For example, the GlcA C5 epimerase does not react with uronic acids that are
O-sulfated or adjacent to O-sulfated glucosamines [1]. suggesting that this modification must
occur immediately after the NDST reaction. It still remains unclear how the arrangement of
modification patterns along the HS chains is regulated by the cell machinery. One proposed
mechanism is that HS biosynthetic enzymes organise in macromolecular complexes, the gago-
somes, that coordinate the sugar polymerisation and modification. This hypothesis is based on
the observations that modification reactions occur rapidly and in a precise sequential order, and
that some of the biosynthetic enzymes interact with each other and/or co-localise in the Golgi
(e.g., C5 epimerase and HS 2-O-sulfotransferase (HS2ST)) [1,14]. According to this model, cells
would regulate HS structure by altering the number and composition of the gagosomes [12].
A further level of regulation is given by the existence of post-synthesis mechanisms that
influence the structure and localisation of HS chains. These mechanisms are carried out by
two classes of extracellular enzymes that act on mature HS chains. The first class includes two
extracellular sulfatases (SULF1 and SULF2) that hydrolytically remove sulfate groups from the
position 6 of glucosamineresidues present in N-, 6-O-, and 2-O-trisulfated disaccharides in HS
and heparin [15]. These enzymes are able to edit HS and heparin sequences and, therefore,
affect their interactions with protein partners. Moreover, it has been shown that the expression
of SULFscanalso indirectly modify the structure of HS chains by a feed-back mechanism that
affect the expression of HS biosynthetic enzymes[16]. The second editing mechanism involves the
extracellular endo-(-D-glucoronidase heparanase (HPSE). HPSE cleaves mature HS chains and,
differently from bacterial heparinases, generates fragments of appreciablesize (10-20 disaccharide
units) [17]. This suggests that HPSE recognises and specifically cleaves relatively rare sequences
on HSchains [18]. The activity of HPSE can rapidly remodel the structure of HS on the
cell surface and in the ECM andalter the localisation, distribution and activity of its binding
partners [19, 20].
1.3. Heparin/HS andtheir interaction with proteins
The structural diversity and conformational flexibility of HS chains allow HSPGstointeract
with a vast numberof extracellular protein partners [21]. The heparin/HS interactome includes
soluble ligandslike cytokines, growth factors and serum proteins, cell surface molecules such as
receptortyrosine kinases and adhesion molecules, and structural components of the ECM such as
laminin, fibronectin and collagens [21]. Also, some pathogens,like the haman immunodeficiency
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virus (HIV-1), express heparin-binding proteins (HBPs) to target HS on the cell surface and
exploit its binding as a mechanism to facilitate cell infection [22, 23}.
Through these interactions, HSPGs havetheability to regulate the activity of their protein
partners and, therefore, influence the biological processes they mediate. Several mechanisms
have been proposed for different interactors. A classic example is the conformational change
induced by heparin in antithrombin III (ATHI)that results in a dramatic increase of the inhibitor
activity of this protein against the coagulation factors thrombin and factor X [24]. Thisis
the main mechanism mediating the anticoagulant activity of heparin. The interaction with
heparin can enhance protein stability, for example, by protecting the interactor against the
activity of extracellular proteases and, therefore, increasing its half-life, as it has been shown
for interferon-y [25]. Other mechanisms rely on the assembly of multicomponent molecular
complexes mediated by the carbohydrate. For example, heparin/HS can induce oligomerisation
of their partners, as observed for chemokines like RANTES[26], but also mediate the assembly of
signalling complexes involving soluble ligands and their cell surface receptors, as in the case of the
fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) systems [21,27].
Finally, heparin/HS can influence the localisation, transport and distribution of HBPs on the
cell surface and in the extracellular space. These mechanismsare crucial for the formation of
morphogens and chemokines gradients, and they have been used to explain the involvement of
HSPGsin organogenesis and immuneresponse [28-31].
Therefore, HSPGs are an important tool exploited by the cell machinery to regulate the
activity of signalling proteins and organise the extracellular space. Cells, in fact, tightly regu-
late the expression of HS in time and space. Characteristic patterns of sulfation of HS chains
have been observed betweendifferent species [32], tissues [33], cell types [34] and developmen-
tal stages [35,36]. The tuning of the HS repertoire allows cell to dynamically regulate the
HSPG interactome, thus affecting the activity and distribution of several key extracellular pro-
teins. Evidence for the crucial regulatory roles mediated by HSPGs derives from the analysis
of mutants for HS biosynthetic enzymes obtained from several model organisms that indicates
the involvement of this family of GAGsin the regulation of organismal development and several
physiological processes (for reviews see [37-39]). Further support is provided by the link between
pathologies, such as cancer, andthe altered expression of enzymes involvedin the regulation of
HS structure. For example, increased expression of HPSE has been observed in several human
cancer types including breast, lung, colon, ovary, prostate, and pancreas tumors [17]. It has been
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proposed that the increased HPSEactivity inducestherelease of active HS-derived oligosaccha-
rides and HS-boundsignalling molecules, and determines a remodelling of the ECM, thereby
promoting tumor aggressiveness and metastatic potential {19]. Currently, therapeutic strategies
targeting HPSE activity are under development for several cancer types and inflammation [40].
1.4 Challenges in the study of protein-heparin/HS interactions
The high level of sulfation, characteristic of heparin and NS domains of HS, determines the
extreme anionic nature of these polymers (average charge for a heparin chain is -70). Conse-
quently, basic patches on the protein surface generally mediate the interaction with heparin/HS.
The protein-heparin/HS binding event has been described as an ion exchange process where pos-
itive charges provided by basic residues on the protein surface replace counter ions on the sugar
chains. The release of counter ions determines an entropy gain, known as the polyelectrolyte ef-
fect, that would represent the main componentof the bindingfree energy of proteins-heparin/HS
interactions [41]. However, several studies reported that, at least for some proteins, the contri-
bution of electrostatic interactions is equal, if not minor, to other components such as hydrogen
bonding and van der Walls interactions [42,43]. This is also supported by structural data ob-
tained for protein/heparin-derived oligosaccharides complexes (for example, [44,45]), and by the
observation that the activity of heparin-derived oligosaccharides does not always have a linear
dependence on the charge state of the polysaccharide [46, 47].
The discussion regarding the charge dependence of protein-heparin interactions is directly
linked to another subject of much debate, which is the level of selectivity that drives the recog-
nition between protein and carbohydrate. One extreme view supports the existence of a HS
sequence code residing on the assembly of modification patterns along the sugar chain. Ac-
cording to this view specific sulfation sequences drive the interaction of HS with different pro-
tein partners. The canonical example is the ATIII binding pentasaccharide GlcNAc6S-GlcA-
GIcNS3S6S8-IdoA2S-GIcNS6S that contains rare features such as the sulfation at position 3 of
the central GlcNAcresidue [48]. Other examples include binding sequences that contains rare
modifications, as in the case of L- and P-selectins, which require an unusual N-unsubstituted
glucosamine residue [49], and cyclophilin B that requires a N-unsubstituted, 3-O sulfated glu-
cosamineresiduefor high affinity binding [50]. The opposite view questions the existence of such
fine selectivity and claims that these interactions are solely dependent on the charge content of
the carbohydrate [51,52]. Finally, others proposed that selectivity may not reside on specific
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sequences per se, but in the way common modification patterns are distributed along the sugar
chains [53]. For example, based on the size and distribution of domains in HS-derived bind-
ing sites, it has been shown that characteristic arrangements of short NS domains separated
by N-acetylated units (SAS domains) mediate the interaction with both monomeric [54] and
oligomeric proteins [55,56]. In this case, the authors propose that the selectivity of the interac-
tions would derive from the spacing between sulfated domains that would provide the optimal
distribution of negatively charged groups to mediate the binding event [53].
Undoubtedly a certain level of degeneracy seems to characterise the binding of HBPs in
vitro, with different sequences that are able to exert similar binding properties and activities
[46,57], and different proteins that are able to interact with similar sugar structures [52, 58).
However, this contrasts with what is observed in vivo, where the regulated expression of HS
chains delineates precise protein binding patterns. HS-mediated protein binding sites have been
probedin sectionsof tissues using either HBPsor antibodies specific for HS epitopes (34,59, 60].
These studies revealed the existence of a precise distribution of HS-dependent protein binding
sites within the tissue architecture, and that different ligands display specific binding patterns
[60]. Moreover, these patterns are dynamically regulated and they vary, for example, between
different developmental stages [59,60].
The discrepancy betweenin vitro and in vivo data, and the debates deving from it, could be
a direct consequence of the limits of our experimental models. The structural complexity of HS
and the difficulties in obtaining homogenous preparations of saccharides posed major challenges
to the investigation of its interactions with proteins. Therefore, heparin has often been used
as a proxy for the highly sulfated NS domains of HS, thanks to its commercial availability and
perceived less complex structure [61]. However, the relatively low structural similarities between
heparin and HS poses limits to its application, even as a model for NS domains. In fact, the
trisulfated units characteristic of heparin IdoA2S-GIcNS6Saccounts for only 3-5 % of the total
disaccharide composition of HS, which is dominated by non-sulfated and monosulfated units (80
%) [6,62], and NS domainsare rarely longer than 8 disaccharides units, with the most frequent
length being only 2 units [6]. The significantly higher negative charge of heparin, together with
the use of the ionic strength of the solution as a measure ofaffinity (as in [52]), could have
contributed, for example, to an over estimation of the ionic component of the interaction and
the role of charges in determining protein selectivity. The existing models are also affected by
the limited knowledge regardingthe solution conformation of HS chains and howthisis affected
 
Introduction
 
by different substitution patterns. Recent studies have shown that some modifications alter
the conformation of the carbohydrate moresignificantly than others [63], and that associated
cations can also have an impact on the conformation [64] and activity [65] of heparin/HS.
Further complexity derives from the influence that protein binding has on the structure of the
carbohydrate [66,67]. This could beparticularly relevant in vivo, given the high macromolecular
concentration of the pericellular space (~400 mg/ml) and the vast number of HBPs[21]. Direct
effects of bound proteins on the sugar structure and mechanisms such as cooperative binding
and competition could be crucial in determining the assembly of protein-binding patterns. All
these aspects must be considered in order to determine how the binding selectivity is achieved
in vivo.
Similarly challenging has been the definition of models able to describe the structural de-
terminants that mediate, at the protein level, the interaction with heparin/HS. Initial efforts
tried to identify linear consensus sequences able to predict the localisation of heparin binding
sites (HBSs) on the basis of the distribution of basic and hydropathic residues in characterised
heparin-binding regions [68-70]. Later studies proposed models based on three-dimensional
structures of known HBSsto delineate spatial patterns [71] and structural motifs [70] that would
recapitulate common features observed in different HBPs. None of these efforts was, however,
able to identify rules that would be sufficient to define a HBS [72]. This is a direct. consequence
of the restricted number of HBSs analysed to generate the models, and of the limited numberof
three-dimensional structures describing protein-heparin complexes that are currently available
(< 10 % ofthe identified heparin interactome[21]). More recent studies have employed auto-
mated docking methods to generate interaction models for two families of HBPs, chemokines
and 4-helix cytokines, taking advantage of the fact that most of the structures of the members
of these families have been resolved [73,74]. One of the most important conclusions of these two
studies was that even in families of structurally related proteins different modes of binding are
likely to occur, involving heparin-binding structures that are poorly conserved between members
and different sugar conformations [73,74]. Also in this case, the difficulty to delineate unifying
models for HBSs can be ascribed to the structural features of HS. The unique characteristics of
these molecules (polydispersity, different arrangement of modification patterns, flexibility) allow
them to accommodatea variety of different protein structures. Only a systematic investigation
of HBSs across a set of HBPs that would be representative of the structural diversity of the
heparin interactomecouldallow the search for, and, if possible, the definition of a set of models
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describing the interaction between proteins and heparin/HS.
1.5 Aimsof the thesis
Thefirst aim of this thesis was to develop an innovative methodfor the investigation of structural
determinants of the interaction between proteins and heparin/HS compatible with medium/high
throughput applications. Such a method, currently missing in the tool kit of glycobiologists,
could facilitate a systematic investigation of structures mediating GAG binding and, in combi-
nation with complementary techniques, speed up the characterisation of the structural determi-
nants of protein-heparin interactions. A new methodfor the identification of HBSs, called the
protect and label strategy, was developed and validated using three well characterised HBPs.
The publication describing the method was published in 2009 [75], and it is available in Appendix
II.
The second aim of this thesis was to perform a systematic analysis of the heparin/HS inter-
actomein order to identify new HBPs, rationalise the data currently available in the literature
and analyse the properties of HBPs at a network level. For this purpose, an affinity proteomic
strategy for the identification of new HBPsfrom tissue extracts was implemented. Thestrat-
egy was focused on the cell surface and extracellular proteome derived from rat liver extracts,
the rationale being that targeting the compartment where HSPGs are expressed increases the
probability of identifying more relevant binding partners likely to co-localise with HS in vivo.
The affinity proteomic data were integrated with literature-derived data and data extracted
from public databases in order to assemble list of identified HBPs (the heparin interactome).
This dataset was then used to investigate the network properties, and functional, structural and
evolutionary features that characterise the heparin interactome at a system-level.
 
Chapter 2
A new method for the identification
of heparin-binding sites
2.1 Overview
Our understanding of the structural determinants required for protein-GAGinteractionsis lim-
ited by the lack of simple methodologies for the identification of binding motifs in the protein
and in the sugar. The available data derive mainly from X-ray crystallography (e.g., [76,77]),
NMRspectroscopy (e.g., {78]) and quantitative biophysics (e.g., [79,80]) with deletion mu-
tagenesis (e.g., [81]), site-directed mutagenesis (e.g., [42]) or HBP derived synthetic peptides
(e.g., [82]). Although providing detailed structural and kinetic information about the interac-
tion, all these methods are limited to the study of single protein-sugar interactions and they
cannot be translated into a high throughput format. More recently, molecular modelling was
successfully employed for a medium throughput prediction of HBSs for the 4-helical cytokine su-
perfamily [74]. The authors used a generic heparin model derived from NMR data [83] to screen
protein surfaces for clusters of basic residues, which offer shape and charge distribution compat-
ible with the pattern of acidic substituents on the sugar chain [74]. The same method wasalso
employed in a numberof studies aimed at the investigation of HBSs in single proteins (72, 84].
A similar approach was used by Lortat-Jacob and colleagues to elaborate four different modes
of interaction between heparin/HS anddifferent chemokine oligomers [73]. Both these studies
generated results in agreement with published data obtained by other means and demonstrated
the usefulness of molecular modelling as a valuable tool to build models of protein-heparin com-
plexes and to generate a hypothesis testable by, for example, mutagenesis and biophysics. Two
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main limitations remain, however. First, in order to perform the docking exercise, a 3D struc-
ture of the HBP and, preferably, knowledge about its oligomeric state are required. Second,all
the predictions generated need to be validated by in vitro experiments that are intrinsically low
throughput, as discussed above.
The first target of this project was the establishment of a workflow for the localisation of
heparin-binding regions on the protein surface compatible with a high throughput format that
would enable a systematic structural investigation of protein-GAG interactions. In the first
instance a protein-GAGcross-linking method based on affinity chromatography on chemically
activated heparin beads [85] was evaluated, using a panel of two well characterised (FGF-1
and FGF-2) and two recently discovered (S100A4 and avidin) HBPs. FGF-1 and FGF-2 are
paradigmatic heparin interactors and structural data of their complexes with heparin are avail-
able [76, 86,87]. The interaction with heparin/HS dramatically influences the activity of these
growth factors, being a prerequisite for the assembly of active signalling complexes with their cell
surface tyrosine kinase receptors [88-90]. FGF-1 and FGF-2 present structural and chemical-
physical diversity, for this reason they represent a suitable test-bed for this technique. S100A4
is a member of the $100 family of vertebrate-specific Ca?* binding proteins that has been iden-
tified as a tumor-associated protein able to increase the ability of tumor cells to form metasta-
sis [91,92]. Although mainly intracellular, the extracellular activity of $100A4 oligomers on the
differentiation of primary neurons has been recently shown [93]. This activity is dependent on
the interaction between S100A4 and HSPGs, which have been proposed as 5100A4 co-receptors
on the cell surface and in the ECM [93]. The HBS of S100A4 has beenidentified by site-directed
mutagenesis (Ismail, T., West, D.C., Yates, E.A., Rudland, P.S., Fernig, D.G. and Barraclough,
R., in preparation) and, therefore, it represents a relevant test protein for the cross-linking
method. Finally, avidin is a tetrameric glycoprotein isolated from egg white of many birds
that has been extensively applied in various experimental systems thanks to its high affinity
for biotin. Avidin differs from streptavidin, a homologous protein purified from the bacterium
Streptomyces, in possessing a higher content of basic residues and in being glycosylated [94]. The
interaction between heparin and avidin has been recently studied using microtiter-plate assays,
a filter binding assay and surface plasmon resonance analysis [94], however the residues that
mediate the interaction with the sugar have not been identified. Avidin was therefore included
in the panel of test proteins as a new HBP, whose HBS has not yet been characterised. The
cross-linking strategy was successful in localising the HBSs of two of the test proteins, FGF-1
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and FGF-2, however important limitations that restrict the application of this method emerged.
Therefore, a new strategy for the localisation of HBSs was devised.
The new method,called protect and label strategy, is based on the protection against chemical
modification given by heparin/HStoresidues located in the HBSs. Through the use of different
N-hydroxysuccinimide (NHS)esters, it was demonstrated that the presence of the sugar chain
can effectively protect amino acids involved in the interaction and that it is possible to selec-
tively label these residues after dissociation of the protein from the sugar. The protect and label
strategy was evaluated for its ability to correctly predict HBSs in a panel of test proteins includ-
ing FGF-2 (asfor the cross-linking method), platelet factor 4 (PF-4) and pleiothrophin (PTN).
PF-4 is a member of the CXC family of chemokines secreted by platelets and involved in the
regulation of a series of physiological processes including hematopoiesis and angiogenesis [95].
PF-4-heparin complexes are the most important antigenes for the induction of heparin-induced
thrombocytopenia (HIT). HIT is an adverse drug reaction associated with heparin treatments
caused by PF-4-heparin reactive antibodies, and it is associated with increased thrombotic
risk [96]. PF-4 exists in solution as a tetramer and its binding to heparin has been extensively
investigated using NMRspectroscopy and molecular modelling [73,78]. Therefore, it represents
one of the best characterised example of HBP that interacts with heparin as an oligomer. PTN
is a heparin-binding growth factor, also known as heparin-binding growth-associated molecule
(HB-GAM)orheparin affin regulatory peptide (HARP). P'TNis involvedin the regulation ofcell
proliferation, tumor growth and angiogenesis, and it forms a two-member-family with another
HBP, midkine [97]. From a structural point of view, midkine and PTN consist of two /3-sheet
domains, both containing a thrombospondin type-1 repeat motif (TSR). In the case of midkine,
the HBS has been extensively characterised by NMR spectroscopy and mutagenesis [98], while
the HBS of PTN has been only recently localised in the C-terminal domain using synthetic
peptides in combination with optical biosensor [97].
Following validation, the protect and label strategy was applied to the investigation of HBSs
in three members of the FGF family of growth factors. The FGF family includes 22 genes in
humans that, according to phylogenetic analysis, group in seven sub-families [99], and most of
them possess heparin-binding activity. The protect and label strategy was used to compare HBS
structures of three FGFs with maximally divergent sequences. Thus, two proteins phylogenet-
ically related but of different chemical-physical properties (FGF-1 and FGF-2) were compared
to a distant homologue (FGF-18). This example shows an interesting application of the pro-
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tect and label strategy to link structural information related to heparin-binding activity and
evolutionary phenomenasuch as gene duplication.
2.2 Materials and methods
2.2.1 Protein analysis
SDS-PAGE
Samples were run on 15 % (w/v) polyacrylamide-SDS gels. Gels were stained with Coomassie
Brilliant Blue (0.25 % (w/v) Coomassie Briliant Blue R250 (Sigma-Aldrich Ltd, Gillingham,
UK), 10 % (v/v) acetic acid, 50 % (v/v) methanol) and destained in 10 % (v/v) acetic acid,
30 % (v/v) methanol. Alternatively, gels were silver stained according to Heukshoven and
Dernick [100]. Gels were dried before scanning.
Western blot
Samples were run on 15 % (w/v) polyacrylamide-SDSgels and then transferred to Hybond™
nitrocellulose membrane (GE Healthcare Life Sciences, Little Chalfont, UK) using a semi-dry
system (Trans-Blot SD, Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). Membranes were
blocked with PBS-BSA (8.1 mM NagHPOg, 1.2 mM KH2POq, 150 mM NaCl and 2.7 mM
KCl, pH 7.0 with 5 mg/ml BSA) for 30 min at room temperature. The membranes were
then incubated in PBST-BSA (PBS supplemented with 0.5 % (v/v) Tween 20 (PBST) and 5
mg/ml BSA) with Strep-Tactin-HRP (IBA, Gottingen, Germany) (1:7,500) for 30 min at room
temperature. After at least five washes of 5 min with PBST, the membranes were developed
using the SuperSignal West Pico Chemiluminescent substrate (Pierce, Cramlington, UK).
2.2.2 Chromatographic techniques
Peptide Maps
Digested proteins were applied to an Agilent (Warrington, UK) Zorbax Eclipse Plus C18 RP-
HPLC column (100 x 2.1 mm, 3.5 pm) equilibrated in 0.08 % (v/v) TFA using a Beckman
Coulter (High Wycombe, UK) System Gold™ HPLC system. Peptides were separated with a
95 min gradient of 0-64 % (v/v) ACNin 0.08 % (v/v) TFA. Elution was monitored at 214 nm.
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Reverse phase chromatography (RP-HPLC)
Proteins were applied to a Vydac (Grace Vydac, Camforth, UK) Diphenyl RP-HPLC column
(250 x 4.6 mm) equilibrated in 0.08 % (v/v) TFA using a Beckman Coulter System Gold™
HPLC system. Products were separated with a 80 min gradient of 0-64 % (v/v) ACN in 0.08
% (v/v) TFA at a flow rate of 0.5 ml/min. Elution was monitored at 214 nm.
Anion-exchange chromatography
Proteins were applied to a Mono Q™ HR 5/5 column (GE Healthcare Life Sciences) equilibrated
in buffer A (17.9 mM NagHPOg,2.1 mM NaH»POg, pH 7.8) using a AKTA™ HPLC system
(GE Healthcare Life Sciences). Proteins were separated with a two step gradient (step 1: 0-40
% buffer B (17.9 mM NagHPOg, 2.1 mM NaH2POu,, 1 M NaCl, pH 7.8) in 15 column volumes;
step 2: 40-100 % buffer B in 2 column volumes) at a flow rate of 0.5 ml/min. Elution was
monitored at 214, 280 and 410 nm.
Desalting
Proteins were desalted with a 5 ml HiTrap™ desalting column (GE Healthcare Life Sciences)
using a AKTA™ HPLC system. Proteins were isocratically eluted with the selected buffer at
a flow rate of 0.5 ml/min. Elution was monitored at 214 and 280 nm.
2.2.3. Protein expression and purification
Recombinant $100A4 (UniProt Accession: P26447; residues: 2-101), fibroblast growth factor
18 (FGF-18) (UniProt Accession: 076093; residues: 28-207) and pleiotrophin (PTN) (UniProt
Accession: P21246; residues: 33-168) were kind gifts of Dr Thamir Ismail (University of Liv-
erpool), Ms Katarzyna Uniewicz (University of Liverpool) and Prof. José Courty (Université
Paris XII). Platelet factor-4 (PF-4) (UniProt Accession: P02776; residues: 32-101) was pur-
chased from Athens Research and Technology Inc (Athens, GA). Egg white avidin (UniProt
Accession: P02701), horse hearth cytochrome c (UniProt Accession: P00004) and chicken egg
lysozyme (UniProt Accession: P00698) were purchased from Sigma-Aldrich Ltd.
Recombinant fibroblast growth factor-1 (FGF-1) (UniProt Accession: P05230; residues: 16-155)
and fibroblast growth factor-2 (FGF-2) (UniProt Accession: P09038b; residues: 1-154) were
expressed in C41 E.coli cells [101] using a pET-14b system (Novagen, Merck Chemical Ltd,
Nottingham, UK) and purified according to the procedure reported below.
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1. Bacterial transformation. Competent CL41 E.coli cells were thawed on ice. One
hundred ng pET-14b-FGF-1 (pET-14b-FGF-2) DNA was mixed with bacterial cells and
incubated on ice for 30 min. Cells were permeabilised by heat shock (1 min at 42°C).
After incubation for 2 min onice, cells were rescued with 1 ml Luria-Bertani (LB) broth
and placed at 37°C for 60 min. Bacteria were collected by centrifugation at 1,500 x g for
5 min and resuspended with 100 pl of LB. Ten pl was plated out onto LB-ampplates (LB
supplemented with 100 g/ml of ampicillin (Sigma-Aldrich Ltd)). Plates were incubated
overnight at 37°C.
2. Bacterial culture. Single colonies were inoculated into 10 ml of LB-amp and cultured
for 8 h at 37°C under shaking (250 rpm). One mlof this culture was then inoculated
into 100 ml of LB-amp and incubated overnight at 37°C with shaking (250 rpm). Ten ml
of the overnight culture was sub-cultured at a dilution 1:50 in 500 ml of LB-amp. Four
cultures were set up for a total volume of 2 1. They were grown at 37°C (250 rpm) until
ODgoo reached 0.5-0.8. The expression of the protein was then induced with IPTG (Bioline
UK, London, UK)at a final concentration of 1 mM,for 3 h at 37°C (250 rpm). Flasks
were chilled on ice. The cultures were transferred to pre-chilled sterile 500 ml centrifuge
tubes and centrifuged for 20 min, at 11,000 x g. Cell pellets were resuspended with 25
mlof pre-chilled sterile PBS and transferred to 50 ml tubes. After a wash with 10 ml of
pre-chilled sterile PBS, pellets were resuspended with 10 ml of Resuspension Buffer (50
mM Tris-HCl pH 6.8, 0.6 M NaCl, 1 mM DTT)andstored at -80°C.
3. Cell breakage. Bacterial cells were thawed on ice and transferred to a pre-chilled 100
ml glass beaker. Cells were sonicated for 30 s (Dawe Ultrasonic Generator 7533A, pulsed
sonication, max power, 40/50 % duty cycle) and placed on ice for 1 min. The procedure
was repeated 6 times. Samples were then centrifuged in pre-chilled sterile 50 ml centrifuge
tubes at 48,000 x g for 30 min.
4. Heparin affinity chromatography I. Three ml of Affi-Hep agarose (Bio-Rad Labora-
tories Ltd) was packed in a small column and equilibrated with washing buffer (9 mM
NagHPO,, 11 mM NaH2POg, 0.6 M NaCl, 1 mM DTT,pH 6.8). The supernatant from
step 3 was loaded on the column with a Pharmacia LKB-P1 peristaltic pumpat a flow rate
of 1 ml/min. The column was washed with washing buffer for 2 h (flow rate 1 ml/min).
Protein was eluted with elution buffer (9 mM NagHPOgq, 11 mM NaH2PO,, 2 M NaCl,
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1 mM DTT, pH 6.8). Elution was monitored at 280 nm with a Bio-Rad ECONO UV
monitor connected to a Kipp and Zonnen (Netherlands) recorder.
5. Heparin affinity chromatography II. The elution peak from step 4 (approx. 4.5 ml)
was diluted 3-fold with 9 mM NagHPOug, 11 mM NaH2POq,, 1 mM DTT,pH 6.8 toafinal
volume of 13.5 ml. Diluted sample was then applied to a Heparin TSK column (Tosoh
Biosciences GmbH, Stuttgart, Germany) using an AKTA™ HPLC system. Elution was
performed with a gradient of 0-100 % elution buffer. Elution was monitored at 214 and
280 nm and peakscollected in 1 mlfractions. Fractions were analysed by SDS-PAGE with
Coomassie staining. Protein concentration was calculated by absorbance measurement at
280 nm (theoretical molar extinction coefficients: 1.0015 for FGF-1 and 0.9375 units for
FGF-2). Fractions were aliquoted and stored at -80°C.
2.2.4 Cross-linking
The cross-linking procedure was performed as described in [85] with minor modifications.
Step 1: Heparin activation. AF-heparin beads (Tosoh Biosciences GmbH; binding capacity
of 4 mg of ATIII/mlresin) 10 jul slurry were washed twice with 200 jul PBS. Heparin wasac-
tivated by incubation with 10 yl 1.8 mM EDC(1-ethyl-3-[3-dimethylaminopropyl] carbodi-
imide hydrochloride) (Fluka, Gillingham, UK), 10 jl 4.5 mM NHS (N-hydroxysuccinimide)
(Pierce), both freshly made, for 15 min at room temperature on a rotating wheel. The
reaction was quenched with 7.5 pl 0.1 M @-mercaptoethanol. Beads were washed with 200
pl PBS.
Step 2-3: Binding and cross-linking. Twenty jg of protein was diluted to 200 pl with PBS
and incubated with AF-heparin beads for 1 h at room temperature on a rotating wheel.
The reaction was quenched by adding 200 yl 1 M Tris pH 7.5. Non-cross-linked proteins
were removed by washing twice with 200 jl PBS supplemented with 2 M NaCl.
Step 4: Digestion. Beads were resuspended in 50 pl 8 M urea, 400 mM NH4HCOs3pH 7.8,
5 wl 45 mM DTTand incubated for 15 min at 56°C. Proteins were carboxymethylated
by addition of 5 il freshly made 0.1 M iodoacetamide for 15 min at room temperature in
the dark. Samples were diluted with 140 yl HPLC grade water and digested with 1 yg
sequencing grade trypsin (Promega, Southampton, UK) overnight at 37°C. Non-cross-
linked peptides were removed by washing twice with 200 yl PBS, 2M NaCl.
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Step 5: Sequencing. Beads were further washed with 200 yl milliQ water. Cross-linked pep-
tides were subject to N-terminal sequencing by Edman degradation [102,103] using an
Applied Biosystems (Warrington, UK) model 471A Protein Sequenator.
2.2.5 Protect and label strategy
The protect and label strategy was performed according to the procedure described in [75].
Step 1: Binding. A 20 pl slurry of AF-heparin beads was packed in a mini-column,consisting
of a P10 tip with a plastic air filter placed at its end to retain the resin. A 5 ml sterile
syringe was used to pack the mini-column and dispense buffers. The heparin column was
equilibrated with 4 x 50 yl PB 150 buffer (17.9 mM NagHPOg, 2.1 mM NaH2PO,, 150
mM NaCl, pH 7.8) and loaded with 20 ug of either FGF-2 (1.2 nmoles), PF-4 (2.6 nmoles),
PTN (1 nmole), FGF-1 (1.2 nmoles) or FGF-18 (0.8 nmoles) dissolved in 200 pul of PB
150 or buffer of compatible ionic strength. Loading was repeated three times to ensure
complete binding. The mini-column was then washed with 4 x 50 zl PB 150.
Step 2: Acetylation of exposed lysines. The heparin column with bound protein was first
equilibrated by a quick wash with 20 yl PB 150 containing 50 mM sulfo-NHS-acetate
(Pierce) and then incubated with 20 1 PB 150 containing 50 mMsulfo-NHS-acetate for 5
min at room temperature to ensure complete blocking (acetylation) of exposed lysines. To
stop the reaction, the column was extensively washed with 4 x 50 41 PB 150. Acetylated
protein was eluted from heparin with 40 ul 2 M NaCl, buffered with PB (44.75 mM
NagHPOg,, 5.25 mM NaH2POu, pH 7.8).
Step 3: HBSlysine biotinylation. Eluted protein was diluted with 200 1 PB (to give a final
NaCl concentration of 0.33 M) and concentrated with a 5 kDa MWCOcentrifugal filter
(Sartorius Ltd, Epsom, UK). After adjusting the volume to 37.2 yl with PB, biotinylation
was performed by the addition of 2.8 yl 145 mM NHS-biotin (Pierce) in DMSO (final
concentration 10 mM) and incubation for 30 min at room temperature. The reaction was
quenched with 4 jl of 1 M Tris pH 7.5. The excess reagent was removed by four cycles
of sequential dilution with 200 pl of ten times diluted PB (4.48 mM Na2HPOs, 0.52 mM
NaH»POq, pH 7.8) and concentration with a 5 kDa MWCOcentrifugalfilter. The sample
was then dried by centrifugal evaporation.
Step 4: Protein digestion. The dried sample was dissolved with 25 jl of 8 M urea, 400 mM
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NH,HCO3 pH 7.8, 2.5 ul 45 mM DTT and incubated 15 min at 56°C. Proteins were
carbamidomethylated with 2.5 yl freshly made 0.1 M iodoacetamide for 15 min at room
temperature in the dark. Samples were diluted with 70 41 HPLC grade water and digested
overnight at 37°C with 1.5 ug chymotrypsin (Sigma-Aldrich Ltd).
Step 5: Biotinylated peptide purification. A 40 jl slurry of Strep-Tactin!™ Sepharose
beads (IBA GmbH) were packed in a mini-column (see above), which was equilibrated
with 4 x 50 pl 500 mM urea, 25 mM NH,HCO3. Digested protein was diluted to a final
volume of 400 pl with HPLC grade water and applied to the column. Loading was re-
peated three times to ensure complete binding. Unbound peptides were removed by 3 x 50
pl washes with 0.5 M urea, 25 mM NH4,HCOs, followed by 2 x 50 ul washes with HPLC
grade water. Biotinylated peptides were eluted with two lots of 20 pl 80 % (v/v) ACN,
20 % (v/v) TFA, 5 mM biotin.
Steps 6 and 7: Identification of labelled peptides. The eluate was concentrated by ro-
tary evaporation, desalted using a C18 ZipTip!™ (Millipore Ltd, Watford, UK) according
to the manufacturer’s instructions and analysed by MALDI-Q-TOF (FGF-2, PF-4 and
PTN) or ESI-Q-TOF (FGF-1 and FGF-18) mass spectrometry (MS) (see below).
2.2.6 MALDI-Q-TOF mass spectrometry
Samples (1 jl) were spotted 1:1 (v/v) in 5 mg/ml a-cyano-4-hydroxycinnamic acid (Sigma-
Aldrich Ltd) in 50 % (v/v) ACN, 50 % (v/v) HPLC grade water. Data dependent analysis
was performed on the top 10-most intense peptides in the parent spectrum, the instrument
switching to the next peptide for MS/MSafter a minimum of 100 counts had been achieved.
Collision gas was argon, laser energy was fixed at 250 (arbitrary units), the instrument was a
SYNAPT!™MALDI HDMS(Waters Corporation, Manchester, UK), where collision induced
dissociation (CID) can occur in either trap or transfer collision cell. A ramp profile in the
trap collision cell of 34-44 V for m/z 700-750 up to 151-161 V for m/z 3,350-3,400 was used.
Depending on the m/z of the peptide selected for MS/MSthe corresponding energy ramp was ap-
plied. MS/MSspectra were processed using the MassLinx v.4.0 software (Waters Corporation).
Peak lists were generated using the MaxEnt3 algorithm applying a 5 % base peak intensity
cut-off. Data analysis was performed using the MS-tag tool of the Protein Prospector pack-
age v.5.2.2 http://prospector2.ucsf.edu using the following parameters: digest = chymotrypsin;
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max missed cleavages = 5; possible modifications = acetyl (Lys), biotin (Lys), carbamidomethy]
(Cys), carboxymethyl (Cys); parental ion tolerance = 100 ppm; fragment ion tolerance = 300
ppm; non-specific cleavage = at 1 termini. Both carbamidomethylation and carboxymethyla-
tion of cysteines were included as variable modifications since S-carbamidomethyl-cysteine can
be hydrolysed to S-carboxymethyl-cysteine under the acid condition used for the elution of bi-
TM similarly to what it is commonly observed during theotinylated peptides from Strep-Tactin
Edman degradation procedure [104]. The UniProt ID of the protein analysed was used asa pre-
search parameter. All other settings were used as default values. In case of modified parental
ions (e.g., sodium adduct ions), the MS-product tool of the Protein Prospector package v.5.2.2
was used with default settings.
2.2.7 ESI-Q-TOF mass spectrometry
The analyses were performed using a Waters quadrupole-time offlight (Q-TOF) micro mass
spectrometer (Waters Corporation). After desalting, samples were diluted with 20 pl of 0.1 %
(v/v) formic acid in HPLC-grade water and directly infused into the mass spectrometer at 0.2
l/min. The mass spectrometer was operated in the positive ion nano electrospray mode with
a source temperature of 80°C andcapillary voltage 2.8 kV. First, a survey scan was performed
in MS-TOF modein the range between 200 and 2,000 Da. Peak lists were generated using the
algorithm MaxEnt3 part of the MassLinx v.4.0 software using the following settings: mass range
= 800-3,000 Da, max number of charges = 3. The 10 most intense ions were then manually
selected and subjected to MS/MSanalysis. For each ion the MS/MS spectrum was acquired in
the MS-Q-TOF mode. The precursor ion was selected in the quadrupole, fragmented by CID
and then fragment ions were recorded by TOF (range: 80-3,000 Da). The collision gas was
argon and the collision energy was manually adjusted during the acquisition between 25 and 45
V. Peak lists were extracted using the MaxEnt3 algorithm applying a 5 % base peak intensity
cut-off. Data analysis was performed using the MS-tag tool of the Protein Prospector package
v.5.2.2 as described before except for parental ion tolerance and fragment ion tolerance that
were set at 0.3 and 0.6 Da, respectively.
2.2.8 Bioinformatics
All the 3D structures images were obtained using MacPyMOLhttp://www.pymol.org and the
surface electrostatic potentials were calculated using the APBS plugin. Coordinate files were
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downloaded as PDB files from the Brookhaven Protein Database http://www.rcsb.org/pdb/
except for FGF-18 whose structure was modelled in this study (see below). Structural alignments
were performed using the DaliLite program [105]. Sequence alignments were obtained using
ClustalW2 with default settings [106] and edited using JalView [107].
The 3D structure of FGF-18 was generated by a homology modelling procedure using Modeller
9v7 http://salilab.org/modeller. Briefly, the HHPred algorithm was used to perform sequence
similarity search for the available 3D structure with best alignment to FGF-18 amino acid
sequence [108]. The modelling was based on one template only since the score of the second
best template was remarkably lower than of the selected one (33 % vs 58 % identity). Using
ClustalW2 the sequence of the top scoring hit (PDB: 2FDB-m; derived from human FGF-8b
(UniProt accession: P55075-3), residues: 32-180) was aligned to FGF-18 (residues: 33-180)
and the resulting alignment was edited in JalViewin order to create input file for Modeller.
Modeller generated five 3D models which were evaluated according to their discrete optimised
protein energy (DOPE)score [109]. The selected model was of the lowest DOPE score and was
examined for the presence of disallowed main chain torsion angles using Ramachandran plot 2.0
(http: / /dicsoft1.physics.iisc.ernet.in/rp/). The PDB file of the modelled structureis a available
in Appendix III.
2.3. Cross-linking
First, a recently published method [85] was evaluated on heparin-interacting proteins with known
HBSs (FGF-1 and FGF-2) and on tworecently discovered interactors (S100A4 and avidin). The
method is based on the formation of protein-GAG cross-linked complexes on heparin affinity
beads. The proteolytic digestion of these complexes followed by N-terminal sequencing of the
cross-linked peptides allows the identification of residues involved in the binding [Fig. 2.1].
Considering the high degree of sulfation characteristic of heparin and NS domains of HS, the
presence of basic residues such as lysines and arginines is one of the characteristic features of
HBSs. In this method the lysines present in the binding site are conjugated to pre-activated
carboxyl groups present on the heparin chain. The pre-activation of heparin is performed by
incubation with EDC in the presence of NHS. EDCcanreact with carboxyl groups, present at
position 6 of both iduronic and glucuronic acid, to form an O-acylisourea intermediate. This
intermediate is amine reactive, but it is rapidly hydrolysed in water (the half-life is measured
in seconds at neutral pH) [110]. In the presence of NHS, EDC converts carboxyl groups to
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Figure 2.1: Protein-GAG cross-linking method on heparin affinity beads. Schematic representation of the cross-
linking method published by Viveset al. [85].
NHSesters, that show a greater stability (half-life of 10 min to several hours). NHS esters
react with a-amine groups at the N-termini of proteins and ¢-amines on lysines. The reaction
results in the formation of a covalent amide bond and release of N-hydroxysuccinimide [111].
Vives and colleagues validated the techniques using two proteins with well characterised HBSs:
RANTESandthe envelope glycoprotein gC from pseudorabies virus. Afterwards, they applied
the method to characterise the HBS of laminin-5 3LG4/5 fragment, for which little data was
then available [85].
Following a similar approach, the method wasfirst evaluated on FGF-1 and FGF-2 and,
subsequently, applied to two recently discovered HBPs,avidin [94] and S100A4[93].
FGF-1
FGF-1 was incubated with EDC/NHSactivated heparin beads, non-cross-linked proteins were
removed by washing with PBS, 2 M NaCl and the conjugated FGF-1-heparin beads were treated
with trypsin. The released peptides were removed by further washes with PBS, 2 M NaCl and
 
21
A new method for the identification of heparin-binding sites
 
cross-linked peptides were subject to N-terminal sequencing by Edman degradation.
Two peptides located within the HBS were identified as cross-linked to the beads. The first
sequence started at residue Asn-121 and ended at residue Lys-127 or Lys-128. The second
started at residue Thr-138 and included the C-terminusof the protein. A peptide corresponding
to the N-terminus of the protein was also found to be cross-linked [Table 2.1] [Fig. 2.2 A].
The identification of the peptides Asn-121:Lys-127/128 and Thr-138:Asp-155 is in agreement
with published crystallography data [86]. Analysis of the structure of FGF-1 in complex with
a heparin derived hexasaccharide shows that both Lys-127 and Lys-143 are in close proximity
to carboxyl groups of the sugar chain and they possess the correct orientation required for the
cross-linking reaction (Fig. 2.2 B].
Moredifficult is the interpretation of the sequence deriving from the protein N-terminus, since
there are no published data supporting an involvement of this region in heparin-binding. The
N-terminal signal could be due to the presence of undigested material or to non-specific cross-
linking. Chromatography peaks assigned to each peptide were quantified by comparison with
a standard mixture of PTH-aminoacids. The three sequenced peptides were present in almost
equimolar amount [Table 2.1] [Fig. 2.2 C]. This observation supports the hypothesis that either
non-specific cross-linking occurred between a residue located at the N-terminus of the protein
and the sugar chain or this represents a novelsite of interaction of FGF-1 with heparin.
Analysis of the HPLC profiles corresponding to cach sequencing cycle revealed the presence of
several unidentified peaks. These may be due to the release of peptide-sugar conjugates from the
beads under the strong conditions of the Edman degradation reactions. Someof the steps of the
Edmandegradation procedure require pH out of the range recommended by the manufacturer of
the heparin beads employed (pH 5-10). For example, a 400 s cycle with 100 % TFA is employed
during the cleavage of the phenylthiohydantoin (PTH)-amino acid conjugate from the rest of
the polypeptide [103]. This extremely low pH can cause destabilisation of the support beads
with consequent release of peptide-sugar conjugates. This could also explain the reduction of
the signal that was observed during the sequencing cycles [Table 2.1].
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Figure 2.2: FGF-1 cross-linking on heparin beads. (A) The sequence of FGF-1 usedin this study (residues:
16-155) is represented. Red font indicates the HBS. Green boxes indicate sequenced peptides and arrows the
beginning of the sequence. Lysines (K) in green represent supposedcross-linked residues. (B) FGF-1 (PDB:
2AXM) is showningrey as lines. Heparin derived hexasaccharide is shown in CPKcoloursas lines. Cross linked
residues (Lys-127, Lys-143) are represented in CPK colours as spheres. Uronic acids in proximity of the cross-
linked residues are shown in CPKcolours as sticks. (C) Initial yield of PTH-aminoacid conjugates assigned to
each peptide were estimated by comparison with a standard mixture of PTH-aminoacids run before each sample
[Table 2.1]. Colours correspondto the arrows indicating the beginning of each sequence in A (black, N-terminus;
orange, residues 121-127; yellow, residues 138-143).
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FGF-2
In the case of FGF-2 sequencing of the heparin cross-linked peptides led to the identification
of two sequences located within the canonical HBS. The two peptides started at the residues
Leu-135 and Tyr-139, respectively. However, the reduction of the signal observed during the
cycles together with the complexity of the chromatogram impaired the identification of the
carboxy-end of these peptides [Table 2.2]. Two peptides derived from the N-terminus of the
protein were co-sequenced also in this case, as well as a fifth peptide corresponding to the C-
terminus [Table 2.2] [Fig. 2.3 A]. Analysis of the structure of FGF-2 in complex with a heparin
derived decasaccharide confirmed that the residues Lys-138 and Lys-144 are in close proximity
to carboxyl groups of the sugar chain and they possess the correct orientation required for the
cross-linking reaction [Fig. 2.3 B]. However, in this case the signal derived from the N-terminus
of the protein was predominant, masking almost completely the sequences derived from the HBS
[Table 2.2] [Fig. 2.3 C].
$100A4 - AVIDIN
The ability of S100A4 and avidin to bind heparin and HS has been recently demonstrated
[93,94]. Both proteins also displayed heparin-binding activity in the conditions used in this
study. Incubation with the heparin bead resulted in a complete pull down of S100A4 and avidin
from the solution (data not shown). However, no sequence deriving from cross-linked peptides
was detected. Increasing the concentration of protein and/or cross-linkers did not result in
any signal. The lack of signal despite the ability of the proteins to interact with heparin can be
explained by failure of the cross-linking reaction. The carboxyl groups activated by EDC/NHS
display selective reactivity towards primary amines such as N-termini of proteins and ¢-amines
on lysines. Therefore, the presence of a lysine located in proximity of the carboxyl groups of
the sugar and displaying an appropriate three-dimensional orientation is a requirement for a
successful reaction. It is possible that the HBSs of $100A4 andof avidin do not contain a lysine
with such characteristics.
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Figure 2.3: FGF-2 cross-linking on heparinbeads. (A) The full-length sequence of FGF-2 is represented. Red
font indicates the HBS. Green boxes indicate sequenced peptides and black arrows the beginning of the sequence.
Lysines (K) in green represent supposedcross-linkedresidues. (B) FGF-2 (PDB: 1FQ9) is showningrey as lines.
Heparin derived decasaccharide is shown in CPKcoloursaslines. Cross linked residues (Lys-138, Lys-144) are
represented in CPK colours as spheres. Uronic acids in proximity of the cross-linked residues are shown in CPK
colours as sticks. (C) Initial yield of PTH-amino acid conjugates assigned to each peptide were estimated by
comparison with a standard mixture of PTH-aminoacids run before each sample [Table 2.2]. Colours correspond
to the arrows indicating the beginning of each sequence in A (black, N-terminus and C-terminus; orange, sequence
starting at residue 135; yellow, sequence starting at residue 139).
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In summary, the cross-linking method successfully identified residues involved in heparin-
binding for both FGF-1 and FGF-2. However several issues that strongly limit its application
emerged. First of all, the interpretation of the PTH-amino acids HPLCprofiles was complicated
by the presence of several unidentified peaks, presumably due to the release of peptide-sugar
conjugates from the beads under the strong conditions of the Edman degradation reactions.
This hypothesis was supported by the yields of material recovered at the end of each cycle that
were found to be lower than those of standard analysis [Tables 2.1 and 2.2]. Furthermore, severe
blockages of the sequencing machine were experienced during sample analysis. The authors of
the original article on this method also reported similar issues in a recent publication, where
they presented a modified in solution version of the cross-linking strategy [112] in order to
overcomethis technical problem. Second, in the case of FGF-2 a predominantsignal derived from
the protein N-terminus almost completely masked the signal derived from the canonical HBS.
Although an involvement of this region in heparin-binding cannot be excluded, this example
highlights the difficult interpretation of HPLCprofiles whensignals of different intensities derived
from more than one peptide overlap on the chromatogram [Table 2.2]. Third, the inability to
achieve a successful cross-linking reaction for S100A4 and avidin despite their confirmed heparin-
binding activity represent an important argument against a broad application of this method
for the study of protein-GAG interactions. Fourth, it is clear that the cross-linking methodis a
low throughput, one-protein-at-a-time approach.
2.4 Protect and label strategy: method development
The limits displayed by the cross-linking strategy substantially restrict the group of proteins
that can be analysed by this method. In order to overcome such limitations, a new strategy
for the localisation of HBSs was devised. The new method is based on the protection against
chemical modification given by heparin/HSto residues located in the HBSs. In 1988 Chang used
a lysine reactive chromophoric reagent to investigate the heparin-binding site of antithrombin-
Il] (ATHI). ATIwas modified in presence or absence of heparin and the coloured peptides
generated by trypsin digestion were analysed by RP-HPLC [113]. Using this approach the author
obtained important insights into the heparin-ATIII interaction. A diminished modification of
Lys-107, Lys-125 and Lys-136 was observed in presence of heparin, suggesting an involvement in
binding to heparin. The increased modification of Lys-236 indicated a possible conformational
change induced by the heparin [113].
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NHSesters are widely used reagents for modification of amino acids, peptides, proteins and
other biomolecules [114] [110]. Their strong and selective reactivity towards primary amines,
in particular e-amines on lysines, and their relative stability in neutral/weakly basic aqueous
solution make them compoundsofchoice for the investigation of HBSs, which are characterised
by a high content of basic residues. The combination of different esters allows the use of the
same chemistry for the protection (acetylation) of residues exposed on the protein surface, but
not involved in heparin binding, and theselective labelling (biotinylation) of those forming the
HBS. The protect and label strategy consists of three main steps [Fig. 2.4]:
Modification/blockage of exposed lysines (steps 1-2) The protein to be analysed is bound
to heparin beads. Once bound, the protein is modified by incubation with sulfo-NHS-
acetate. This results in the acetylation of primary amines exposed on the protein surface:
N-terminus and e-aminesof lysines.
Labelling of lysines protected by heparin/HS (step 3) The protein is then dissociated
from the sugar by increasing the ionic strength of the solution. A subsequent incubation
with NHS-biotin leads to selective labelling of lysines involved in the interaction with
heparin that were not blocked in the previous step.
Identification of labelled peptides (steps 4-6) The modified protein is then denatured,
carboxymethylated and enzymatically digested. Biotinylated peptides are purified by
affinity chromatography using Strep-Tactin™™ beads. After elution, captured peptides
are identified by mass spectrometry (MS).
2.4.1 Modification/blockage of exposed lysines
Modification of primary amines by NHS reagents: kinetics and optimisation of
reaction conditions
The blockage of exposed lysines is the critical step of the procedure. Infact, the signal/noise
ratio is highly dependent on the level of acetylation achieved during this step. The failure to
completely block all the residues reactive towards NHS esters, but not protected by heparin,
would lead to non-specific labelling during the following steps, so generating false positive signals.
For this reason the first part of the method development was devoted to the optimisation of
conditions able to guarantee the maximum level of acetylation achievable.
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Figure 2.4: Protect and label strategy: flowchart. A) The protect and label strategy is schematised. Blue
colour indicates unmodified lysine residues. Blocked (acetylated) lysines are represented as red arrows. Labelled
(biotinylated) lysines are shown as green circles. B) The reactions of protection (acetylation) and labelling
(biotinylation) mediated by NHSesters are schematised. The figure was adapted from [75] with permission from
the authors.
Despite the widespread use of NHS derived reagents in chemistry and biochemistry, the
kinetics of reaction with biomolecules in aqueous solution has been only partially elucidated
[115] [116] [114]. The reactivity and, as a consequence, the stability of NHS esters is strongly
pH-dependent. In aqueous solution, the acylation of primary amines by NHSesters competes
with their hydrolysis and both the reactions are accelerated in basic buffer solutions [117]. For
example, the reaction rate of sulfo-NHS-LC-biotin with protein amino groups after 5 minutes
of incubation is increased more than 50 % when performed at pH 8.0 instead of 7.2, however,
this is accompanied by a decrease in half life of the NHS groups from 40.6 to 12.7 minutes [117].
Both the completion of the reaction and the incubation time, which has to be limited in order
to minimise the dissociation of the protein from the bound sugar, are primary concerns for the
method. Consequently, a slightly basic buffer (17.9 mM NagHPOg, 2.1 mM NaH2POuq, 150 mM
NaCl, pH 7.8) was chosen to ensure a high reaction rate.
A series of experiments using two different model proteins, lysozyme and cytochrome c,
were performed, in order to establish optimal NHS reagent concentration and incubation time.
Lysozyme and cytochromec were acetylated by incubation with different concentrations of sulfo-
NHS-acetate. Each reaction was stopped and analysed after 1 and 5 minutes of incubation. For
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each experiment, an extensively modified product, obtained by two consecutive incubations of
30 minutes each with sulfo-NHS-acetate, was used as control. The level of modification obtained
was assessed by comparing the chromatographic behaviour of modified and native products. In
the case of lysozyme, modified products were separated by RP-HPLC using a Vydac™Diphenyl
column. Acetylation of primary amines reduces the overall charge of the protein at the low pH
used in reverse phase chromatography, resulting in an increase in retention time proportional
to the level of acetylation [Fig. 2.5]. For cytochrome c, anion-exchange chromatography (Mono
Q™HR5/5, GE Healthcare) was used. In this case the effect of lysine acetylation on the
overall protein charge (substitution of the positively charged ¢-amino group with an acetyl
group, negatively charged at neutral/slightly basic pH used during chromatography) enables
cytochrome c to bind the anion exchange support with a strength proportional to the level of
modification achieved [Fig. 2.6]. Both the techniques allowed the kinetics of the reaction to
be followed and so accurately compare different conditions. In both cases the kinetics of the
reaction was strongly influenced by the NHSester concentration. For the lower concentration
used (13 mM),a partial level of acetylation wasachieved after 1 and 5 minutesof incubation (Fig.
2.5 A, B] (Fig. 2.6 A, B]. However, when the sulfo-NHS-acetate concentration was increased (50
mM), the rate of protein modification was drastically accelerated, obtaining an almost complete
acetylation after just 5 minutes of incubation (compare Fig. 2.5 B vs E and Fig. 2.6 B vs E).
Surprisingly, the reaction profiles appeared similar for both test proteins despite their different
content of NHS-reactive groups as total numberof lysines + 1 (the protein amino terminus);
9 for lysozyme and 20 for cytochrome c. The results confirmed that, to a large extent, the
reaction is not dependent on substrate concentration, but on the NHS ester concentration and
incubation time only, as previously observed [116]. In fact, in the presence of a relatively low
concentration of protein (in this case < 2 mg/ml) the primary reaction consuming reagent is
hydrolysis, making the contribution of target amines irrelevant [116].
In order to confirm this hypothesis, the dependency on substrate concentration was further
investigated. Equimolar amounts of lysozymediluted at four different concentrations (0.5, 0.75,
1, 1.9 mg/ml) were acetylated in the same condition used in Fig. 2.5 E (50 mM sulfo-NHS-
acetate; 5 min at room temperature). In this case the level of acetylation was assessed by
exposing the acetylated lysozyme to NHS-biotin and detecting the eventual biotinylation by
western blot [Fig. 2.7]. This alternative method for evaluation of protein acetylation was
important to confirm the result obtained by RP-HPLC and to mimic the experimental condition
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of the protect and label strategy (see Protect and label strategy step 3). Western blot confirmed
the result obtained by RP-HPLC. An almost complete protection of NHS-reactive groups was
in fact achieved as shown by the drastic reduction of biotinylation level between sample 3
(acetylated in the same condition as used for the chromatographic experiment) and control
(sample 2, lysozyme biotinylated without prior acetylation) [Fig. 2.7]. Furthermore, the level
of protection was almost completely independent of protein concentration, in the concentration
range considered, as previously proposed (samples 3-6) [Fig. 2.7]. However, the presence of some
unreacted lysines was indicated by a low, but present, biotinylation signal in samples 3-6 [Fig.
2.7]. This background signal was considered acceptable in order to find the best compromise
between minimisation of incubation time andefficiency of the acetylation reaction. This choice
was further supported by the substantial signal to noise ratio observed for the sample acetylated
using the same conditions, but in the presence of heparin (see Section 2.4.2, Fig. 2.9 compare
sample 3 vs 4).
In summary,this series of experiments enableda set of reaction conditions to be selected that
allowed a high level of lysine protection in a relatively short incubation time (5 minutes) and
with a guaranteed stable reaction across a range of substrate concentrations (0.5-1.9 mg/ml).
These conditions were then applied in the context of the protect and label strategy and series
of pilot experiments were performed in order to prove the principle of the method.
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Figure 2.5: Kinetics of lysozyme acetylation by sulfo-NHS-acetate: RP-HPLC. Native (A inset) and acetylated
proteins (A-F) were separated by RP-HPLC(see Section 2.2). Twenty jug of lysozyme were acetylated in PB 150
with 13 mM (A-C) or 50 mM (D-F) sulfo-NHS-acetate of for 1 min (A, D) or 5 min (B, E) at room temperature.
For both the concentrations an extensively modified product, obtained by two consecutive incubations of 30 min
each with the specific sulfo-NHS-acetate concentration, was used as control (C, F). The chromatograms shown
were recorded at 214 nm.
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Figure 2.6: Kinetics of cytochrome c acetylation by sulfo-NHS-acetate: anion-exchange chromatography. Native
(A inset) and acetylated proteins (A-F) were separated by anion-exchange chromatography (see Section 2.2).
Twenty pig of cytochrome c were acetylated in PB 150 with 13 mM (A-C) or 50 mM (D-F)sulfo-NHS-acetate for
1 min (A, D) or 5 min (B, E) at room temperature. For both the concentrations an extensively modified product,
obtained by two consecutive incubations of 30 min each with the specific sulfo-NHS-acetate concentration, was
used as control (C, F). The chromatograms shown were recorded at 410 nm.
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Figure 2.7: Dependency of lysozyme acetylation on protein concentration: western blot. Samples were separated
on a 15 % (w/v) polyacrylamide-SDS gel. Proteins were transferred onto nitrocellulose membrane. Biotinylated
proteins were revealed with Strep-Tactin-HRP (1:7500). 1) Lysozyme. 2) Lysozyme. 3-6) Acetylated lysozyme.
Forty jug of protein at different concentrations (0.5 mg/ml (3); 0.75 mg/ml (4); 1 mg/ml (5); 1.9 mg/ml (6))
were incubated with sulfo-NHS-acetate at a final concentration of 50 mMfor 5 minutes at room temperature. All
samples were buffer exchanged to the same buffer (PB150) by gel filtration chromatography. Samples 2-6 were
then biotinylated with NHS-biotin at a final concentration of 10 mMfor 30 minutes at room temperature.
Heparin/HSprotect residues involved in their binding
To demonstrate the ability of heparin to selectively protect lysines present in the HBS,a series
of pilot experiments were performed using FGF-2 as a model protein. Employing the conditions
developed in the previous section, FGF-2 was acetylated in the absence or in the presence of
heparin (see Section 2.2: Protect and label strategy step 1-2). Samples were buffer-exchanged
into PB150 and their heparin-binding activity was tested by application to a mini-heparin column
(see Section 2.2: Protect and label strategy step 1). The same amount of native FGF-2 was
applied to a mini-columnas a control. A fourth sample obtained by reacting NHS-biotin with
FGF-2 acetylated in presence of heparin (see Section 2.2: Protect and label strategy step 3) was
tested. This last sample representsthe final product of the protect and label strategy. Equivalent
fractions of loaded (L) and unboundfractions (FT) were separated on a polyacrylamide gel and
proteins were detected by silver staining [Fig. 2.8]. Lysine acetylation clearly impaired the
binding of FGF-2 to heparin. The protein was in fact recovered almost completely in the
unbound fraction (FT) [Fig. 2.8 sample 2]. However, when the acetylation was performed in
the presence of heparin the protein retained its binding activity almost completely [Fig. 2.8
sample 3]. This suggests a selective protection given by the sugar chain to lysines involved in
heparin binding. Furthermore, the retained binding activity of sample 3 (acetylated in presence
of heparin) can be abolished by further exposure to NHS-biotin [Fig. 2.8 sample 4].
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Figure 2.8: Modification of FGF-2 in presence or absence of heparin: heparin affinity chromatography. Samples
were separated on a 15 % (w/v) polyacrylamide-SDSgel andsilver stained. All samples were buffer exchanged
into PB150 bygel filtration chromatography before application to the heparin mini-column(see Section 2.2). The
heparin mini-column was packed using 20 jl of AF-heparin beads and equilibrated in PB150. S = standard, L =
1/10 of the protein loaded onto the mini-column, FT = 1/10 of the unbound fraction. 1) FGF-2. 2) Acetylated
FGF-2: protein was incubated with sulfo-NHS-acetate at a final concentration of 50 mMfor 5 minutes at room
temperature. 3) FGF-2 acetylated in presence of heparin (see Section 2.2: Protect and label strategy step 1-2).
4) FGF-2 acetylated in presence of heparin (same of 3) and then biotinylated, after dissociation from the sugar,
with NHS-biotin at a final concentration of 10 mM for 30 minutes at room temperature.
2.4.2 Labelling of lysines protected by heparin/HS
After demonstrating that heparin can effectively prevent the modification of residues crucial for
its binding, the next step was to show that these residues can beeffectively labelled (biotinylated)
after dissociation of the protein from the sugar. FGF-2 was acetylated in absence or presence of
heparin and buffer-exchangedas described before. Both the samples were then biotinylated as in
step 3 of the protect and label strategy. Native and fully-biotinylated FGF-2 (same conditions as
above, but without prior acetylation) were used as negative and positive controls, respectively.
Biotinylated proteins were identified by western blot. Confirming the result shown in Figure
2.7, the acetylation conditions chosen guaranteed a high level of protection against further
biotinylation [Fig. 2.9 sample 3]. A weak backgroundsignal was still detectable, as in Figure
2.7, but the biotinylation level was drastically reduced compared to control (sample 2) [Fig.
2.9]. However, the presence of heparin during the acetylation step prevented the modification of
specific residues that can, therefore, be biotinylated after dissociation from the sugar [Fig. 2.9
sample 4].
In conclusion, I) heparin caneffectively prevent the modification of residues in a protein that
are crucial for its binding to the polysaccharide [Fig. 2.8 sample 3], II) further exposure to NHS-
biotin after dissociation of the protein from the sugar can abolish the retained heparin-binding
activity [Fig. 2.8 sample 4], II) the residues that remained unmodified during acetylation in
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Figure 2.9: Labelling of lysines protected by heparin/HS: FGF-2 western blot. Samples were separated on
a 15 % (w/v) polyacrylamide-SDS gel. Proteins were transferred onto nitrocellulose membrane. Biotinylated
proteins were revealed with Strep-Tactin-HRP (1:7,500). 1) FGF-2. 2) FGF-2. 3) Acetylated FGF-2 (protein
was incubated with sulfo-NHS-acetate at a final concentration of 50 mM for 5 minutes at room temperature).
4) FGF-2 acetylated in presence of heparin (see Section 2.2: Protect and label strategy step 1-2). All samples
were buffer exchanged into PB150 by gel filtration chromatography. Samples 2-4 were then biotinylated with
NHS-biotin at a final concentration of 10 mMfor 30 minutes at room temperature.
the presence of heparin can beeffectively biotinylated [Fig. 2.9 sample 4]. Thus, the application
of the protect and label strategy (step 1-3) allows the specific labelling of lysines crucial for
heparin binding, which, by definition, represent the HBS. Therefore, the identification of labelled
peptides obtained by enzymatic digestion of the protect and label strategy product should allow
the mapping of the region of the protein involved in the interaction with the sugar.
2.4.3 Identification of labelled peptides
The last step in the implementation of the method was the optimisation of a high efficiency
protocol for the purification andidentification of labelled peptides derived from the enzymatic
digestion of the product of the protect and label strategy. An efficient recovery of labelled
peptides, together with the high sensitivity of MS techniques used for the identification are
indeed fundamental to limit the amount of starting material required.
In thelast two decadesthehighaffinity interaction (Kd = 10~!° M) between biotin (vitamin
H) and egg white avidin or streptavidin has been engineered into a number of tools exten-
sively used by molecular biologists and biochemists [118-123]. Among these, the use of affinity
chromatography for the purification of biotinylated biomolecules becamepossible thanksto de-
velopment of avidin/streptavidin conjugated chromatographic resins and biotinylating agents
such as NHS-biotin [124]. The high affinity of the avidin/biotin interaction allows the use of
stringent conditions. At the same time, however, it limits the yield of recovery achievable,
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especially when a mild elution buffer is used in order to retain biological activity.
Initial experiments using a monomeric avidin affinity resin, specifically designedto facilitate
the release of biotinylated molecules, were unfruitful, as recovery of biotinylated peptides did
not exceed 10 % of the input (data not shown). Following a series of pathfinding experiments
with streptavidin, Strep-Tactin'™ Sepharose wasidentified as the best affinity capture support.
A panel of clution buffers was then compared in a model experimental setting to maximise the
efficiencyof recovery of biotinylated peptide. This was designed to be as close as possible to the
protect and label strategy setting, where biotinylated peptides of different lengths and amino acid
composition, possibly containing multiple biotins per peptide, are mixed with non-biotinylated
peptides. For this reason, a fully biotinylated FGF-2 (obtained as previously described) was en-
TMynini-column (see Sectionzymatically digested and applied to a pre-equilibrated Strep-Tactin
2.2: Protect and label strategy step 4-5). Biotinylated peptides were recovered using different
elution buffers. Loaded, unbound and eluted samples were analysed by RP-HPLC [Fig. 2.10
A]. The yield of recovery (r) was estimated as a fraction of bound material via the integration
of each chromatogram and using the formula:
r=e/(I-ft)
where r = yield of recovery, e = total area of eluted fractions, | = total area of loaded sample,
ft = total area of unboundfraction.
Elution buffers commonly used include solutions of competitors such as free biotin or its
derivatives (e.g., desthiobiotin) and mildly acid solutions (e.g., 10 % (v/v) acetic acid; 0.1
M glycine, pH 2.8). Being quite gentle, these are the general buffers of choice, despite their
low yield of recovery, when the characteristics of the sample might be altered by a change
in its conformation. In the case of peptide purification, however, stronger conditions can be
considered, since the solution conformation of the sample is not a primary concern. For this
reason, different combinations of extreme of pH, chaotropic agent, solvent and competitor were
evaluated with the method described above. As summarised in Figure 2.10 B, the peptide
recovery was enhanced by increasing the concentration of both acid (TFA) and solvent (ACN),
up to the point where water was excluded from the buffer (80% ACN, 20% TFA). Further
improvement derived from the addition to the elution buffer of a large excess of competitor (5
mM biotin). During the analysis, emphasis was given not only to the total yield of recovery, but
also to its homogeneity along the chromatogram. Thus, the main differences between buffers
were in fact mainly observed in peptides eluting late during RP-HPLC, whose recovery was
 
37
A new method for the identification of heparin-binding sites
 
 
1.8x105 —L— Et— E2
= 1.4x10° — &
 6x104
OD
21
4n
m
(u
AU
  wtFSa
2x104    
 
Retention time (min)
=
_
° @
° n
Pep
tid
er
eco
ver
y(
fra
cti
on
of
bou
nd)
@
°
°
ND
o
  al
4M UREA 60% ACN 60% ACN 80% ACN 60% ACN 80% ACN
3M NaOH 0.1% TFA 10% TFA 10% TFA 10% TFA 20% TFA
5 mM biotin 5 mM biotin
Figure 2.10: Comparison of different elution buffers for the purification of biotinylated peptides. A mixture of
biotinylated and not-biotinylated peptides were obtained by enzymatic digestion of biotinylated FGF-2. Twenty
pg of FGF-2 were extensively biotinylated by incubation with 10 mM NHS-biotin in 50 mMphosphate buffer
pH 7.8 for 30 min at room temperature. After buffer exchange, the sample was digested with chymotrypsin (see
Section 2.2: Protect and label strategy step 4). Digestion mix wasdiluted 1:4 with HPLC grade water and 200 pl
were loaded onto a mini-column systemas described before (see Section 2.2: Protect and label strategy step 5) and
eluted using different elution buffers. (A) Load (L), flow through (FT) andthree sequential elutions (E1-3) were
analysed by RP-HPLC (see Section 2.2) loading proportional amounts. The chromatograms obtained with 80%
ACN,20% (v/v) TFA, 5 mM biotin as elution buffer are shown as example. (B) Chromatograms were analysed
using 32 Karat™software (Beckman Coulter). Biotinylated peptide recovery was estimated for each condition
using the formula r=e/(I-ft, where r= recovery expressed as a fraction of bound material, e= total area of eluted
fractions, |= total area of loaded sample, ft= total area of unboundfraction. Someregions of the chromatograms
were excluded from the analysis due to the presence of extra peaks deriving from the buffer (marked with stars
in A). All the experiments were repeatedat least three times, average values + SD are shown.
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Figure 2.11: Fragment ion spectrum of a biotinylated peptide generated by the protect and label strategy.The
MS/MSspectrum of a biotinylated peptide derived from PTN is shown. The spectrum has been recorded in
a MALDI-Q-TOFinstrument as described in Section 2.2. The assigned peptide sequence is reported and the
fragment ions are annotated. Greencircles highlight the ions corresponding to Lys(biotin)-NH3 (m/z: 310.18)
and biotin (m/z: 227.11).
dramatically enhanced by an increase in solvent concentration and the presence of competitor.
We speculate that the higherefficiency obtained by the solution 80% ACN, 20% TFA, 5 mM
biotin may be the result of the combination of at least two different mechanisms. First, the
extremeacid conditionsin the presenceof solvent and the absence of water can induce a rapid and
complete unfolding of the bead-conjugated Strep-Tactin?!™. Second, the presence of competitor
can enhance the previous mechanism, especially in the case of multi-biotinylated species, by
reducing the probability of re-association of the biotinylated residues with the Strep-Tactin!™.
2.4.4 Test proteins
The protect and label strategy was then evaluated for its ability to correctly identify HBSs in
well-characterised HBPs. Two growth factors were selected as test proteins, FGF-2 and PTN.
The first is a prototypical member of the FGF family of growth factors and one of the most
studied HBPs, while the second is characterised by the presence of a TSR motif responsible
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for the interaction with the sugar [125]. PF-4 was added as an example of a chemokine that
interacts with heparin as an oligomer and which possesses a bipartite HBS [73].
Labelled peptides were identified by MS/MS in Q-TOFinstruments. Matrix-assisted laser
desorption ionisation (MALDI) was chosen as preferred ionisation source. Considering the rel-
ative low complexity of the protect and label strategy samples deriving from a single purified
protein, the MALDI platform permits fast analysis, automated selection of precursor ions and
minimal sample dilution. However, in two of the cases reported in the next paragraph the MS
data acquisition was successfully performed by direct infusion in an instrument equipped with
an electrospray ion source (ESI). This second platform should be the preferred choice in case
of analysis of more complex samples (e.g., a protein mixture), especially in combination with
an on-line chromatographic separation. Independently from the ionisation source, the ten most
intense ions for each sample were selected in the quadrupole and MS/MSdata acquired to assign
chemical modifications introduced during the protect and label strategy procedure (Figure 2.4
step 6 and 7). Furthermore, fragmentation spectra allowed an additional control on the affinity
purification of labelled peptides. A modification-specific marker ion at m/z 310.16, assigned as
deaminated Lys-biotin conjugate (Lys(biotin)-NH3), was in fact observed in all the fragmen-
tation spectra analysed [Fig. 2.11]. This is consistent with the ion at m/z 126.1 previously
described as a marker for lysine acetylation (biotin - acetyl = 184) [126] and with the presence
in most of the spectra of the ions m/z 227.08 and 84.08 corresponding to biotin and Lys-NHs3,
respectively [Fig. 2.11].
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FGF-2
The structure of FGF-2 is described as a (-trefoil, comprising a three-fold repeat of a four-
stranded antiparallel 3-sheet {129]. The primary HBS of FGF-2 has been extensively charac-
terised by different methods including site-directed mutagenesis, synthetic peptides and X-ray
crystallography [42, 76, 127, 129-131]. It consists of residues Lys-35, Asn-36 and the cluster of
basic amino acids located in the region 128-144 [42] [Table 2.3]. These residues form an ex-
tremely basic surface including strand I-strand II loop (Lys-35, Asn-36), strand X-strand XI
loop, strand XI and strand XI-XIIloop [Fig. 2.12 B].
The biotinylated peptides identified by the protect and label strategy mapped to three areas on
the protein surface [Fig. 2.12 A]. These include the previously described HBS (peptides 1, 2, 6, 7,
9 and 10), a region located in strand VI/strand VII loop (peptide 5) and the beginningof strand
I (peptides 3, 4 and 8) [Table 2.4] [Fig. 2.12]. The loop identified by peptide 5 locates to the
same surface of the sequence 115-YRSRKYSSWY-124 described by Baird and colleagues [127]
and the sequence 117-SRKYTSWYVA-126 described by Kinsella and colleagues [82] as a pos-
sible secondary HBS of mMaffinity. Residue Lys-86 and Arg-118 and Lys-119 locate in two
adjacent loops (distance Lys-86 Ca/Lys-119 Ca: 9.3 A) [Fig. 2.12 B], forming a basic patch on
the protein surface that could better describe the secondary binding site proposed with the use
of synthetic peptides [Fig. 2.12 A].
The signal derived from the protein’s N-terminus is more difficult to interpret. FGF-2’s N-
terminusis a highly disordered and mobile region [129,132]. Its involvement in heparin-binding
has been excluded by deletion mutagenesis [133], since mutants lacking 23 (N14 FGF-2) and 49
(N41 FGF-2) N-terminal aminoacids displayed unaltered affinity for heparin compared to a 146
amino acid form (FGF-2 11-157), as judged by heparin-affinity chromatography [133]. However,
this analysis is qualitative and both the mutants were lessefficient in stimulating DNA synthe-
sis in BALB/c3T3 cells when compared to FGF-2 11-157 [133], supporting a functionalrole for
these residues. Additionally, a direct interaction between N-terminal lysines and heparin was
also suggested for both FGF-1 and FGF-2 by the cross-linking experiments described before
[Figs 2.2 and 2.3}.
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Figure 2.12: Labelled peptides and heparin-binding site: FGF-2/heparin complex. (A) FGF-2 (25-153) is shown
using overlaid cartoon and surface representations (PDB:1FQ9). Heparin derived octasaccharide is shown as
sticks. (B) FGF-2 (25-153) is shown using cartoon representation only (PDB Number 1FQ9). Heparin derived
octasaccharide is shown as sticks. Previously described HBS lysines are shown in red. Lysines labelled by the
protect and label strategy are shown in green. Yellow indicates an overlap between labelled amino acids and
previously described HBSresidues. Other residues are shown in grey
43
A new method for the identification of heparin-binding sites
 
PF-4
PF-4 belongs to the CXC family of chemokines. The monomeric structure consists of a triple
stranded anti-parallel 3-sheet overlaid by a C-terminal a-helix, while the N-terminal regionis
essentially disordered [73,78]. PF-4 exists as a tetramerin solution. Dimerisation occurs through
the anti-parallel association of the first strands to form a larger J-sheet [73]. The tetramer results
from the further assembly of two dimers, mediated by contacts between N-terminal regions [73].
The HBShasbeen characterised by site-directed mutagenesis coupled to NMR spectroscopy[78]
and by molecular modelling [73]. The bindingsite consists of a ring of positively charged residues
around the surface of the tetramer formed by two pairs of lysines located within the C-terminal
a-helix (92-KKIIKK-97), two arginines from the N-terminus/strand I loop (61-RPRH-64), Lys-
77 and Arg-80 from the strand II/strand IIloop (77-KNGR-80) [73,78], and the residues Lys-62
and Thr-56 [73,78] [Table 2.3] [Fig. 2.13].
Using the protect and label strategy, peptides including biotinylated Lys-77 (peptides 11-13, 15-
17 and 20) and Lys-62 (peptide 19) were identified, in agreement with published data [Table 2.5]
[Fig. 2.13]. Lys-81 was found to be biotinylated in five cases in association with labelled Lys-77
(peptides 11-13, 15 and 16) andin onecaseasa single biotinylated peptide (peptide 18) [Table
2.5] [Fig. 2.13]. Therefore, all the lysines that are affected by major chemical shift changes
upon binding of heparin to a tetrameric form of PF-4 [78] were successfully identified by the
protect and label strategy with the exception of the twopairs of lysine located in the C-terminal
helix. The sequence 92-KKIIKK-97 was first proposed as the main HBS of PF-4 [134] and
also used for the development of a heparin-binding consensus by Cardin and Weintraub [68].
However, investigation by NMRspectroscopy and site-directed mutagenesis revealed only a
minor contribution of this region to sugar binding [78]. First, chemical shifts of residues Arg-53,
His-54, Thr-56, Lys-62 and Arg-80 were more pronounced upon heparin binding than those of C-
terminal lysines [78]. Second, substitution of all the four C-terminal lysines to alanines reduced
the affinity of the mutant PF-4 for heparin by only a factor 4, as assessed by a fluorescence
binding assay [78]. In agreement with these data, the protect and label strategy supports the
ADinterface of the PF-4 tetramer [Fig. 2.13 B] as the core of the heparin-binding region with
C-terminal lysines involved in secondary and more transitory contacts, which are unable to
ensure protection of these residues against chemical modification.
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Figure 2.13: Labelled peptides and heparin-binding site: PF-4. (A) Tetrameric PF-4 (38-101) is shown using
overlaid cartoon and surface representations (PDB Number 1F9Q). Previously described HBSlysines are shown
in red. Lysines labelled by the protect and label strategy are shown in green. Yellow indicates an overlap between
labelled amino acids and previously described HBS residues. Other residues are shown in grey. (B) Tetrameric
PF-4 is shown as in A, but in addition the HBS sequence 51-RPRH-54 of each monomeris highlighted in orange.
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PTN
PTNis a heparin-dependent growth factor characterised by the presence of two TSRmotifs. It
consists of two disorderedbasic clusters at its N- and C-terminus and two (-sheets containing
the TSRmotifs (N-TSRresidues 45-71; C-TSR residues 97-129) [97,125]. The two TSR motifs
have been proposed as possible HBSs [125], however Hamma-Kourbali and colleagues recently
demonstrated the involvement of only the C-TSRin heparin binding by using synthetic peptides
and affinity studies [97] [Table 2.3]. Theselective labelling of lysines located at the beginning
(peptides 24-28) and in the centre (peptide 30) of the C-TSR confirmed the dataindicating
the C-TSR as main HBS [Table 2.6] [Fig. 2.14]. However, the biotinylation of other residues
including Lys-81, Lys-86, Lys-92 and Lys-93 (peptides 21-23 and 28), located at the boundaries
between N-TSRand C-TSR, suggests a possible involvement of this region, not investigated
previously, in heparin binding [Table 2.6] [Fig. 2.14].
SDCGEWQWSVCVPTSGDCGLGTREG
TRTGA AECKYQFQAWGEC
DLNTALKTRTGSL“RALHNA
 
 
(Labelled lysines
MEE Literature annotated HBSlysines
(7) Overlap
[a] Otherresidues   
Figure 2.14: Labelled peptides and heparin-binding site: PTN. Primary structure of PTN (1-167). Previously described
HBSlysines are shownin red. Lysines labelled by the protect and label strategy are shownin green. Yellow indicates an
overlap betweenlabelled aminoacids and previously described HBSresidues. Other residues are shown ingrey.
In summary, the examples cited above indicate that the protect and label strategy provides
a useful tool for the localisation of HBSs in heparin-binding proteins. The method displayed
a good sensitivity for the detection of heparin-binding surfaces, together with a goodlevel of
specificity, despite the high lysine content of the proteins tested (14 for FGF-2, 8 for PF-4 and 28
for PTN), with the possible exception of the highly flexible N-terminal region of FGF-2. Tandem
mass spectrometry and partially manually curated data interpretation performed with the Pro-
tein Prospector package (see Section 2.2) allowed the assignment of labelled residues in 28 of the
30 peptides selected for the three samples analysed, despite the complex patterns of modifica-
tion observed. MS/MSspectra interpretation allowedthe identification of peptides derived from
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non-specific cleavage (e.g., peptide 4 of FGF-2) or other chemical modifications (e.g., deamina-
tion, peptide 1 of FGF-2; sodium adduct, peptide 9 of FGF-2). The unsuccessful assignment of
peptides was in both cases a consequenceof poorsignal to noise ratio in the MS/MSspectrum.
Only in the case of the ion at m/z 1371.71 (FGF-2, peptide 5) was a double assignment nec-
essary. Fragments ions derived from both the isobaric peptides 83-LAMK(biotin)EDGRLL-92
(MH-+1 monoisotopic mass: 1371.7123) and 27-K(biotin)DPK(biotin)RLY-33 (MH+1 monoiso-
topic mass: 1371.6912) were in fact assigned in the MS/MSspectrum.
The inability to identify regions involved in the sugar binding that do not contain lysines
(e.g., the 51-RPRH-54 region of PF-4, Figure 2.13 B) emerged as the main limitation of the new
technique.
2.5 Protect and label strategy: application
One of the main advantages of the protect and label strategy procedure is the possibility to
rapidly obtain information on heparin-binding surfaces with a minimal requirement of starting
material. It is, therefore, a powerful technique to perform comparative studies between, for
example, different HBPs belonging to the same family. The human FGF family includes 22
members, 17 of which have been proved to possess heparin-binding activity [Fig. 2.15]. Dif
ferent members are characterised by differences in their expression in time and space, receptor
specificity and heparin-bindingactivity [58,99]. The combinatorial space for the regulation of
FGFs’activities is further expanded by other mechanisms, such as alternative splicing of both
ligand and receptor and post-translation modifications that drammatically affect binding speci-
ficities [135,136]. Through these mechanisms the FGFsignalling system has evolved an extreme
functional diversity responsible for its involvement in many developmental and physiological
processes.
Here, three divergent members of the FGF family were analysed by the protect and label
strategy. The biotinylated residues were then mapped on the 3D structures available for FGF-1
and FGF-2, and modelled in this study for FGF-18, to compare conservation and variation of
heparin-binding surfaces. FGF-1 and FGF-2 are the most studied members of the FGF family
and they form together the FGF-1 sub-family [Fig. 2.15], however these two proteins show
different chemical-physical and structural features despite their sequence similarity [87, 132]
[Table 2.3]. FGF-18 is less well characterised and it belongs to the phylogenetically distant
FGF-8 sub-family [Fig. 2.15).
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Figure 2.15: Phylogenetic tree of the human FGF family. The sequencesof 17 human FGFsthat display heparin-
binding activity were aligned using the phylogenetic reconstruction by automatic likelihood modelselector (PALM,
http: //palm.iis.sinica.edu.tw/index.html). The proteins compared by protect and label strategy in this study are
highlighted in red.
The labelled residues identified by the protect and label strategy are summarised in [Fig.
2.16]. According to their alignment four main clusters of biotinylated lysine can be defined
[Figs 2.16 and 2.17]. In all three proteins, the region comprising the loop between strand X
and XI, strand XI and the loop between strand XI and XII (cluster 4) was labelled during
the protect and label strategy procedure. This region was identified as the primary HBS of
FGF-1 and FGF-2 and predicted by multiple sequence alignment in the case of FGF-18 [Table
2.3]. These data are the first experimental evidence of the conservation of the primary HBS
in FGF-18. A second cluster located in the strand I-strand II loop (cluster 2) was common
between FGF-2 and FGF-18. This loop was also identified as part of the main HBS of FGF-2
[Table 2.3]. In the modelled structure of FGF-18 this loop is adjacent to the primary HBS
and the orientation of the side chain of Lys-65 is compatible with its involvement in extending
the main heparin-binding surface [Fig. 2.17]. It must be emphasised that the corresponding
region in FGF-1 does not contain a lysine residue and, therefore, it cannot be detected by the
protect and label strategy. However, also in this case the strand I-strand II loop has a direct
role in the interaction with the sugar mediated by the side-chain of Asn-33 [86]. The main
divergence between the closely related FGF-1 and FGF-2 and the more evolutionary distant
FGF-18 is represented by cluster 1 located in strand I. This cluster is part of a sequence of
high similarity between FGF-1 and FGF-2 whichis characterised by a high proline content and
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Figure 2.16: Localisation of biotinylated lysines on the aligned sequences of FGF-1, -2 and -18. The sequences
of FGF-1, -2 and -18 were aligned using ClustalW2 [106]. Secondary structure predictions were performed using
JalView and its plugin JNet [107]; predicted @-sheets are shown as green arrows and a-helices as red cylinders.
The G-sheets of FGF-2 are numbered according to [132].The residues assigned as biotinylated by the protect and
label strategy are highlighted in green and grouped in four main clusters (boxed) according to their alignment.
its basicity (consensus: PPG**K*PK). This sequence is not conserved in FGF-18 [Fig. 2.16]
nor in any other member of the FGF family and it appears to be a prerogative of the FGF-1
subfamily. The protect and label strategy data suggest that these residues create a secondary
binding site on the surface opposite to the canonical one [Fig. 2.17]. This hypothesis is also
supported by the results obtained by the cross-linking experiment described earlier [Figs 2.2
and 2.3]. Finally, cluster 3, located in strand VI-strand VII loop, was labelled in both FGF-2
and FGF-18. However, a detailed structural comparison revealed a possible divergent role for
the lysine residue located in this loop between the two growth factors. Structural alignment
between the FGF-2 crystal structure and the modelled FGF-18 revealed an overall conservation
of the protein folding (RMSD: 1.4 A). Also in the case of strand VI-strand VII loop the protein
backbones were highly superimposed. However, the shift of the position of the lysine residue
located in this loop seems to inducea rotation of the side chain orientation of approximatively
90° between the two structures [Fig. 2.18]. Thus, assuming the correctness of the modeled
structure, the side chain of Lys-114 in FGF-18 appears to point in the direction of the main
HBSandit is likely to be part of this site (cyan in Fig. 2.18). Contrary, Lys-86 of FGF-2 is
oriented perpendicularly to the canonical HBS (green in Fig. 2.18) and is more likely to form a
secondary binding site as discussed in the previous paragraph.
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CLUSTER3        CLUSTER1
90°
CLUSTER 4 CLUSTER1 CLUSTER4
pater (main HBS) —
(main HBS)  
Figure 2.17: Comparison of surface potentials andlabelled clusters for FGF-1, -2 and -18. The surface electro-
static potentials of FGF-1 in complex with a heparin derived hexasaccharide (PDB: 2AXM), FGF-2 in complex
with a heparin derived decasaccharide and FGF-18 (modelled in this study, see Section 2.2) are shown. For
clarity, charge potentials are coloureddifferently for the three structures according to the legend. Heparin derived
oligosaccharides are shownas sticks using grey colour. Clusters of lysines labelled by protect and label strategy
as defined in [Fig. 2.16] are indicated by green arrows. Theelectrostatic potentials were calculated using the
APBSplugin for MacPyMOL.
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Figure 2.18: Different structural arrangement of biotinylated cluster 3 in FGF-2 and FGF-18. The superimposed
Catraces of FGF-2 (PDB:1BFF) and FGF-18 (modelled in this study, see Section 2.2) are shownin green and
cyan respectively. The main HBS is shownin yellow for FGF-2 and in red for FGF-18. Lys-86 (FGF-2) and
Lys-114 (FGF-18) are shownas spheres in CPK colours. Carbon atoms are shownin green for FGF-2 and cyan
for FGF-18. Structural comparison was performed using the DaliLite tool [105].
To summarise, three mechanismsof structural variation of HBSs among homologous proteins
have been described here. i) In the caseof cluster 2 the sameloop is involved in the formation
of the main HBSinthe three proteins, despite variations at the sequencelevel. ii) For cluster 3
the sameloop participates in heparin binding in both FGF-2 and FGF-18, however, despite a
conserved backbone topology, variation in side chain orientation seems to bring alysine residue
to extend the primary binding site in one case (FGF-18) and to form a potential secondary
binding site in another (FGF-2). This observation, derived from the structural alignment of
FGF-2 and the modelled FGF-18, will need to be confirmed whenthe structure of FGF-18 will
be resolved at high resolution. iii) Finally, the secondarybindingsite identified by cluster 1 has
emerged as a prerogative of FGF-1 and FGF-2 and represents an important divergent feature
from FGF-18 and all the other members of the FGF family.
In conclusion these and other data [60,137] add afurther plausible mechanismfor the gen-
eration of functional diversity in the FGF system. Structural variations of HBSs introduced
by gene duplication and divergence can varyaffinity andspecificity for HS, therefore affecting
localisation [138], diffusion of the molecule through the extracellular space and formation of
growth factor gradients [137], and the assembly of active signalling complexes [139]. For ex-
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ample Allen and Rapraeger compared the ability of FGF-1 and FGF-8b (a homologueclosely
related to FGF-18) to form ternary complexes in combination with different receptors in situ on
sections of mouse embryos [60]. FGF-FGFR pairs displayed unique HSspecificites resulting in
a differential spatial-temporal regulation of complex assembly driven by drastic changes in HS
expression during embryonic development [60]. More recently, Mohammadi and collaborators
demonstrated that it is possible to convert FGF-10into a functional mimic of FGF-7 by a single
point mutation in its HBS. FGF-10 and FGF-7differ in fact in their affinities/specificities for
HS.This results in the formation ofdifferent gradients responsible for the different activities of
these growth factors during branching morphogenesis [137].
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Chapter 3
An affinity proteomic approach for
the identification of heparin-binding
proteins
3.1 Overview
A major challenge for the post-genomic era is to establish functional and structural relation-
ships between the componentsofbiological systems. In the last decade, the developmentof high
throughput methods for the study of genetic interactions [140] and PPIs [141-143] has enabled
the collection of large datasets describing binary relationships between primary gene products.
These constitute the vast majority of interaction data currently available. The chemical com-
plexity of secondary gene products, such as glycans and lipids, and the technical challenges
associated with the study of their interactions has generated a gap in our current models of
interaction networks. In this chapter, an affinity proteomic approachfor the identification of
interactors of heparin/HSis described.
Previously, two publications by Middaugh’s group described the investigation of the interac-
tions of a series of polyanions, including heparin and HS, at a proteomic level. In a first paper,
they used 2-D gel electrophoresis to estimate that several hundred proteins from a cell lysate
of COS-7 cells are able to bind to heparin beads and theyidentified 29 of these by antibody
microarrays [51]. In a subsequent work they interrogated yeast protein arrays using biotiny-
lated heparin and HS andidentified 264 and 348 binding partners, respectively (144]. Affinity
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proteomic strategies have been also applied to identification of GAG-binding proteins from
serum [145] and seminal plasma [146]. In this study a strategy for the identification of HBPs
from plasma membraneenrichedfractions isolated from rat livers was devised. This choice was
purely driven by the aim of targeting the predominant sub-cellular compartment of HSPGsin
order to be able to contextualise the observed interactions with the probability of co-localisation
between protein and HS. Therefore, a plasma membraneenriched fraction was obtained from rat
liver microsomes by flotation on a sucrose gradient. After solubilisation, the plasma membrane
proteome wasfractionated by heparin-affinity chromatography. Low-, medium- and high-affinity
sub-proteomes, as defined by the ionic-strength tolerated for their binding to a heparin column,
were separated using a three step gradient. Samples were then processed using a filter-aided
sample preparation (FASP) procedure [147] and analysed by MSin a LTQ-Orbitrap instrument.
A bioinformatic pipeline was used to filter the database search outputs in order to extrapolate
sets of proteins that localise on the cell surface or in the extracellular space and are therefore
morelikely to represent potential HBPs.
3.2 Materials and methods
3.2.1 Preparation of a plasma membraneenriched fraction
All the following procedures were performed on ice or at 4°C. Female rat livers were minced
and homogenised with buffer H (10 mMHepes pH 7.5, 5 mM MgClo, 25 mM KCl, 0.25 M su-
crose supplemented with Complete!™protease inhibitors cocktail (Roche Products Ltd, Welwyn
Garden City, UK)) using a 30 ml Potter-Elvehjem homogeniser (10-12 strokes). The microso-
mal fraction was isolated by sequential steps of centrifugation, essentially as described in {148}.
Briefly, the homogenate was centrifuged for 20 min at 1,000 x gina Sorvall™centrifuge (SS-34
rotor) (DuPont UK, Stevenage, UK). The pellet was resuspended with buffer H, homogenised
and centrifuged as above. The two supernatants were combined (S1) and centrifuged for 20 min
at 25,000 x g. The supernatant was transferred to a fresh tube and the centrifugation repeated.
Thefinal supernatant (S2) was centrifuged for 45 min at 135,000 x g in a Sorvall Ultra Pro 80
ultracentrifuge (T.865.1 rotor). Thefinal pellet (microsomalpellet) was washed with 10 ml of
buffer H (W) andcentrifuged as above.
Plasma membraneenriched fractions were isolated by flotation of the microsomal pellet on a su-
crose gradient as described in [149]. The pellet was resuspended by homogenisation in a Dounce
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homogeniser (5 ml) with 4 ml of 1.55 M sucrose in buffer H and transferred to a swing-bucket
ultracentrifuge tube and then overlaid with 2.5 ml of 1.33 M, 2 ml of 1.2 M, 2 ml of 1.1 M, 1 ml
of 0.77 M and 1 mlof 0.25 M sucrose in buffer H. The gradient was formed by centrifugation
for 16 h at 116,000 x g in a Sorvall Ultra Pro 80 ultracentrifuge (AH-629 rotor).
Fractions were collected by pumping Maxydens!™(Nycomed Pharma AS, Oslo, Norway) into
the bottom of the tube using a peristaltic pump and collecting 1 ml fractions (F1-F12) from
the top layer. The first and last fractions were discarded and the remaining (F2-F11) were
diluted four times with buffer H and centrifuged for 45 min at 135,000 x g. The pellets ob-
tained from this (P2-P11) were washed with 5 ml buffer H and then resuspended with 400 pl
of 2 % (v/v) Triton X-100 (Sigma Aldrich Ltd) in PBS using a Dounce homogeniser (1 ml).
Protein concentration was meaured by the Bradford protein assay (Bio-Rad Laboratories Ltd)
on 1:20 dilutions of the resuspended pellets (final Triton X-100 concentration: 0.1 % (v/v)).
Equal amounts of resuspended P2-P11 were analysed by SDS-PAGEandby western blot, using
a polyclonal anti-caveolinl antibody (Santa Cruz Biotechnology Inc., Heidelberg, Germany).
After gel electrophoresis, samples were transferred to Hybond™nitrocellulose membrane (GE
Healthcare Life Sciences) using a wet system (Mini Trans-Blot Cell, Bio-Rad Laboratories Ltd)
for 1 h at 100 V. Membranes were blocked with TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.5)
supplemented with 10 % (w/v) skimmed milk powderfor 1 h at room temperature. The mem-
branes were then incubated in TBST-1 % milk (TBS supplemented with 0.1 % (v/v) Tween 20
(TBST) and 1 % (w/v) skimmed milk powder) with anti-caveolinl antibody (1:200) overnight
at 4 °C. After three washes of 20 min with TBST, the membranes were incubated in TBST-5
% milk (TBST supplemented with 5 % (w/v) skimmed milk powder) with anti-rabbit-HRP
secondary antibody (Sigma Aldrich Ltd) (1:5,000) for 1 h at room temperature. After at least
three washes of 20 min with TBST, the membranes were developed using the SuperSignal West
Pico Chemiluminescent substrate (Pierce).
3.2.2 Heparin affinity chromatography
Membranepellets P2-P4 were selected according to their sedimentation profile and caveolin-1
signal intensity. Isolation of HBPs and their separation into three fractions (high affinity (H),
medium affinity (M) and low affinity (L)) was achieved using a reverse three step gradient on a
heparin column.
Step 1: resuspended pellets were pooled, adjusted to 0.6 M NaCl and 1 % (v/v) Triton X-100
 
57
An affinity proteomic approach for the identification of heparin-binding proteins
 
and centrifuged for 5 min at 4,000 x g. The supernatant containing 7 mg of protein was
applied to a 1 ml Hi-Trap™ heparin column (GE Healthcare Life Sciences) equilibrated
with buffer WH (0.6 M NaCl, 13.7 mM Na2HPOg, 6.3 mM NaH2POu, 0.1 % (v/v) Triton X-
100, pH 7.2) using an AKTA™HPLCsystem. After loading, the column was extensively
washed with buffer WH until the absorbance at 280 nm reached the baseline. Bound
proteins (fraction H) were then eluted with a 1 column volume of buffer E (2 M NaCl,
13.7 mM NagHPOsg, 6.3 mM NaH2POg, 0.1 % (v/v) Triton X-100, pH 7.2).
Step 2: the unboundfraction from step 1 was then diluted to 0.4 M NaCl using phosphate
buffer (13.7 mM NagHPO,, 6.3 mM NaH2POq, pH 7.2) and reapplied to the heparin
column equilibrated in buffer WM (0.4 M NaCl, 13.7 mM NagHPOsg, 6.3 mM NaH)POg,
0.1 % (v/v) Triton X-100, pH 7.2). After extensive washing with buffer WM, bound
proteins (fraction M) were eluted, as described above.
Step 3: the unboundfraction from step 2 was diluted to 0.15 M NaCl using phosphate buffer,
reapplied to the heparin column equilibrated in buffer WL (0.15 M NaCl, 13.7 mM
Na2HPO,, 6.3 mM NaH»POg, 0.1 % (v/v) Triton X-100, pH 7.2) and eluted (fraction
L) after extensive washing, as previously described.
Protein concentration was measured by the Bradford protein assay. The protein concentration
of the final unboundfraction was too low to be measured by these means and therefore it was
estimated from the difference between loaded and eluted (H+M+L) material, assuming minimal
sample loss during the washsteps.
3.2.3. Sample preparation for MS
The heparin-chromatographyfractions were processed accordingto thefilter-aided sample prepa-
ration (FASP)described in [147], with slight modifications. In this procedure a spin filter is used
as a mini-reactor to perform sample concentration, detergent removal, cysteine alkylation and
protein digestion. Concisely, 200 pg of each fraction was concentrated on a NanoSep!™ cen-
trifugal ultrafiltration device, 10 kDa molecular weight cut-off (PALL Corp., Portsmouth, Hants,
UK), for 5 min at 14,000 x g, 20°C. The volume remaining in the filter was diluted with 300 pl
buffer U (8 M urea, 200 mM NH4HCOs,pH 7.8) and centrifuged for 10 min at 14,000 x g, 20°C.
This step was repeated 3 times. Proteins were carbamidomethylated with 100 yl freshly made
0.1 M iodoacetamide in buffer U for 10 min at room temperature in the dark. Iodoacetamide
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was removed by centrifugation for 10 min at 14,000 x g, 20°C and two washes with 100 pl buffer
U. The remaining volume (approximatively 50 jl) was diluted four times with HPLC grade wa-
ter and digestion was performed overnight at room temperature with 2 ug of sequencing grade
trypsin (Promega UK, Southampton, UK). Digested peptides were recovered by centrifugation
for 30 min at 14,000 x g, 20°C and a wash ofthefilter with 50 yl 0.5 M NaCl. The sample
was then desalted with an in-house made C18 mini-column, concentrated by centrifugal evapo-
ration and finally resuspended with 0.1 % (v/v) TFA, 5 % (v/v) ACN in HPLC grade water.
Peptide concentration was assessed by absorbance at 280 nm assuming an extinction coefficient
of 1.1 absorbance units for a 0.1 % (w/v) solution of vertebrate proteins (corresponding to a
concentration of 1 mg/ml) [147].
3.2.4 Mass spectrometry data acquisition and analysis
Up to 10 jg of peptide from eachfraction was analysed by nanoLC-MS/MSusing a nanoAcquity!™
UPLCsystem (Waters Corporation) connected online to a LTQ-Orbitrap XL instrument (Thermo
Fisher Scientific UK, Hemel Hempstead, UK). Peptides were separated on a BEH300 C18 (75
ym x 250 mm, 1.7 ym) nanoAcquity UPLC column (Waters Corporation) using a 65 min linear
gradient (0-36 % (v/v) ACN in 0.1 % TFA). Data acquisition was performed using a TOP-10
strategy where survey MSscans were acquired in the orbitrap (R. = 60,000) and up to 10 of the
most abundant ionsperfull scan were fragmented and analysed in the LTQ. Rawfiles were pro-
cessed using the Protein Discoverer software v.1.0 (Thermo Fisher Scientific UK) and generated
peak lists were searched against the SwissProt rat database release 57.5 using the Mascoten-
gine. The following parameters were applied: digest = trypsin; max missed cleavages = 2; fixed
modification = carbamidomethyl (Cys); variable modifications: oxidation (Met), pyroglutamic
acid and deamidated (Asn, Gln); parental ion tolerance = 7 ppm; fragment ion tolerance = 0.6
Da. Thesignificance threshold was set at p < 0.01.
3.2.5 Bioinformatics
The UniProt accession numbers for hits above significance threshold were extracted from the
Mascot outputfiles. Gene ontology (GO) terms [150] for cellular components were extracted
from the UniProtKB database release 15.11 [151] using the biomaRt package of the Bioconductor
software based on R [152]. Extracellular proteins were selected on the basis of an inclusion list
containing terms associated with the extracellular space and the plasma membrane and an
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exclusion list containing the main intracellular compartments [Table 3.1]. In parallel, proteins
were assigned to a cellular compartment using the software Ingenuity Pathway Analysis v.7
(Ingenuity Systems Inc., Redwood City, USA). The hits with annotation “Extracellular Space”or
“Plasma Membrane” were selected. Finally, the outputs of two approaches were merged and
manually curated to check for the presence of an extracellular portion in each selected protein
using the UniProtKB annotation. The humanorthologues of the selected proteins were assigned
using the Inparanoid v.7 orthology database [153].
3.3. Heparin affinity chromatography of a plasma membrane en-
riched fraction extracted from rat liver
A classic biochemical approach was employed for the isolation of a plasma membrane enriched
fraction from rat liver homogenate [Fig. 3.1 A]. Thus, differential centrifugation was applied
to separate the microsomal fraction (typically containing plasma membranevesicles, endoplas-
mic reticulum, Golgi membranes and mitochondrial outer membrane) from other organelles
and cytosol [148] [Fig. 3.1 B]. Resuspended microsomes were then separated by flotation on
a continuous sucrose gradient (0.77-1.55 M). The gradient was harvested into 12 fractions and
the distribution of a plasma membrane marker (caveolin-1) [154] was assessed by western blot
[Fig. 3.1 C]. As expected, the caveolin-1 content was inversely correlated with the equilibrium
density of the fractions. Plasma membranes are in fact known to possess lower density than
other microsomal membranesand they typically sediment as a light fraction in sucrose gradients.
Therefore, the three most intense fractions corresponding to the top of the gradient were pooled
and selected as plasma membraneenriched fraction (PM). After solubilisation by a non-ionic de-
tergent, PM was subject to heparin-affinity chromatography to isolate HBPs. In order to reduce
the sample complexity and obtain qualitative information about the affinity of the interaction
a reverse three step gradient was chosen[Fig. 3.2 A]. With this strategy the PM proteome was
fractionated on the basis of the maximum electrolyte concentration required to retain the sugar
binding capacity. Therefore, PM was adjusted to a concentration of 0.6 M NaCl, applied to
the heparin columnand the retained proteins were eluted, after extensive washing, with a short
gradient to 2 M NaCl(highaffinity fraction (H)). The unbound material was diluted to 0.4 M
NaCl and re-applied to the column to separate a medium affinity fraction (M). Finally, a low
affinity fraction (L) was obtained after further dilution of the second unbound material to a
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Figure 3.1: Preparation of a plasma membrane enriched fraction from rat liver. (A) Schematic diagram of
the procedure used for the extraction of a plasma membraneenriched fraction from rat liver. (B) Coomassie
stained SDS-PAGEgel of samples obtained during the rat liver homogenate fractionation by sequential steps of
centrifugation. S1 = post-nuclear supernatant; S2 = post-mitochondrial supernatant; Nu = nuclear pellet; Mt
= mitochondrial pellet; C = cytosol (post-microsomal supernatant); W = wash of the microsomalpellet; Mc =
microsomal pellet. (C) SDS-PAGEand western blot analysis of 10 fractions (F2-F11) from the microsomalpellet
after flotation on a sucrose gradient (0.77-1.55 M). Fractions are ordered according to their equilibrium density
from light (left) to heavy (right). The enrichment of plasma membrane was assessed by western blot using an
antibody specific for the plasma membrane marker caveolin-1 (CAV-1).
quasi-physiological electrolyte concentration (0.15 M NaCl). The distributionof protein content
across the three heparin-binding and final unbound fractions showed that more than a third of
the PM proteome was able to bind the columnat physiological ionic strength or higher [Fig. 3.2
Bj.
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Figure 3.2: Heparin affinity chromatography and protein identification by shot-gun mass spectrometry. (A)
Schematic diagram of the work-flow for the isolation of HBPs from a plasma membraneenriched fraction and their
identification by MS/MS.(B) Distribution of protcin content between the three heparin binding and the unbound
fractions. For protein quantification procedure see Section 3.2. (C) Venn diagramindicating the distribution of
the 277 proteins identified across the three samples analysed. ‘The percentage of the total number of proteins
belonging to each groupis indicated.
3.4 Protein identification by shot-gun mass spectrometry and
data filtering
The three heparin-binding fractions were then processed using a procedure namedfilter-aided
sample preparation (FASP). This method combinestheefficient removal of detergent and other
contaminants typical of gel-based protocols with the advantages of in-solution digestion. It has
been successfully applied to the analysis of a mouseliver fraction enriched in mitochondria, dis-
playing better sequence coverage for membrane proteins than the standard in-solution digestion
method [147]. Confirming these data, the FASP procedure allowed an average digestion effi-
ciency of 37 % (ratio between recovered peptides’ mass and starting amount of protein), despite
the challenging nature of a sample being highly enriched in membraneproteins.
The desalted peptides were identified by LC-MS/MS on a LTQ-Orbitrap XL instrument. In
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ID Name
Inclusion list
GO:0005576 extracellular region
GO:0005604 basement membrane
GO:0005615 extracellular space
GO:0005624 membranefraction
GO:0005886 plasma membrane
GO:0009986 cell surface
GO:0016020 membrane
GO:0016021 integral to membrane
GO:0044421 extracellular region part
GO:0045121 membraneraft
Exclusion list
GO:0005622 intracellular
GO:0005737 cytoplasm
GO:0005739 mitochondrion
GO:0005741 mitochondrial outer membrane
GO:0005783 endoplasmic reticulum
GO:0005789 endoplasmic reticulum membrane
GO:0005829 cytosol
GO:0005856 cytoskeleton
GO:0031227 intrinsic to endoplasmic reticulum membrane
 
Table 3.1: Gene ontology terms used to select cell-surface and extracellular proteins.
a single run a total of 277 proteins were identified using a stringent significance threshold (p
< 0.01). The Venn diagram in [Fig. 3.2 C] shows the distribution of the protein hits across
the three samples analysed. Approximately a third of the proteins were identified inall three
fractions. This result was unexpected, since the chromatographic procedure was designed to
maximise the separation between the fractions. In particular, since the total protein content of
each fraction (ranging from 189 yg for H fraction to 1.5 mg from L fraction) was significantly
lower than the column capacity (estimated by the manufacturer at 4 mg of ATTII), the pos-
sibility of cross-contamination due to column saturation was excluded. Moreover, the reverse
chromatography procedure used, where fractions are not separated by elution, but by applying
stepwise less stringent loading conditions, should minimise phenomena of carry-over between
fractions. Therefore, being independentof the ionic strength of the binding solution,it is likely
that the affinity of this set of proteins for the chromatographic material derives from interactions
of non-electrostatic nature either with heparin or with the chromatographic support (agarose).
Next, a bioinformatic pipeline was used to select cell surface and extracellular proteins from
the set of identified hits [Fig. 3.3]. In order to maximise coverage and circumvent possible
incorrect annotations, a combination of two data filtering procedures based on independent
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Figure 3.3: Data filtering and identification of extracellular heparin-binding proteins. (A) Schematic diagram
of the bioinformatic pipeline used to extract cell surface and extracellular proteins from the MS-identified hits.
(B) Distribution of structural categories between the selected extracellular proteins (see Table 3.2).
repositories was applied. Gene ontology (GO) terms [150] associated with the identified proteins
were used to select hits on the basis of an inclusion list composed of cell component terms related
to extracellular space and plasma membraneandanexclusionlist including terms associated with
intracellular compartments (e.g. cytoplasm, endoplasmic reticulum, mitochondria) [Table 3.1].
As a parallel approach, the commercial package Ingenuity Pathway Analysis software was also
used to assign sub-cellular localisations, since it relies on a proprietary high-quality knowledge
base different from the one used by the GO consortium. Finally, the proteins selected by the
two methods were merged and manually filtered using information on sub-cellular localisation
retrieved from the UniProtKB database [151] using the following selection criteria: described
or predicted localisation in the plasma membrane or extracellular space and presence of an
extracellular portion. Manual curation was necessary to remove proteins associated with the
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internal lumen of the plasma membrane that are annotated as plasma membraneproteins but
do not possess an extracellular moiety.
A total of 62 proteins satisfying the criteria stated above were identified of which 12 (19 %)
were previously described HBPs or memberof a family that contains previously described HBP
[Table 3.2]. The set contained an equal distribution of secreted, multipass-transmembrane and
single-pass transmembrane proteins [Fig. 3.3], further confirming the efficiency of the imple-
mented protocol for the analysis of membrane proteins. Finally, it has to be noted that, like
in any other pull-down strategy, the interactions described do not necessarily indicate a direct
association of the identified protein with heparin, since they can betheresult of a co-purification
of a protein complex where only one componentis responsible for the interaction with the sugar.
Therefore, further experiments using purified components and/or protect and label identifica-
tion of HBSsin the protein mixture are required in order to assign accurate binary interactions.
However, it can be speculated that the chromatography procedure described here minimises the
isolation of protein complexes by using a reverse gradient where proteins are selected on the ba-
sis of their ability to bind to heparin in the presence of decreasingly stringent buffer conditions
(ie. NaCl concentration). This should reduce the association of proteins in complexes, at least
in the cases where protein-protein interactions are mediated by electrostatic forces.
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3.5 Discussion
The approachdescribedis thefirst affinity proteomic analysis undertaken for the identification
of HBPsfrom the plasma membrane sub-proteome. Two main reasons drove the design of this
experimentalsetting: (i) the need to contextualise the observed interaction with the probability
of co-localisation between sugar and interactor and(ii) the fact that the transmembraneproteins
are under-represented in the current heparin interactome, which is mainly based on literature-
derived data {21]. Membrane proteins have in fact been a challenge for classic biochemistry-
based studies that require expression of a soluble form of the protein of interest, but also for
proteomic experiments, dueto difficulties of extraction, solubilisation and enzymatic digestion
of hydrophobic polypeptides. A significant under-representation of membraneproteins has also
been observed in all published large scale datasets of PPIs, irrespectively from the method
used [155].
Here, a plasma membraneenrichedfraction extracted from rat liver homogenate was analysed
by heparin-affinity chromatography. The application of a protein digestion protocol based on
the use of centrifugal spin filters as mini-reactors [147] allowed efficient removal of detergent and
good average digestion efficiency, despite the high content of membrane proteins. Thus, 277
proteins were identified across three heparin chromatography fractions in a single MS run per
sample. A bioinformatic pipeline was designed for the extraction of cell surface and extracellular
proteins from the dataset. Twelve known and 50 potentially new HBPs were identified with an
almost equal distribution of secreted, single-pass and multipass transmembraneproteins [Fig.
3.3]. In both the entire dataset and the selected HBPs,a significant fraction of proteins (31%
and 24%, respectively) were identified in all the three heparin fractions and, therefore, did not
show any dependency on ionic-strength of the solution for its binding. It can be speculated
that at least a part of this sub-set derives from spurious interactions with the chromatographic
support and that, therefore, these figures represent a pessimistic estimate of the false positive
rate of this method.
Previously, heparin-affinity proteomic strategies have beenapplied to only extracellular fluids
such as plasma and seminal serum [145,146]. In two publications the Middaugh group explored
the heparin interactome by applying twoalternative approaches. Inafirst paper they employed
an antibody array on total cell lysate before and after depletion of HBPs by heparin agarose
beads. They identified 29 proteins whose signal wassignificantly reduced after incubation of
the cell lysate with heparin beads [51]. However, only three of the identified proteins had
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an extracellular localisation. Interestingly, one of these three proteins, macrophage colony-
stimulating factor 1 receptor, was also identified as a high affinity HBP in this work andit is,
therefore, likely to represent a real heparin interactor. In a second publication they assessed
the binding of biotinylated GAGs, including heparin and HS, to a yeast protein microarray
[144]. The commercial array was built from more than 4,000 yeast proteins expressed as soluble
GST-fusions and, therefore, did not include transmembrane proteins. The authors observed a
significantly higher numberof proteins that were able to bind to HS than heparin (348 vs 264),
reflecting the higher structural diversity of the HS chains. However, the authors failed to show
any dependency of the total numberof binding proteins on the ionic strength of the solution in
a NaCl range between 0 and 0.75 M, even though they observed a partial reduction following
displacement with the highly charged dermatan sulfate. These data could indicate a high level
of non-specific binding of the biotinylated GAGsto the array surface. Furthermore, the choice
of the protein source from an organism that does not express GAGsis questionable and raises
doubts about the physiological relevance of the interactions described, except in the context of
a potential host-parasite interaction.
In summary, the pipeline described proved to be successful for the study of the interaction
of cell surface and secreted proteins with heparin. Two thirds of the identified proteins were
transmembrane, a distribution that contrasts with the known, literature based, heparin inter-
actome which is dominated by secreted polypeptides. Bearing in mind the need for validation
of the reported interactions, it can be speculated that the number of transmembrane proteins
interacting with heparin/HSis currently underestimated. The remaining third ofidentified pro-
teins includedsecreted, extracellular proteins that were co-purified with the plasma membrane
fraction. These soluble factors were therefore associated with membranes via interactions with
transmembrane components,likely to be the proteoglycans themselves.
Three uncharacterised proteins were present in the extracellular heparin-binding dataset,
two secreted and one multipass transmembrane protein. One of them, uncharacterised pro-
tein Cl0orf58 homologue, presents high structural similarity with several extracellular serine
proteases known to interact with heparin (e.g., thrombin, complement Cl component, coagu-
lation factor XIa) and, therefore, it represents a new HBP memberof this family of enzymes.
Also, thrombopoietin, a member of the 4-helix cytokine family recently predicted to possess
heparin-binding activity by molecular modelling [74], was identified in the high affinity fraction.
These data therefore represent the first experimental evidenceof the interaction between heparin
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and thrombopoietin and shows the potential of combining molecular modelling and proteomic
strategies for the discovery of new heparin-protein interactions.
The identification of new heparin/HS binding partners can help to unravel new molecular
circuits involving HSPGs. For this reason, in the next chapter, the experimental data derived
from this affinity proteomic approach will be integrated with literature-derived data on HBPs
to perform a network-level analysis of the heparin interactome that will cover both functional
and structural aspects and will allow to link the evolution of HSPGsto the one of their protein
partners.
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A system-level analysis of the
heparin interactome
4.1 Overview
During the last decade, a number of public databases for molecular interaction data were de-
veloped [156]. These resources report thousandsof interactions derived from both small- and
large-scale experiments [156]. The accumulation of these large datasets required new ways of
representation and analysis of molecular networks, stimulating the development of a completely
new discipline known as network biology [157-160]. Almost contemporaneously, the concept
of systems biology was emerging from a growing need for collaboration between experimental
and computational research [161]. These new approaches have been successfully used to inte-
grate data from different experimental platforms [162], infer properties of interaction networks
by applying statistical theories [158], assign protein function [163], identify network signatures
characteristic of diseases such as cancer [160, 163] and investigate the evolution of interaction
networks [164,165]. However, these vast datasets include almost exclusively protein-protein
interactions and, therefore, the interactions of proteins with secondary gene products such as
GAGs have been excluded from the systematic analysis mentioned above.
Thefirst aim of this section was to integrate and rationalise available data on heparin/HS-
protein interactions. The current coverage of heparin/HS-protein interactions in public databases
is largely incomplete [Table 4.1]. Therefore, a literature mining effort [21] was combined with
the proteomic data described in Chapter 3 and data retrieved from public databases to generate
a comprehensivelist of the interactions between heparin/HS and proteins described so far [Fig.
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Source Search criteria Output Ref.
GO consortium (December 2009) GO:0008201 heparin binding 103 human genes [150]
GO:0043395 heparan sulfate binding 4 human genes
UniProtKB (Release 15.7) KW-0358 heparin-binding 65 human genes [151]
DB-PABP (December 2009) heparin+heparan sulfate 25 human genes [166]
MatrixDB (December 2009) heparin+heparansulfate 90 human entries [167]
Literature based review 216 human genes [21]
Table 4.1: Current coverage of human HBPsin publicly available databases.
4.1]. This dataset then enabled a new systematic way of analysing heparin-protein interactions
using tools widely applied in genomic and proteomic studies. The system-level analysis allowed
to investigate how HBPsinteract with each other by computing the topological properties of
the network they form, to identify functional and structural features that are associated with
the heparin-binding activity, and, finally, to generate insights on the role of HSPGs during the
evolution of multicellular organisms[Fig. 4.1].
4.2 Methods
4.2.1 Construction of the heparin interactome
The heparin interactome wasbuilt using a combinationof literature curation, data retrieval from
public databases and experimental data obtained by the affinity proteomic approach described
in Chapter 3 [Fig. 4.1]. A first version of the literature curated dataset was first published
in [21] and originally included 216 HBPs. For each interactor, a selected publication describing
experimental evidence for the interaction was referenced and the UniProt accession number of
the human homologue was reported, independently from the source of the protein used in the
cited publication. This is still the largest, referenced, data-set of HBPs available in literature
so far. The original dataset was expanded andin its current version (December 2009) includes
280 interactors. Additional data were retrieved from publicly available databases and GOclas-
sifications using the search criteria listed in [Table 4.1]. For GO [150], UniProtKB [151] and
DB-PABP [166], the search was restricted to human genes, while this was not necessary for
MatrixDB,since all the interactions described in it are associated by default to human protein
identifiers [167]. Finally, the 62 HBPs identified by the heparin-affinity proteomic approach
described in Chapter 3 were included, as a set of experimentally derived, non-literature-based
data. The integration of these datasets resulted in a non-redundantlist of 373 human proteins.
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Figure 4.1: Flowchart for the construction and analysis of the heparin interactome
This list, hereinafter referred to as the heparin interactome, was used for the all the subsequent
analysis presented in this chapter andit is available in Appendix III.
4.2.2 Construction and analysis of the heparin-interacting network
A PPI network based on the heparin interactome was built using Cytoscape v.2.6.3 {168, 169].
The PPI resource was the Cytoscape Human Interactome Dataset (2007), which was obtained
by merging molecularinteraction data from a variety of sources including IntAct [170], DIP [171]
and HPRD[172]. The dataset contains information on how interactions were identified, and IDs
to link back to source databases and pubmedarticles. The NCBI Entrez gene ID for each HBP
was obtained from their UniProt accession number using DAVID 2008 [173] and used to extract
HBPsandtheir interactions from the human interactome dataset. Topological parameters of the
heparin-interacting network, treated as undirected network, were computed using the Cytoscape
plugin Network Analyzer v.2.6 [174]. For a context relevant analysis, the topological parameters
of the extracellular human interactome were compared to the one of the network formed by
extracellular HBPs. Thus, the extracellular interactome was extracted from the human dataset
by applyingfilters based on GO cellular component terms. The terms used were: GO:0005576
(extracellular region), GO:0005615 (extracellular space), GO:0031012 (ECM) and GO:0005604
(basement membrane). Extracellular HBPs and their interactions were then selected from the
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extracellular proteome using the NCBI Entrez gene IDs from the heparin interactome. The
properties and topological parameters of the networks are summarised in Fig. 4.3 B.
4.2.3. Functional and structural analysis of the heparin interactome
The over-representation (enrichment) of GO terms [150], Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways [175] and Pfam domain families [176] in the heparin interactome
was analysed using the web-accessible program DAVID 2008 [173]. The list of HBPs’ UniProt
accession numbers was used as the input list and the default human proteome wasused as the
backgroundlist. The significance of the enrichments wasstatistically evaluated with a modified
Fisher’s exact test (EASE score), to calculate a P-value for each term [173]. Cutoff values were
0.01 for GO terms and Pfam domainsenrichments, 0.05 for KEGG pathways. Furthermore, Pfam
domainssignificantly enriched in the heparin interactome were associated with the corresponding
Structural Classification of Proteins (SCOP) superfamilies [177] in order to reduce redundancy
and perform the analysis described in Section 4.6.
4.3 Topological analysis of the heparin-interacting network
Thefirst step was towards a systematic analysis of the heparin interactome was to build and
analyse the topological parameters of the network of PPI formed by HBPs. This analysis is
based on the representation of PPI networks as graphs, where proteins are represented as nodes
connected by edges that indicate the presence of an interaction between them [Fig. 4.2]. By
applyingstatistical tools used for graph theory,it is then possible to compute topological param-
eters describing the properties of the network {158,174,178]. Thus, HBPs andtheir interactions
were extracted from a dataset of human protein interactions obtained by merging data retrieved
from different repositories (see Section 4.2.2). Since the predominant location of HSPGsis ex-
tracellular, the analysis was performed by comparing the properties of the extracellular heparin-
interacting network with the total extracellular human interactome and the network formed by
extracellular non-heparin-interacting proteins. These networks were extracted from the human
interactome using filters based on GO cellular component terms associated with extracellular
protein localisation (see Section 4.2.2). The characteristic of the networks used are summarised
in Fig. 4.3 B.
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Figure 4.2: The heparin-interacting network. The heparin-interacting network was built as described in Section
4.2.2. HBPs are shown as purple nodes and the node label indicates their NCBI Entrez gene ID. Heparin/HS
are represented as a yellow node. Black and green edges represent heparin-protein and PPIs, respectively. The
statistical analysis described in Section 4.3 was based on PPI only. The heparin-interacting network view was
generated using Cytoscape v.2.6.3 [168].
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B Avg. clustering Average Characteristic
Data set Proteins PPI coefficient degree path length
HumanInteractome 10203 61262 0.134 11.5 4.05
Extracellular (Ec) 1049 1718 0.066 2.66 4.55
Ec_hepint 244 396 0.094 2.42 4.09
Ec_nothepint 805 684 0.032 1.16 7.01
Ec_hepintRANDOM 244 334 0.025 2.74 3.73
Ec_RANDOM 244 152(22) 0.022(0.012) 0.64(0.16) 3.90(0.88) 
Figure 4.3: Topological analysis of the heparin-interacting network. The topological parameters of the extra-
cellular human interactome and heparin-interacting network were analysed as described in Section 4.2.2. In (A)
nodes are binned according to their degree (numberof neighbours) and the average clustering coefficient for each
bin is plotted in green for the extracellular human interactome, blue for the extracellular heparin-interacting
network and red for the set of the extracellular proteins that does not interact with heparin. The distribution of
the clustering coefficients is characterised by the typical slope of PPI networks, which indicates the presence of
hierarchical modularity. The properties and topological parameters of the network used are summarised in (B).
The “Ec_hepintRANDOM?”network was generated from the extracellular heparin-interacting network by applying
a degree preserving randomshuffle of the edges (1320 shuffles). The “Ec-RANDOM”network was generated by
randomly selecting a network of the same size as the extracellular heparin-interacting network from the total
extracellular interactome. The procedure was iterated 50 times and mean network parameters are shown with
standard deviation in brackets. The average degree indicates the mean numberof neighbours per node in the
network. The characteristic path length is the average over the shorter distances (numberof links) separating all
pairs of nodes in the network and offers a measure of a network’s overall navigability. The clustering coefficient
is defined as the numberoflinks connecting the first neighbours of a given node divided by the total possible
number of connections between them. It is a measure of the tendency of nodes to form highly interconnected
modules. The average clustering coefficient for a network is calculated as the meanof the clustering coefficients
for each node having a degree (numberof neighbours) > 2. The average clustering coefficient of the extracellular
heparin-interacting networkis six standard deviations higher than the mean value calculated for randomly picked
networks.
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By comparing the properties of the three extracellular networks, the main topological pa-
rameter associated with the heparin-binding function was the high meanclustering coefficient
displayed by the heparin-interacting network. The clustering coefficient is a measure of the
modularity of a network (i.e., the tendency of nodes to form groups or clusters). Therefore, a
high mean clustering coefficient indicates the presence of highly interconnected groups of nodes
(modules) within the network. For a given node, the clustering coefficient is calculated as the
ratio between the links connecting its first neighbours and the total possible number of connec-
tions between them. The average clustering coefficient for a network is then calculated as the
meanof theclustering coefficients for each node having a degree (numberof neighbours) > 2.
The scaling of the clustering coefficient with the number of neighbours represented in Fig.
4.3 A is typical of PPI and other real networks [158]. It indicates the presence of a hierar-
chical architecture, in which sparsely connected nodes (with low degree) are part of highly
clustered areas interconnected by hub nodes (with high degree) [158]. Clustering coefficients of
the heparin-interacting network distribute at higher values when compared to the total extra-
cellular interactome and with the non-heparin-interacting network [Fig. 4.3 A]. The high mean
clustering coefficient of the extracellular heparin-interacting network indicates a stronger ten-
dency of HBPsto form highly interconnected modules than other extracellular proteins [Fig. 4.3
B]. In Fig. 4.4 selected examples of highly clustered modules extracted from the heparin inter-
actome are shown. These examples show how the tendency to form highly connected modulesis
independent of the nature of the HBP. Theclusters shownare in fact formed by secreted growth
factors such as vascular endothelial growth factor (VEGF) and placental growth factor (PGF)
and their transmembrane receptors [Fig. 4.4 A], but also structural components of the ECM
suchasfibrillins [Fig. 4.4 B], and plasmaproteins such as coagulation factors [Fig. 4.4 D]. Fur-
thermore, this architecture of the heparin-interacting network has also functional implications.
These clusters represent in fact examples of functional modules responsible for the regulation
of complex biological processes such as angiogenesis [Fig. 4.4 A] [27], ECM assembly [Fig. 4.4
B] [179] and regulation of the coagulation cascade [Fig. 4.4 D] [180]. These data support the
view of HSPGsas key mediators of the assembly of molecular complexes at the cell surface and
in the extracellular space [181].
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Clustering coefficient
Figure 4.4: Examples of highly clustered modules of the heparin-interacting network. HBPswitha high clustering
coefficient were extracted together with theirfirst neighbours from the extracellular heparin interacting network.
Node color indicates the clustering coefficient of each node, according to the legend. Node label indicates the
UniProt short name of the HBP. PPIs are represented as green edges. The presence of a loop-back indicates
the ability of a node/protein to homodimerise. ‘The highest clustering coefficients represented were 1 for PGF
(A), 0.67 forfibrillin-2 (FBN2) (B), 0.67 for platelet-derived growth factor subunit A (PDGFA) (C) and 0.6 for
coagulation factor-IX (F9) (D). The graphs were generated using Cytoscape v.2.6.3 [168].
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4.4 Functional analysis of the heparin interactome
In order to gain insights into functional roles of HBPs, the over-representation (enrichment) of
ontology terms and components of molecular pathways in the heparin interactome was analysed.
Gene ontologies are based on acontrolled vocabulary that defines encoded terms describing fea-
tures of genes and gene products. The aim is to annotate and organise the biological knowledge
available for a given gene and to create a framework for the integration of new data [150]. The
Gene Ontology Consortium beganthis effort in early 2000 by defining three independent ontolo-
gies (biological process, molecular function and cellular component) for three model organisms
Saccharomyces cerevisiae, Drosophila Melanogaster and mouse [150]. The consortium now in-
cludes 17 memberinstitutions world-wide and provides annotations for more than 40 animal,
plant and microbial genomes(statistics as of January 2010, http://www.geneontology.org). More
recently, statistical tools based on ontologies were developed to systematically extract biological
meaning from gene/protein lists, typically from “omic” experiments(e.g., [173, 182]). The com-
monstrategy of these tools is to map ontology terms to the genes of interest and then highlight
those terms that are statistically enriched when compared to a backgroundlist: generally the
whole genome annotation of the species studied [173].
Following this strategy the enrichment of GO biological process terms in the heparin in-
teractome was analysed using the human proteome as the backgroundlist. The GO biological
process terms describe biological objectives to which the gene or gene product contributes [150]
and they can be cither broad, generic terms such as “response to stimulus” or more specific one
such as “fibroblast growth factor receptor signalling pathway”. Therefore, the identification of
biological process terms associated with a particular set of genes, in this case the HBPs, can
be useful to highlight their functional roles at a network level. Ninety-two % (345 / 373) of
the HBPs were annotated with at least one biological process term and the twenty terms most
significantly enriched in the heparin interactome are listed in Table 4.2. This analysis indicates
a strong correlation between the heparin interactome and biological functions characteristic of
multicellular and higher organisms. These include terms associated with basic processes common
to all multicellular organisms, such as cell-cell signalling, cell migration and response to stress,
but also terms directly linked to organismal development and to complex biological processes
such as wound healing and the immuneresponse that are prerogative of higher organisms.
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Term Description Count % P-value
GO:0009605 response to external stimulus 132 35.7% 2.17E-92
GO:0009611 response to wounding 106 28.7%  3.29E-81
GO:0042330 taxis 62 16.8%  6.99E-62
GO:0006935 chemotaxis 62 16.8%  6.99E-62
GO:0006954 inflammatory response 76 20.5%  8.18E-58
GO:0007626 locomotory behaviour 63 17.0% 2.25E-54
GO:0006950 responseto stress 118 31.9%  2.88E-50
GO:0006952 defense response 90 24.3% 4.28E-50
GO:0007610 behaviour 69 18.7%  1.43E-46
GO:0032501 multicellular organismal process 206 55.7%  1.06E-44
GO:0007267 cell-cell signalling 89 24.1%  4.04E-44
GO:0048856 anatomical structure development 151 40.8%  9.85E-42
GO:0048731 system development 135 36.5%  1.16E-40
GO:0032502 developmental process 179 48.4%  1.44E-36
GO:0007275 multicellular organismal development 149 40.3%  7.85E-36
GO:0002376 immune system process 104 28.1% 1.02E-35
GO:0048513 organ development 109 29.5%  1.05E-35
GO:0042221 response to chemical stimulus 76 20.5% 3.99E-35
GO:0050896 response to stimulus 169 45.7% 4.66E-34
GO:0016477 cell migration 52 14.05%  1.12E-32
 
Table 4.2: GO biological process terms enriched in the heparin interactome. The enrichment of GO biological
process termsin the heparin interactome was analysed using DAVID 2008 [173] (see Section 4.2.3). Countindicates
the total number of HBPsbelonging to each category and the % is calculated on the total heparin interactome
(373 proteins). It has to be noted that a protein can belong to more than one category. Only the twenty most
significant terms are displayed for clarity. The completelist of the terms significantly enriched (p < 0.01) can be
found in Appendix III.
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Figure 4.5: Graphical representation of GO biological process terms enriched in the heparin inetractome. The
biological process terms enriched in the heparin interactome are shown as nodes connected by directed edges that
indicate hierarchies and relationships between terms. Nodesize is proportional to the number of HBPsbelonging
to the functional category. Node color indicates the P-value for the enrichment of the term according to the
legend. For clarity, only highly significant terms are displayed (p < 1 E-20). The graph was generated using
Cytoscape v.2.6.3 [168] and its plugin BiNGO v.2.3 [182].
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As with other ontologies, the biological process terms can be visualised as a graph where
directed links describe the hierarchy and relationships between terms [150]. This kind of visu-
alisation helps to group highly related/redundant terms typical of ontology classifications and
identify relevant functional modules. The graph shownin Figure 4.5 highlights the existence of
four main functional groups strongly enriched in the heparin interactome. These include two
clusters of biological process involved in the control of the immune system and of developmental
processes and other two interconnected clusters related to the regulation of cellular processes
such as cell proliferation and cell communication [Fig. 4.5]. It has to be highlighted that both
Table 4.2 and Figure 4.5 are based for clarity only on the subsets of terms with the highest
P-value, therefore other significant, and perhapsless investigated, biological functions (such as,
for example, “cation homeostasis”, P-value 1.9 E-17) were not included in this analysis. A
completelist of terms significantly enriched in the heparin interactomeis available in Appendix
IIL.
Next, a similar approach to identify those pathways that have a statistically significant
over-representation of HBPs was applied by projecting the heparin interactome on the KEGG
collection of pathways. KEGG pathways are manually drawn graphs that are based on the
current knowledge of molecular interactions and reaction networks [175]. The KEGG collection
includes 347 pathway maps(statistic as of January 2010, http://www.genome.jp/kegg) asso-
ciated with biological functions and disease conditions. Sixty-six % (248 / 373) of the HBPs
were assigned to at least one KEGG pathway. In Table 4.3 the pathways enriched in HBPs
are summarised. HBPsare involved in pathways responsible for the control of key physiological
and pathological processes characteristic of multicellular organisms. In particular, the enriched
pathways highlight the role of the heparin interactome in key mechanisms implicated in the
regulation of the cellular response to external stimuli. These include interactions betweensol-
uble ligands and their cell surface receptors (“Cytokine-cytokine receptor interaction”) as well
as cross-talk with components of the ECM (“ECM-receptor interaction”). These mechanisms
are directly linked to the control of cell behaviour via the regulation of processes such as cy-
toskeleton reorganisation (“Regulation of actin cytoskeleton”) and activation of intracellular
signalling cascades (e.g., “TGF-beta signalling pathway”). These processes are then involved
in complex biological phenomenasuch as neural system development (“Axon guidance”) and,if
deregulated, they can participate in the establishment of pathological conditions such as cancer
(e.g., “Melanoma”). Furthermore, pathways linked to other pathologies caused by structural
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Term Description Count % P-value
hsa04060  Cytokine-cytokine receptor interaction 72 19.4%  5.60E-32
hsa04610 Complement and coagulation cascades 36 9.7%  6.61E-26
hsa04512 ECM-receptor interaction 31 8.4%  2.57E-16
hsa04510 Focal adhesion 41 11.1% 1.21E-12
hsa05218 Melanoma 22 5.9%  1.25E-10
hsa01430 Cell Communication 27 7.3%  4.52E-08
hsa05010 Alzheimer’s disease 11 3.0%  2.05E-06
hsa04350 TGF-beta signalling pathway 19 5.1%  3.02E-06
hsa04810 Regulation of actin cytoskeleton 31 8.4%  4.70E-06
hsa04010 MAPKsignalling pathway 30 8.1%  4.44E-04
hsa05060 ‘Prion disease 6 1.6%  8.59E-04
hsa04640 Hematopoietic cell lineage 14 3.8%  1.17E-03
hsa05219 Bladder cancer 8 2.2% 7.70E-03
hsa05222 Small cell lung cancer 12 3.2%  1.19E-02
hsa01510 Neurodegenerative Diseases 7 1.9%  2.44E-02
hsa04360 Axon guidance 14 3.8%  4.40E-02
hsa04340 Hedgehogsignalling pathway 8 2.2%  4.71E-02
 
Table 4.3: KEGG pathways enriched in the heparin interactome. The enrichment of KEGG pathways in the
heparin interactome was analysed using DAVID 2008[173] (see Section 4.2.3). Count indicates the total number
of HBPs belonging to each pathway and the % is calculated on the total heparin interactome (373 proteins). It
has to be noted that a protein can belong to more than one pathway.
alteration of extracellular proteins and their subsequent accumulation in the extracellular space
(c.g., “Alzheimer’s discasc”) are significantly correlated with the heparin-binding activity, since
most of these proteins directly interact with GAGs [144,183,184]. It has to be noted that, as in
the case of ontologies, the same protein can participate in more than one pathway. A schematic
representation of the pathwayslisted in Table 4.3 can be found in Appendix III.
In summary, the functional analysis of the heparin interactome highlighted that: (i) HBPs
are functionally enriched in biological processes that are prerogative of multicellular and higher
organisms;(ii) HBPs are key mediators of the information flow between the extracellular space
and intracellular signalling pathways; (iii) this role implies a direct involvement of the heparin
interactome in complex physiological and pathological systems, such as organismal development
and cancer.
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4.5 Structural analysis of the heparin interactome
The same strategy used for the fuctional analysis of the heparin interactome was performed at
structural level by investigating the enrichment of protein domains in HBPs. Protein domains
are evolutionary conserved structural entities with distinctive secondary structure content and a
hydrophobiccore [185]. The Pfam databaseis a large collection of protein domain families repre-
sented by multiple sequence alignments and hidden Markov models [176,186]. A hidden Markov
model is a probablistic model that transforms a multiple sequence alignment into a position-
specific scoring system. Hidden Markov models are used in Pfam to scan the UniProt database
for homologous sequences and to classify them in families that are acollection of related pro-
teins [186]. The currentrelease of Pfam (v24, October 2009, http://pfam.sanger.ac.uk/) includes
11912 families that cover 75.15 % of all the protein sequences found in the UniProt database
v15.6. Ninety-five % (356 / 373) of the HBPs were annotated to at least one Pfam domain
and the domain families significantly enriched in the heparin interactomeare listed in Table 4.4.
Highlighting the structural diversity of the heparin interactome, the list includes domains that
are characteristic of small soluble, single-domain, proteins such as cytokines and growth factors
(e.g., “Small cytokines, interleukin-8 like”, “Fibroblast growth factor”, “Transforming growth
factor beta like domain”), domains that assemble in large multi-domain proteins (e.g., “Throm-
bospondin type 1 domain”, “Laminin G domain”, “Fibronectin type III domain” ) and domains
associated with enzymatic activity (e.g., “Trypsin family”, associated with proteolytic activity).
Therefore, the enrichment of some domain families is the result of the presence of families of
paralogous HBPs that expanded during evolution (e.g., the chemokine and FGF family). While
in other cases, non-homologous proteins contribute to the same domain family by the arrange-
ment of the same structural unit in various multi-domain architectures (e.g., Thrombospondin
type 1 domain). Furthermore, some domain families are enriched in the heparin interactome
without being directly responsible for the interaction with the carbohydrate (e.g., EGF-like do-
main), thanks to their co-occurrence with heparin-binding domains in multi-domain proteins
(see below).
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Term Description Count P-value SCOP S.family
PF00048 Small cytokines, interleukin-8 like 40 2.60E-65 54117
PF00167 ‘Fibroblast growth factor 17 8.54E-21 50353
PF01391 Collagen triple helix repeat 23 1.31E-18
PF00090 Thrombospondin type 1 domain 19 8.15E-16 82895
PF00008 EGF-like domain 25 7.99E-15 57196
PF00089 ‘Trypsin family 21 6.44E-13 50494
PF00093 ~=von Willebrand factor type C domain 12 1.48E-10 57603
PF02210 Laminin G domain 12 1.04E-09
PF01410  Fibrillar collagen C-terminal domain 8 1.65E-09
PF00019 Transforming growth factor beta like domain 11 2.89E-09 57501
PF00052 Laminin B (Domain IV) 6 3.36E-07
PF05735 Thrombospondin C-terminal region 5 7.21E-07 49899
PF02412 Thrombospondin type 3 repeat 5 7.21E-07 103647
PF00219 Insulin-like growth factor binding protein 7 8.39E-07 57184
PF06009 Laminin DomainII 5 2.13E-06
PF06008 Laminin Domain I 5 2.13E-06
PF01759 UNC-6/NTR/C345C module 7 4.20E-06 50242
PF00053 ~=Laminin EGF-like 9 4.58E-06 57196
PF00084 Sushi domain 10 5.44E-06 57535
PF00688 TGF-beta propeptide 7 7.12E-06 57501
PF00086 Thyroglobulin type-1 repeat 6 1.45E-05 57610
PF00055 Laminin N-terminal 6 1.45E-05 57196
PF01823 MAC/Perforin domain 5 2.80E-05
PF00341 Platelet-derived growth factor 5 2.80E-05 57501
PF00079 Serpin 8 3.41E-05 56574
PF00051 Kringle domain 6 4.47E-05 57440
PF00041 Fibronectin type III domain 14 1.26E-04 49265
PF00057 Low-density lipoprotein receptor domain class A 7 7.10E-04 57424
PF00092 von Willebrand factor type A domain 9 7.43E-04 53300
PF07703 Alpha-2-macroglobulin family N-terminal region 4 8.15E-04
 
Table 4.4: Pfam domain families enriched in the heparin interactome and their SCOPsuperfamily classification.
The enrichment of Pfam domain families in the heparin interactome was analysed using DAVID 2008 [173] (see
Section 4.2.3). SCOP superfamilies associated with Pfam domain families were manually retrieved from the Pfam
and SCOP databases. Count indicates the total number of HBPs belonging to each group. It has to be noted
that multi-domain proteins are associated with all their components. Only the thirty most significant terms are
displayed for clarity. The complete list of the domainssignificantly enriched (p < 0.01) can be found in Appendix
Il.
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Next, the Pfam domain superfamilies enriched in the heparin interactome were mapped
to the corresponding Structural Classification Of Proteins (SCOP) superfamilies. The SCOP
classification uses structural information derived from the PDB database instead of sequence
alignments to establish evolutionary relationships between proteins and domains [177]. There-
fore, true relationships can be established even for cases when sequences have diverged beyond
the limit of detection of sequence comparison approaches andthese relationships are linked to
reference structures deposited in the PDB database. Seventy-five % (39 / 52) of the Pfam do-
main families significantly enriched in the heparin interactome (p < 0.01) were mapped to a
SCOPsuperfamily [Table 4.4]. This approach allowed the reduction of the redundancy of the
Pfam classification by grouping domainsofrelated structure into 31 superfamilies (for example
the entries “EGF-like domain” and “Laminin EGF-like” of Pfam are grouped in the SCOP su-
perfamily “EGF/Laminin”) [Table 4.5]. As mentioned above, notall the structures are directly
associated with heparin-binding activity. Literature curation of the HBSs identified so far re-
vealed that 13 of the 31 superfamilies were never described as mediating the interaction with
the carbohydrate [Table 4.5]. Even though the lack of evidence in current literature does not
necessarily exclude a role of these structures in heparin-binding, this analysis highlights those
structures that are predominantly mediating the interaction with GAGs. For each of these struc-
tures, a referenced example and, whenavailable, a three-dimensional structure of the domain in
complex with heparin or a heparin-related molecule are reported in Table 4.5.
In summary, the structural analysis of the heparin interactome revealed a high level of
diversity between structures associated with heparin-binding function, possibly with a direct
link to the structural complexity of GAGs. These structures can either occur in single-domain
proteins, that are in general part of large families of paralogues, or as units mediating the
heparin-binding activity that have been arranged during evolution in different multi-domain
architectures. Finally, a fraction of the structures enriched in the heparin interactome does not
seem to be directly involved in the interaction with sugar and they might be over-represented
because they are functionally and structurally linked with the heparin-interacting modules.
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SCOPS.family Description HBS Ref. PDB
54117 Interleukin 8-like chemokines P02776 [75] 1U4L
50353 Cytokine P09038 [75] 1AXM
82895 TSP-1 type 1 repeat Q9UHI8 [187]
57196 EGF/Laminin
50494 Trypsin-like serine proteases P04070 [188] 1A7S
57501 Cystine-knot cytokines P01137 [189]
49899 Concanavalin A-like lectins/glucanases
103647 TSP type-3 repeat
57184 Growth factor receptor domain
50242 TIMP-like 095631 [190]
57535 Complement control module/SCRdomain P04003 [191]
57610 Thyroglobulin type-1 domain P18065 [192]
56574 Serpins PO1008 [193] 1AZX
57440 Kringle-like P00749 [194] 1GMN
49265 Fibronectin type III P02751 [195]
57424 LDLreceptor-like module
53300 vWA-like
49410 Alpha-macroglobulin receptor domain
48239 Terpenoid cyclases/Protein prenyltransferases
56491 A heparin-binding domain P05067 [184]
48726 Immunoglobulin P11362 =[196] 1FQ9
50923 Hemopexin-like domain
57603 FnlI-like domain P02751 [197]
55486 Metalloproteases catalytic domain P09237 [198]
57630 GLA-domain
47686 Anaphylotoxins (complement system)
57362 BPTL-like P10646 [199]
47090 PGBD-like
57552 Blood coagulation inhibitor (disintegrin)
57581 TB module/8-cys domain Q14766 [200]
49503 Cupredoxins P52797 [201]
 
Table 4.5: SCOP superfamilies associated with the Pfam domain families enriched in the heparin interactome.
The SCOP superfamilies associated with Pfam domain families significantly enriched (p < 0.01) in the heparin
interactome were retrieved from the Pfam and SCOPdatabases. Not all the superfamilies are directly associated
with heparin-binding activity. In the cases where an HBS was located in a domain belonging to a superfamily, the
columns “HBS” and “Ref.” report the UniProt accession number of the HBP and the publication describing the
interaction, respectively. The column “PDB” reports, when available, the PDB numberof a three-dimensional
structure including a domain belonging to a superfamily in complex with heparin or heparin derivative. The
superfamilies are listed in the same order as in Table 4.4, therefore, reflecting the significance of the enrichment
of the domainsincluded in the superfamily.
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4.6 Evolutionary aspects of the heparin interactome
Since a strong association emerged between HBPsandbiological functions and pathways char-
acteristic of higher organisms, the evolution of the domains enriched in the heparin interactome
was analysedin correlation with organism complexity across thetree oflife. In a recent publica-
tion, Vogel and Chothia investigated the expansion of domain superfamilies across the genomes
of 38 uni- and multi-cellular eukaryotes and correlated it to the increase in organism complexity,
as measured by the numberof different cell types of which the organisms are composed [202].
They mapped the occurrence of different superfamilies using a database of 1219 hidden Markov
models, based on the SCOPclassification of domains, called Superfamily [203]. For each genome,
they annotated one-domain proteins and the individual domains of multi-domains proteins to
their respective superfamily and then calculated the abundance of each superfamily, as the
numberof proteins that contain at least one domain belonging to that particular superfamily.
The normalised abundanceprofiles were then used to calculate a Pearson Correlation coefficient
(PCC), R, describing the correlation between superfamily abundanceand the estimated number
of cell types per genome [202].
The PCCsfor the 31 superfamilies enriched in the heparin interactome were extracted from
the dataset of Vogel and Chothia and they are plotted in Figure 4.6. The distribution of PCCs
of the heparin interactome superfamilies indicates a strong correlation between their abundance
and organism complexity (mean R = 0.83, with R > 0.8 indicating a strong positive correla-
tion). In order to establish a link between domain functions andtheir correlation with organism
complexity, the authors extended the domain annotations by manually assigning functional cat-
egories to each superfamily. They observed that only 15 % of the superfamilies have a strong
positive correlation (R > 0.8) with organism complexity. Moreover, just two functional cate-
gories contributed nearly half of these positively correlated superfamilies. These two functional
categories are superfamilies associated with extracellular processes (20 %) and regulation (29
%) [202]. Therefore, since most of the superfamilies characteristic of the heparin interactome
are also associated with extracellular processes, their relative contribution to the extracellular
functional category was investigated. Thus, the heparin interactome superfamilies were anno-
tated using the functional classification described in [202] and the distribution of the correlation
coefficients of superfamilies enriched in the heparin interactome and annotated as extracellular
was compared to one of the whole extracellular category and other superfamilies annotated as
extracellular but not enriched in the heparin interactome [Fig. 4.6]. The mean correlation co-
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Figure 4.6: Correlation between the abudance of superfamilies associated with the heparin interactome and
organism complexity. The Pearson Correlation Coefficients (PCCs) describing the association between superfamily
abudance and organism complexity were extracted from [202]. The PCCs for superfamilies: enriched in the
heparin interactome (HEPINT), enriched in the heparin interactome and annotated as extracellular in [202]
(EC_HEPINT), annotated as extracellular (EC) and annotatedas extracellular but not enriched in the heparin
interactome (EC_NOTHEPINT)are plotted along the y axis. For each group the mean PCCis indicated by a
horizontal bar. The dashed redline indicates the threshold for strong correlation between superfamily abundance
and organism complexity.
efficient of the heparin interactome superfamilies annotated as extracellular is even higher than
the whole heparin interactome set (mean R = 0.92), and, most importantly, the distribution
of their PCCs is significantly different from the one of the whole extracellular category (p =
0.0193) and other extracellular superfamilies (p = 0.0037).
Next, the analysis of the correlation between HSPGsand organism evolution was extended
to their biosynthetic enzymes. In this case the analysis was not performed using the SCOP
superfamilyclassification, since functional specificity cannot be entirely recapitulated by the
structural annotation (i.e., structurally related enzymes can be grouped in the same superfamily
despite having different substrate specificity). Only the HS co-polymerases EXT1 and EXT2 are
currently annotated to a superfamily (“Nucleotide-diphospho-sugar transferases”, 53448), which
also includes other sugar transferases such as galactosyltransferases. However, this superfamily
also showsa positive correlation with organism complexity (R = 0.77).
The occurrence of HS biosynthetic enzymesacrossthetree oflife was, therefore, investigated by
multiple sequence alignment across 638 sequenced genomes using STRING [204]. The results are
schematically summarised in Figure 4.7. HS biosynthetic enzymes appear to be the prerogative of
the eumetazoan lineage and,therefore, strongly associated with the emergence of multicellularity.
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Figure 4.7: The occurrence of heparin/HS biosynthetic enzymes across the tree of life. The occurrence of
heparin/HS biosynthetic enzymes across 630 organisms was analysed using STRING 8.2 [204]. The UniProt
Accession numbers of the human HS biosynthetic enzymes were used as input. The conservation of each gene
across different species is indicated by squares colored according to the sequence homology detected by STRING
(see legend). For clarity, some species (e.g. Bacteria) were grouped in collapsed nodes, colored in grey, and the
numberindicated between brackets reports the numberof species grouped in each node.
No homology is detectable in uni-cellular eukaryotes such as fungi and in plants [Fig. 4.7].
Interestingly, some level of homology is detected in certain species of bacteria. The occurrence
of enzymes able to synthesise GAG-related carbohydrate has been already described in some
vertebrate pathogens such as Streptococci [205]. The emergence of these microbial enzymes
may have occurred by either convergent evolution or horizontal gene transfer under the selctive
pressure of the vertebrate host defense, as a mechanisms to enhance the pathogenvirulence [205].
Interestingly, some post-synthesis editing mechanisms appearto be evolved ata later stage than
the core biosynthetic machinery. No homology is in fact detectable for the extracellular HS
cleaving enzymes heparanases (HPSEs) in the nematode C.elegans, while homology, albeit low,
is observed for the extracellular HS sulfates (SULFs) [Fig. 4.7].
The association between increase in organism complexity and HSPGsis further corroborated
by the expansion of the biosynthetic enzymes,in particular in the vertebrate lineage. Thus, while
C.elegans possesses only one isoform for each of the key enzymes involved in HS biosynthesis
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(EXT: HS co-polymerase; NDST: N-deacetylase / N-sulfotransferase; GLCE:glucuronicacid C5
epimerase; and the sulfotransferases HS2ST, HS6ST and HS3ST), in humansall these enzymes
have expanded by gene duplication with the exception of GLCE and HS2ST. Two EXT, four
NDST, three HS6ST and six HS3ST isoforms together with one isoform each for GLCE and
HS2ST form the HS biosynthetic machinery in humans. A similar pattern is observed for the
HS core proteins. Only one syndecan and two glypican genes are found in C.elegans, while
humanspossess four syndecan andsix glypican isoforms[206]. Interestingly, a similar expansion
is not observed for the ECM core proteins perlecan and agrin [206].
In summary, a strong correlation emerged between the abundance in a genome of domain
superfamilies associated with the heparin interactome and organism complexity. This correlation
wasalready observed for extracellular domains [202], but it is statistically more pronounced for
the heparin interactome superfamilies than others. A similar correlation is also suggested for
HS biosynthetic enzymes and core proteins based on the occurrence of these proteins across the
tree of life and their expansion during evolution, especially in the vertebrate lineage.
4.7 Discussion
The analysis undertaken of the heparin interactomeallowed the investigation of the properties of
the heparin-interacting network of PPI and the analysis, at a system-level, of the functional and
structural features characterising HBPs. The heparin interactome was built combiningliterature
mining, proteomic experimental data and dataretrieval from public databases. The resulting
dataset includes 373 human proteins, mostly extracellular.
The analysis of the heparin-interacting network revealed that HBPs tend to form more
highly clustered modules than other extracellular proteins. These clusters can assemble both
at the cell surface and in the ECM , andthey often also represent functional modules. From a
functional point of view, the heparin interactomeis strongly associated with biological processes
characteristic of multicellular organisms and with pathways that are crucial for the conversion
of extracellular cues into intracellular signalling events and, finally, into a phenotypic response.
These processes and pathwaysare central to complex biological phenomena particular to higher
organisms such as development and the immune response, and they are consequently linked to
pathological conditions such as cancer and neuro-degenerative disorders.
The structural analysis of the heparin interactome revealed the existence of two main cat-
egories of domains associated with heparin-binding activity: domains that are characteristic of
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soluble single-domain proteins and domains that occur mainly in multi-domain proteins and that
have been assembled during evolution in different architectures. From an evolutionary perspec-
tive, the expansion of domainsassociated with the heparin interactome strongly correlates with
an increase in organism complexity, independently of their nature. The samesort of correlation
was also observed when the analysis was focused on enzymes and core proteins responsible for
the synthesis and localisation of HS chains.
These data suggest a central role for HSPGsfirst, during the emergence of multicellularity,
and,later, during the evolution of more complex organisms. The core HSPGsbiosynthetic ma-
chinery evolved in early eumetazoans concomitantly with the emergence of multicellularity [207].
Biochemical data describing the presence of heparin/HS-like GAGsin phyla at the root of the
eumetazoan lineage, such as Cnidaria and Ctenophora [208, 209] support this view. HSPGs
might have beena critical step for the organisation of an extracellular network of proteinsre-
quired for the structural organisation of the extracellular space and for the establishment of
cell-cell communication and cell differentiation. Later on, gene duplication events, in particular
the whole genome duplications that occurred at the root of the vertebrate lineage (210], con-
tributed to expand the repertoire of both HSPGsbiosynthetic enzymes and their interacting
partners on which evolution could act. The fact that domains characteristic of the heparin in-
teractome are strongly correlated with organism complexity could indicate that their expansion
has been one of the driving forces towards the organisation of more sophisticated and tunable
extracellular networks that are required for the development of higher organisms and for the
control of organism-level biological processes such as the establishment of an immune system.
In support of this, HSPGs have already been proposed by others as key molecules for the emer-
gence of neural connectivity [206,211]. The authors collected a series of experimental evidence
obtained in different model organisms describing the specific involvement of HSPGsin all the
key processes required for the establishment of neural connectivity including axon guidance,
neuron-target interaction and synapse development [206]. Similarly to what has been proposed
here, the authors suggested a role for HSPGsas versatile extracellular scaffolds that modulate
extracellular cues influencing the response of neurons to their environment [206].
The versatility of HS derives as a direct consequence of its molecular complexity. The
structural diversity of HS chains and their size (40 to 160 nm) are key factors that enable
HSPGsto organise macromolecular structures over substantial length scales by interacting with
an extremely diverse spectrum ofprotein structures. In the future, the integration at the network
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level of data on the selectivity of particular HS-protein interactions could provide the means to
start to model how these extracellular molecular assemblies are built.
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Chapter 5
Conclusion and perspectives
The aim of this thesis was to introduce a new systematic approach for the analysis of the in-
teractions between heparin/HS and proteins in order to promote an advancement of the field
from the one-protein-at-a-time logic that has dominated the majority of the studies available
today. Therefore, experimental platforms for the investigation of protein-heparin/HS inter-
actions, compatible with medium/high throughput implementation, were developed, together
with a bioinformatic pipeline for the integration of new andavailable datasets on HBPs and the
analysis of their properties at a network level.
Chapter 2 describes the development and validation of a new method for the identification
of HBSsin proteins. The method, called the protect and label strategy, is based on the selective
chemical labelling of residues involved in the interaction with heparin and their identification
by MS/MS[75] (the publication describing this workis available in Appendix II). The protect
and label strategy is cost and timeeffective, requiring low nano-molar amounts of protein and
only two bench-days to complete the analysis. Therefore, it can easily be applied as a routine
method,either as a hypothesis generator for further mutagenesis studies or for the confirmation
of other data derived, for example, from molecular modelling [74]. Section 2.5 describes an
exemplar application of the protect and label strategy for a structural comparison of HBSs be-
tween three divergent members of the FGF family of growth factors. Moreover, the new method
is compatible with a medium/high throughput implementation. Several proteins can in fact
be quickly processed in parallel experiments, but also, in theory, in multiplexed experiments,
where more than one protein is analysed in a single experiment, thanks to the unique peptide
signatures deriving from MS/MS data. The main limitation of the protect and label strategy
is the inability to identify binding sites that do not contain lysine residues. The development
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of new protein modification reagents able to selectively target other amino acids (e.g., [212] for
arginine residues) could further expand the applicability of this new technique. In the near
future, the protect and label strategy has, therefore, the potential of becoming part of an inte-
grated experimental platform for the systematic structural investigation of protein-heparin/HS
interactions. Such a platform would include complementary techniques focused to investigate
the three-dimensional structures of protein-sugar complexes, affinity and kinetic parameters of
the interactions, and structural properties and specificity of different GAGs. In this direction, a
novel method for measurement of the thermo-stabilising effect induced by GAGs on the protein
partner was developed in collaboration with K.A. Uniewicz and Dr. E.A. Yates (University of
Liverpool). This methodis able to discriminate betweenthe interactions of a protein with GAGs
of different structures by measuring the melting temperature of the complexes they form. The
procedure is performed in 96-well plate format (compatible with automation and high through-
put implementation), and it provides insights into the specificity of the interactions of proteins
with GAGs [46].
The second target of this project was to perform a systematic investigation and identifi-
cation of HBPs. In Chapter 3, the implementation of an affinity proteomic strategy for the
identification of HBPs from tissue extract is described. In order to identify the most relevant
heparin interactors, the key challenge was to target the sub-proteome that co-localises with
HSPGsin vivo. This was accomplished by isolating a plasma membraneenriched fraction from
total rat liver homogenate, by means of sequential centrifugation and subsequent flotation of
the microsomalfraction on a sucrose gradient. The isolated plasma membraneenriched fraction
was then subjected to heparin-affinity chromatography and HBPs wereidentified by shot-gun
MS.Theidentified proteins were furtherfiltered using a bioinformatic pipeline based on ontol-
ogy classification in order to extract extracellular proteins, either secreted or transmembrane.
This procedure allowed the identification of sixty-two HBPs, including twelve previously de-
scribed heparin interactors, and with a good coverage (2/3) of transmembraneproteins, which
are usually under-represented in proteomic studies and in the current heparin interactome [21].
In the future, a similar strategy could be implemented in combination with quantitative MS
techniques, such as iTRAQ [213] and staple-isotope labelling with amino acids in cell culture
(SILAC) [214], to investigate dynamic changes of the heparin interactomeassociated, for exam-
ple, with different developmental stages or pathological conditions. These data complemented
by the characterisation of the dynamic changes of HS structure could be extremely valuable to
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elucidate HSPGs-mediated mechanismsinvolved in the control of physiological and pathological
processes.
The experimental approaches described above were complemented with a bioinformatic strat-
egy for the integration and rationalisation of available data on HBPs. The strategy was im-
plemented by combining literature-derived datasets, both from manual curation and public
databases, with the experimental data obtained by the affinity protcomic strategy. This led to
the compilation of the heparin interactome that includes 373 human proteins with at least one
piece of experimental evidence for their interaction with heparin/HS. This dataset allowed the
first investigation of the functional and structural properties of HBPs at a network level. The
analysis described in Chapter 4 provides a picture of the heparin interactomeas a highly inter-
connected network of proteins involved in the cross-talk between the inside of the cell and the
extracellular environment. HBPsare consequently strongly correlated to biological processes and
pathways that are characteristic of multicellular organisms and associated to complex patholo-
gies such as cancer and neuro-degenerative diseases. These data provide an important resource
for new functional investigations of HSPGsandtheir protein partners. From a structural point
of view, two major classes of domain associated with the heparin interactome wereidentified.
Thefirst class includes domains that occur in small, secreted proteins such as chemokines and
growth factors. This subset of HBPs generally belongs to families of paralogous proteins that
expanded strongly during evolution, in particular in the vertebrate lineage (e.g., the FGF family
of growth factors). The second class is characterised by domains that occur as modules medi-
ating the heparin binding that have been arranged during evolutionin different multi-domain
architectures (e.g., Thrombospondin type 1 domain). These data can be extremely valuable in
the design of systematic structural analysis of protein-heparin interactions.
The analysis of the heparin interactome also provided important insights on the correlation
between HSPGs/HBPsandthe evolution of multicellular and higher organisms. Domains that
are characteristic of the heparin interactome were in fact significantly retained during evolution
following the genome duplications that occurred in the metazoan lineage, and their expansion
correlates with an increase in organism complexity. A similar correlation was already described
for domains and proteins generically associated with extracellular processes[202, 215], however,
also within this set, the heparin interactome-associated domainsdisplay a statistically significant
higher correlation than other extracellular domains. It has been shown that the evolutionary
rate of the extracellular proteomeis faster then the intracellular one, probably due to the less
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Figure 5.1: A representation of the structure of a hypothetical protein-GAG interaction entry. The
summary-page would report the interactor identifiers, link to external databases and provide a concise sum-
mary of structural and thermodynamic parameters of the interaction. Each field would be then linked to an
interaction-data page where detailed parameters, literature reference, interactor features and detailed experimen-
tal conditions would be described, together with an optional comment by the curators.
chemically constrained environment faced by extracellular proteins [216]. This evolutionary
plasticity of the extracellular proteome could have been a driving force for the organisation of
more complex systems of intercellular communication and organisation. The functional and
structural link between the heparin interactome and biological processes characteristic of com-
plex organisms and the fact that HBPs are more correlated than other extracellular proteins
with an increase in organism complexity, strongly suggests a pivotal role of HSPGsin driving
the evolution of multicellular and higher organisms.
As mentioned in Chapter 4, the vast majority of interaction data currently available are
based on primary gene products and the genetic material. The chemical complexity of secondary
gene products such as glycans andlipids and technical challenges related to the study of their
interactions have generated a gap in current modelsof interaction networks. The coverage of
protein-GAGsinteractions in public database is highly incomplete and the few resourcesavailable
are not integrated, resulting in a dispersion of data across different repositories [Table 4.1].
With the development of higher throughput tools to catalogue and quantitatively analyse
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the heparin/HSinteractome, the glycobiology community has reached a position where data ac-
quisition in the absenceof a global data structure to permit data mining and sharing no longer
affords a means to provide understanding of the functions of HSPGs. The development of a
knowledge base for protein-GAG interaction would provide a means to collect and rationalise
available interaction data, make them publicly available and exchangeable in standard formats,
and provide a platform for the integration of newly generated data. As an example, Figure 5.1
shows a hypothetical database entry, describing a protein-GAGinteraction, with fields based on
the controlled vocabulary of the HUPO Proteomics Standards Initiative for Molecular Interac-
tion (PSI MI) [217]. Such a resource would solve major challenges such as the representation
of sugar structure (for example, via the extension of controlled vocabularies to GAGs), and the
establishment of rules for curation of protein-GAG interaction data, which would allow data
reconciliation and provide a core resource of quantitative parameters. The availability of these
data would in the end broaden the horizon of glycobiology research by creating a virtual space
of encounter and exchange between experimentalists and systems biologists. This would be a
cornerstone for the modelling of biological processes that involve GAGs andtheir interactors,
and the application of glycomolecules to the development of new, network based, therapeutic
agents.
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1. ABSTRACT
The cell-extracellular matrix interface is a
crowded space whose structure is dependent on
macromolecular assemblies that are dynamic in time,
molecular composition and location. Signals travel from
one cell to another (or to the same cell) by the regulated
assembly / disassembly of molecular complexes. These
signals can evoke relatively simple biological responses
such cell proliferation and migration, but once integrated,
they guide cell fate in complex biological phenomena such
as embryonic development and organism homeostasis.
Heparan sulfate proteoglycans are ubiquitous components
of this space and important actors of these processes in all
tissue-organized life forms. A key feature of heparan
sulfate is its size, 40 nm to 160 nm, which enables it to
integrate self-assembling macromolecular structures over
substantial length scales. What is the structure of heparan
sulfate? Why do we think heparan sulfate is so important?
How do wetry to explain its activity? What do we know
about its interactions? These questions together with a
final look to the future are the “menu”ofthis review.
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2. INTRODUCTION
Heparin was identified in 1916 as a material
extracted from dog liver able to inhibit clotting of plasma
ex vivo (1, 2). For its anticoagulant activity, heparin entered
the list of approved drugs of the American Food and Drug
Administration (FDA) from 1939 and it is nowadays the
largest, by weight, biotechnology productused in the clinic.
More than thirty years after its discovery, a family of
compoundsrelated to heparin was identified. Because of
their lower level of sulfation compared to heparin, they
were named heparin monosulfuric acid (3). These
compoundsare nowreferred to as heparan sulfate (HS) and
we know that it is more correct to consider heparin as a
particular form of HS rather than vice-versa. In the last
twenty years, HS took a curtain call in the theatre of the
scientific community for its involvement in a large number
of fields of major biomedical interest and fundamental
biological importance. New therapeutic agents targeting HS
function are today under investigation to tackle high impact
pathologies such as cancer and atherosclerosis (4-6). Many
scientists around the globe have contributed to the
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production of an impressive amount of important,
sometimes contradictory literature. For many of the main
subjects related to HS detailed and complete reviews are
available.
The aim of this review is to introduce the world
of heparan sulfate proteoglycans through a brief summary
of what we know about these fascinating molecules,
highlighting the many questions thatare still open and ones
that are emerging, and to identify what may be important
future research. In the first part the structural features that
characterize HS and howits expressionis finely regulated
by the cell machinery are described. The second part
outlines a series of in vivo evidences for the central role of
HSin crucial biological processes and proceeds with the
illustration of some of the mechanisms proposed to explain
its activity. In the third part some thermodynamic and
structural concepts underlying the interaction of HS with
proteins are summarized. Our view of the future is put
forwardat the end.
3. COMPLEX STRUCTURES FINELY REGULATED
3.1. The heparansulfate proteoglycans
Heparan sulfate (HS) is a linear polysaccharide
containing a characteristic disaccharide repeating unit. It
belongs to the family of glycosaminoglycans (GAGs)
together with chondroitin sulfate (CS), dermatan sulfate
(DS), hyaluronic acid (HA) and keratan sulfate (KS). First
identified as a low sulfated form of heparin (3), HS
attracted a growing numberof scientists from different
areas of biology for its involvement in the regulation of
many events that take place at the interface between cell
and extracellular matrix (ECM). Its expression is almost
ubiquitous in mammalian cells and its complex structure
differentiates HS from other GAGs(7).
HS polysaccharides represent one of the main
components of the cell surface and ECM. They are
synthesized as covalent complexes with core proteins
containing sugar attachment consensus sequences,
consisting in general of a Ser-Gly motifflanked by atleast
two acidic aminoacid residues (8), forming heparan sulfate
proteoglycans (HSPGs). Three major families of HSPGs
have been characterized. They include the transmembrane
proteins syndecans (four members in mammals), the
glypicans, proteins attached to the cell membrane by a
glycosylphosphatidylinositol (GPI) anchor (six members)
and ECM proteins such as perlecan, agrin and collagen
XVIII (for reviews see (9-14)). The nature of the core
protein determines the localization of the HS chainsat the
cell surface (syndecans, glypicans) or in the ECM
(perlecan, agrin, collagen XVIII). Other proteins such as
CD44v3, betaglycan and testican are not synthesized by
default as HSPGs but they can be modified with HS chains
underparticular circumstances(15).
The structural variability of these polysaccharides
results from the arrangement of postpolymerization
modifications, mainly sulfation, along the sugar backbone
and on their polydispersity. The repeating unit consists of
1-4-linked  pyranosyluronic acid and  2-amino-2-
4310
deoxyglucopyranose (glucosamine) residues. The uronic
acid maybeeither beta D-glucuronic acid (GlcA)or its C-5
epimer alpha L-iduronic acid (IdoA). The beta D-
glucosamine may be N-acetylated (GlcNAc), N-sulfated
(GIcNS)or, rarely, unsubstituted (GlcN). Variable degrees
of O-sulfation may occur at position 2 of the uronic acid
andat positions 3 and 6 of the glucosamine (Figure 1A).
The complexity of HS derives from the
characteristics of its biosynthesis (reviewed in (16)).
Different sequences are assembled by a non template-
driven process, in which a set of enzymes acts on the
growing saccharide polymer introducing modifications to
the sugar backbone. These modification reactions depend
on the enzymes' specificity and cellular physiology and do
not go to completion (Figure 2) (16). Three phases can be
distinguished: chain initiation, polymerization and polymer
modification. The first step is the assembly of a linker
tetrasaccharide attachedto specific serine residues of newly
translated core proteins. The transfer of a UDP-xylose by
xylosyltransferase, followed by the addition of two D-
galactose residues by galactosyltransferases and a GlcA by
glucuronosyltransferase I, forms the linker tetrasaccharide,
GlcAbetal-3Galbeta1-3Galbetal-4Xy1-L-[ser]. This is
commonto heparin, HS, CS and DS.The following addition of
an alpha4GIcNAcresidue or of a beta4GalNAcresidueto the
linker region commits the process toward the synthesis of
heparin or HS,in the first case, and CS or DS in the second
(16). After hexosamine has been added, the polymerization of
the heparin / HS chain occurs throughthe alternate transfer of
UDP-GlcAbeta4 and UDP-GlcNAcalpha4to the non-reducing
end of the growing polysaccharide. The reaction seems to be
catalyzed by hetero-oligomeric complexes of members of the
EXTgene family (copolymerases, two isoforms in humans),
which possess both transferase activities (17). The chain
elongation proceeds to variable extents generating
polysaccharidesofdifferent length (16).
Growing precursor polymers are subject to a
maturation process in which the sugar backbone undergoes
different modifications. These modifications are carried out
by a series of enzymes, four classesof sulfotransferases and
an epimerase,that act in an ordered and regulated way. The
first modification is the replacement of the N-acetyl groups
of GleNAc with sulfate groups. Both reactions are
catalyzed by dual functional N-deacetylase / N-
sulfotransferases (NDSTs, four isoforms) and are normally
tightly coupled. However, rarely they can occur in
dissociative fashion, explaining the presence of small
amounts of unsubstituted GlcN residues in heparin and in
HS (16). The presence of N-sulfated groups is a
prerequisite for all other modifications and thus this step
plays a key role in determining the structure of polymer
chain.
The C5 epimerization of some GlcA to IdoA is
catalyzed by C5 epimerase (EPI, one isoform), whose
substrates are GlcA attached to the reducing end of
GlcNS. This enzyme does not react with uronic acids
that are O-sulfated or adjacent to O-sulfated glucosamines
(16), suggesting that this modification must occur
immediately after the NDST reaction.
The heparanome
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Figure 1. A. Heparin and HS monosaccharides. The repeating units consist of an iduronic acid, GlcA or its C5-epimer IdoA, 1-4-
linked with a glucosamine residue. The glucosamine may be N-acetylated (RI= COCH3), N-sulfated (RI= SO;)or, rarely,
unsubstituted (R1= H). Further complexity derives from variable degree of O-sulfation that may occurat position 2 of the uronic
acid (R4) and at positions 3 (R3) and 6 (R2) of the glucosamine. B. Conformation of heparin-derived dodecasaccharide obtained
by NMR(PDB: IHPN). The sugar backbone is showedassticks and the sulfate groups as spheres. The color code for sulfate
groups is the same offigure 1A. Picture obtained from 1HPN file using PyMol (http://www.pymol.org). C. Glycosidic bond
dihedral angles. The dihedral angles defining the rotation of the sugar chain around glycosidic bondsare defined as phi (H1-C1-
O-C4') and psi (C1-O-C4'-H4'). D. The pyranose rings of heparin / HS can assumedifferent conformations. GlcA and GlcN
assume the rigid “C, chair conformation, while IdoA tends to be moreflexible, with its usual conformation being an equilibrium
between the 'C, and 7Sp skew-boat conformers.
Variable extents of O-sulfation expand the
sequence complexity. The uronosyl-2-O-sulfotransferase
(2OST,one isoform) catalyzes the O-sulfation in position 2
of both GlcA and IdoA,preferring the latter substrate. The
glucosamine can be O-sulfated at position 6 and, rarely, at
position 3. These reactions are catalyzed by 6-O-
sulfotransferases (6OST, three isoforms) and 3-O-
sulfotransferases (3OST, six isoforms), respectively (18).
The polymerization of the sugar chain begins in
the lumen of the endoplasmic reticulum (ER) with the
xylose incorporation into core proteins and proceeds in the
Golgi apparatus. Despite the cloning of cDNAs encoding
most of the biosynthetic enzymes involved and
characterization of the enzymes, the architecture of the
machinery and its regulation remain poorly understood
(19). Nevertheless, the rapidity of the process and the
ability of some of these enzymesto interact with each other
suggest the existence of a biosynthetic complex
(““gagosome”) (16). How the whole process is coordinated
and the regulatory mechanisms that determine the pattern
of chain modification are not known (20).
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Heparin shares with HS the same disaccharide
units (Figure 1A). However, expression, localization, chain
lengths and level of sulfation distinguish these two classes
of molecules. Heparin presents a far more homogeneous
and high level of sulfation (21) and its expression is a
prerogative of connective-tissue mast cells and
oligodendrocyte-type-2 astrocyte progenitors (22, 23).
Heparin proteoglycan consists of a unique core protein
(serglycin) with multiple heparin chains attached. In the
mast cell the sugar chains are then cleaved at some ofthe
GlcA residues by an endo-beta-glucuronidase, to give a
mixture of smaller polydisperse heparin polysaccharides
that are stored in the cytoplasmic secretory granules as non-
covalent complexes with basic proteases (24).
Nevertheless, due to its commercial availability and more
homogeneous/ simpler structure, heparin or its derivatives
have been used in the last decades as a model for HS,
especially in the study of sugar-protein interactions that
often involve the sulfated region ofthe polysaccharide (25).
Their structural complexity makes heparin / HS
extremely challenging molecules to characterize. A
The heparanome
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Figure 2. The polymerization and chain modification steps of HS are schematically represented. The size of the chains is
arbitrary. Monosaccharides are represented according to the guidelines of the Nomenclature Committee of the Consortium for
Functional Glycomics(http://glycomics.scripps.edu/CFGnomenclature.pdf).
complete structural analysis of these polysaccharides would
require the identification of the chain composition, its
sequence and the characterization of its solution
conformation. The majority of data available derives from
compositional analysis of HS preparations obtained by
enzymatic / chemical degradation of the sugar chains. The
existence of a domain organization in the HS chains was
first demonstrated by pioneer works of Linker and Cifonelli
(26, 27). They investigated the structural features of HS
combining degradation with nitrous acid (27) and / or
enzymatic digestion with heparinase I (26, 28) with
separation techniques such as paper chromatography and
gel filtration chromatography. The interpretation of the
complex profiles obtained led the authors to propose a
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model for HS structure where more abundant unmodified
regionsare alternated with block of sulfated units along the
chain (26-28). Furthermore, they observed that the region
proximal to the linker tetrasaccharide is composed mainly
of an N-acetylated sequence of 6 or 7 units resistant to
nitrous acid treatment (27). The characterization of HS
structure obtained from a single cell type allowed the
definition of a more complete and accurate model (29-32).
Turnbull and Gallagher investigated the structure of HS
purified from human skin fibroblasts using an approach
derived from the one of Linker and Cifonelli (30-32). In the
proposed modelregions with a high degree of modification
and sulfation (NS domains) alternate with unmodified
regions, rich in GleA and GleNAc, (NA domains) and
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mixed regions containing both NA and NSunits (NA/NS
domains) lie at the boundaries of the NA and NS domains
(32, 33) (Figure 2). The model includes the presence of a
highly conserved N-acetylated region of eight disaccharide
units contiguous with the protein-linkage region identified
in humanskin fibroblast HS, too (29) (Figure 2). Although
informative, these data describe only the average
composition of HS chains and are not sufficient for a
comprehensive characterization of their structure. In the
last decade two new sequencing strategies have been
implemented. These methodsallow the identification of the
sequence of purified oligosaccharides (up to 10 sugars in
length), combining partial chemical cleavage and
enzymatic digestion with separation techniquessuch asgel
electrophoresis, HPLC and MALDI-MS(34-36). However,
sequencing of an entire chain (50-200 saccharides) is well
beyond current technical capabilities.
Structural data have been obtained in the last
decades by X-ray crystallography, NMR and molecular
modeling performed on heparin or HS derivatives (37-41).
NMRandcrystallography studies suggested that heparin
may assume a right handed helical structure with
successive disaccharide units in the chain related by a
rotation of 180() and a translation of 0.82 to 0.87 nm (39)
(Figure 1B).
The pyranose rings of heparin / HS can assume
three main conformations. While the glucuronic acid and
the glucosamine have alwaysbeen observed in the rigid 4c,
chair conformation, the iduronic acid tends to be more
flexible and it can also assume the 'C, and *Sp skew-boat
conformations (42) (Figure 1C). The IdoA conformation
depends on its substitution pattern and on the location of
the residue along the chain. When the residue is at the
reducing end all three conformers 4C), 'Cy and 7So are
permitted. The balanceofthis equilibrium depends both on
the iduronate 2-O-sulfation and on the substitution of
adjacent glucosamine residues (43). The flexibility
introduced in the chain by IdoA is considered crucial for
protein binding, as it facilitates the docking between
anionic groups of the sugar and cationic patches on the
protein surface (44).
The glycosidic dihedral angles phi (H1I-C1-O-
C4') and psi (C1-O-C4'-H4') (Figure 1D), which define the
overall chain conformation, have been studied by molecular
modeling and NMR (39, 45). These early studies showed
that rotation around the glycosidic bondis limited by steric
interactions, in particular for the GleNbetal-4IdoA bond
(39). Further studies revealed the relative flexibility of
chemically modified heparin chains, in comparison to an
unsubstituted polysaccharide (E.Coli polysaccharide K5)
(46). NMR analysis of selectively modified heparin
derivatives showed the influence of O- and N-sulfation on
the glycosidic linkage geometry and iduronate ring
conformation (40, 41), as exemplified by the effect of 2-O-
sulfation on the iduronate conformer population ('C4:?So
ratio) (40). The conformational changes induced by
modifications do not affect only residues subjected to
sulfation, but also more remote positions with a possible
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influence on the overall chain conformation and hence on
the biological activity of the sugar (40).
Recently new spectroscopic approaches have
opened the door to understanding the conformation of
entire chain (47). In a recent work the solution
conformation of heparin and eight systematically modified
heparin derivatives has been investigated using a
combination of synchrotron radiation circular dichroism
(SRCD) and NMRspectroscopy. This study reports for the
first time that the conformation and flexibility of heparin
chain can be affected not only by the substitution pattern,
but also by the nature of the cation associated with the
sugar. Interestingly, the conversion to different cationic
formsaffects also the biological activity of heparin in an in
vitro assay of fibroblast growth factor signaling activation
(BaF3 proliferation assay) (47). The role of different
cations have been implicatedalso for the binding of heparin
/ HS to annexin 2 (48), annexin V (49) and L-selectin (50)
(Ca’*), and endostatin (51) (Zn?*). However, while for
annexin 2 both the sugar and protein participate in the
coordination of the cations, in the other cases the
interaction with the cation seems to be restricted to the
protein. In this last case the role of cations would be to
induce a conformation of the protein more favorable for
sugar binding (49, 51).
3.2. Regulation of chain expression
One of the main features of HS that emerged
from early studies is the spatial and temporal regulation of
its expression. Analysis of HS preparations obtained by
enzymatic and chemical degradation revealed heterogeneity
in the sugar composition between different samples.
Reproducible variations have been observed between
samples extracted from different species and_ tissues.
Differences in chain length, total, N- and O-sulfation
levels, IdoA / GleA ratio as well as the distribution of the
modification patterns along the chain characterize HS from
different sources (21, 52-55). For example, rat liver
heparan sulfate on syndecan-2 presents a terminal heparin-
like structure with an unusually high content of N- and O-
sulfate that result in a total sulfate content at least 50%
higher than other HS species such as endothelial and skin
fibroblast HS (53).
Characteristic changes of HS structure have been
associated with certain pathological conditions. The
structure of liver and spleen HS isolated from patients
affected by AA amyloidosis and from patients control was
compared. Interestingly, HS from AA amyloidosispatients
showedstructural similarity, independently from the organ
of origin, and differences were observed when compared to
control samples (56). This study characterized for the first
time a specific modification of HS structure (variation of
the O-sulfation profile, especially 6-O-sulfation) associated
to a pathological degeneration of organ architecture (56).
Using a similar approach, Lindahl and colleagues
performed a structural comparison between HS extracted
from cerebral cortex of patients affected by Alzheimer’s
disease (AD) and control subjects. In this case no
significant variation was observed between AD patients
and controls. Brain HS showed characteristic disaccharide
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composition in comparison to other organs and
homogeneity was observed between HS samples from
different regions of the brain (57).
A gradual modulation of HS structure has been
observed during ageing. Human aorta HS obtained from
patients of different ages presented an age-dependent
increase of GlcN 6-O-sulfation and, by consequence,of the
trisulfated units IdoA(2S)betal-4GIcNS(6S). This
modification has been associated with an increased binding
of plateled-derived growth factor A and B chains to HS
extracted from elderly patients, suggesting a possible
mechanism for the involvement of HS in the
patophysiology of atherosclerosis (58).
Modification of HS chain composition has been
correlated to the tumorigenicity of different cell lines (59).
The association between HS structural changes and cell
transformation has been further investigated using an in
vitro model of the progression of human colon cancer from
adenoma to carcinoma. The comparison of HSisolated
from adenoma and carcinoma cell lines revealed
differences in O-sulfation pattern (decrease of 2-O-
sulfation associated with increase of 6-O-sulfation in
carcinomaderived material), even if the overall structure of
the sugar chains was conserved (60).
All the studies cited above take in consideration
the total pool of HS chain extracted from whole organs or
cell lines without any possible discrimination between
polysaccharides deriving from different core proteins. A
first work described a modification of the HS structure in
two different murine neuroepithelial cell lines derived
from embryonic days 9 and 11. At these early stages
neuroepithelial cells secrete essentially one type of
HSPG, a perlecan related proteoglycan (HSPG-PRM)
(61). The HSPGsisolated from the medium of the two
cell lines shared the same core protein, but they
displayed different binding ability to FGF-1 and to FGF-
2. A simple structural analysis of the polysaccharides
revealed differences in the number of chains and chain
length between the two samples. This report gave the first
evidence that the nature of the sugar chains is sufficient to
change the binding specificity of a proteoglycan (62). Two
other works analyzed in more detail the structural features
of HS chain obtained from a single type of HSPG
(syndecan-1) expressed by different cell lines, that
displayed variations in the binding affinity for HS
interacting proteins such as collagen type 1 and FGF-2.
These variations were associated to modification of the HS
structure in term of content and pattern of sulfation (63,
64).
The use of antibodies able to recognize different
HS epitopes provides a single and defined structural
framework with which to probe HS structures. These
antibodies have revealed specific epitopes distributions
amongdifferent cell types in the context of the same organ
(65-67). Using similar approaches, a spatial-temporal
regulation of HS epitopes expression has been observed
during development in hamster embryo,rat skeletal muscle
andrat lung (65, 68, 69).
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An alternative approach is to exploit the
specificity of HS binding proteins to probe the spatial and
temporal distribution of HS structure. Exogenous FGF-2
identifies changes in binding sites between basement
membrane of rat mammary gland ducts and terminal end
buds, the structures responsible for ductal growth and
branching (70). Similarly, Rapraeger and colleagues used a
panel of FGFs and FGF / FGFRto probe HSstructures that
bind the growth factors and are competent to assemble
ligand-receptor complexes. Again, remarkable specificity
was demonstrated in term of tissue domains possessing HS
binding sites with such functions (71-73).
What are the mechanisms involved in the fine
and dynamic regulation of HS expression at the cell and
tissue level? Nowadays we do not have an answerto this
question. However, many recent studies point out the
existence of several possible levels of control. The
regulation of HSPG biosynthesis is of course the most
obvious. Due to its complexity many mechanismscould be
involved. (i) The core protein expression can influence the
number of HSPGs expressed by cell, the localization of
HS chains and their activity. (ii) The assembly of the
biosynthetic machinery can affect the structure of the sugar.
The existence of different isoforms (16) and different splice
variants (74) of the biosynthetic enzymes possessing
different tissue distribution and different specificity (18,
75) is the central core of HS regulation. How the machinery
is assembled and whatis its influence on the activity of
individual modification enzymes are probably the keys to
understand the regulation of the process (16, 19). (iii) The
availability of substrates (e.g. rate of PAPS synthesis and
import into the Golgi) can be a further level of control of
the HS synthesis (16).
Furthermore, different post-synthesis
mechanisms exist to edit the structure of HS. (i) The
extracellular domain of both syndecan and glypican can be
shed from the plasma membrane byproteolytic cleavage
(syndecans and glypicans) or by cleavage of the GPI-
anchor(glypicans) (9). The shedding can result in a drastic
changein the concentration of HS chainsat the cell surface
and in the ECM, potentially affecting the activity and
distribution of their ligands. Syndecan-1 shedding has been
associated directly with mesenchymal induction of
epithelium (76). Recently a new lipase (Notum) has been
identified in Drosophila as negative regulator of Wingless
(Wg) signaling pathway. The Wginhibitor activity resides
in its ability to release the extracellular domain of Dlp, a
Drosophila glypican (77). (ii) The HS chains can be
degraded by extracellular endo-beta-glucuronidase
(heparanase) (78). In this case, the degradation of the sugar
results in the liberation of associated proteins and in the
release of active HS fragment of 5-7 kDa of size able to
sustain the activation of growth factors signaling such as
FGF-2 (79). Furthermore, acting on ECM proteoglycans
the enzyme can take part in the remodeling of the
extracellular environment promoting phenomena such as
cell spreading and angiogenesis (79). Heparanase has
become object of intense studies in the last year for its
involvement in tumor growth and invasion (80). Several
therapeutic approachestargeting the activity of this enzyme
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are under investigation (6). (iii) Finally, the sulfation
pattern of the HS chains can be modified by cell surface
sulfatases (81). Sulfl and Sulf2 are two 6-O-endosulfatases
specific for HS chains anchored to the cell surface through
interactions of a hydrophilic domain with cell components.
Their activity influences the function of heparin / HS
binding proteins such as Wnt, BMP and FGF-2 (82). These
enzymesact as proper editors of the HS code;selectively
removing 6-O sulfate they can affect conformation and
binding properties of the sugar. The effects of these
modifications depend on the nature of HS-protein
interactions. The activity of the quail orthologue has been
shown to enhance Wntsignaling (81). The proposed model
is that the removal of 6-O sulfate drastically reduces the
affinity of Wnt for HS, allowing the growth factor to
interact with and activate its receptor Frizzled with higher
efficiency (81). Vice-versa, in the case of the FGF system,
where the 6-O-sulfation is required for the formation of an
active signaling complex (83), the activity of Sulf shows an
inhibitory effect (84).
4. REGULATION OF CELL FUNCTION
4.1. Humandiseases and model organisms
When it was already demonstrated that the
complex structures of HS are not generated randomly,
instead the consequence of biosynthesis and post
polymerization editing, the identification of Drosophila
melanogaster defective phenotypes and human hereditary
diseases associated to HSPG core proteins and biosynthetic
enzymesprovidedthe in vivo evidence ofthe central role of
these molecules in the regulation of cell function (for
reviewssee (85-87)).
The EXTI and EXT2 genes, encoding the
enzymesresponsible for the polymerization of the heparin /
HSchains, are considered possible bone tumor suppressor
genes, since heterozygousnull mutations predispose to the
development of benign cartilage capped tumors from the
growth plates of bones, characteristic of the autosomal
dominant disorder multiple exostoses (HME; MIM 133700)
(88). Deletions and mutations in the gene encoding
glypican-3 core protein (GPC3) are responsible for the X-
linked Simpson-Golabi-Behmel overgrowth syndrome
(SGBS; MIM 312870). This syndromeis characterized by a
pre- and postnatal overgrowth and increased susceptibility
to the formation of certain tumors (89, 90). Interestingly,
Gpc3 null mice display a phenotype characterized by
developmental overgrowth similar to the SGBS condition
(90). Moreover, changes in glypican-3 expression have
been associated to the progression of certain tumors(i.e.
hepatocellular carcinoma) (91) and increased levels of
glypican-1 have been found in cervical and pancreatic
cancer (92). In these cases, a deregulation of HS expression
affecting either its synthesis or its localization leads to an
impairmentoftissue homeostasis and aberrantcell growth,
even though effects solely due to alteration of protein
structure can not be excluded.
At the same time Drosophila melanogaster
defective phenotypes bearing mutations in genes encoding
enzymes involved in the biosynthetic pathway of GAGs
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were isolated. Mutations in both genes coding HSspecific
biosynthetic enzymessuch as HS glycosyltransferases (tout
velu (ttv), brother of tout velu (botv), sister of tout velu
(sotv)) and NDST (sulfateless (sff)) and in proteins
involved in the synthesis and transport of biosynthetic
precursors, as in the cases of sugarless (sgl), fringe
connection (frc) and slalom (sil) (see (86, 87) and
references therein) cause abnormal embryonic segment
polarity indicative of the possible role of HSPGsin the
control of development. The most intriguing observation
from these studies is the similarity between these
phenotypes and the ones bearing mutations in the Wnt /
Wingless (Wg) and Hedgehog (Hh) signaling pathways.
These pathways, together with the transforming growth
factor-beta (TGFbeta) — Decapentaplegic (Dpp) and FGF
signaling pathways, play a central role in development
processes and all of them include heparin / HS binding
proteins (see Table 1). Another gene, pipe (pip), involved
in dorsal / ventral patterning has been associated to the
mammalian gene encoding for 2OST, however its
involvement in HS_ biosynthesis has been recently
questioned (93). The functional role of the genes /As3st and
hs6st has been investigated using RNAi-mediated knock
down. These genes, encoding the fly homologues of 30ST
and 6OST, show genetic interactions with Notch and
breathless (FGFR)(87).
Genes encoding HSPG core proteins have also
been associated with defects in development. Mutations of
Dally and Dlp, two Drosophila glypicans, result in a weak
segment polarity defect and defects in wing, antennae and
genitalia morphogenesis (90, 94). Dally and Dlp are
required for Hh diffusion and signaling during embryo
development and they are essential for Wg gradient
formation in the wing disc (95, 96). Their activities are also
required for Dpp signaling and distribution during wing
development. In contrast, it seems that the Dpp control of
embryonic dorsoventral patterning is Dally / Dlp
independent(97, 98).
The genes encoding the core proteins syndecan
(sdc) and perlecan (terribly reduced optic lobes (trol)) are
involved in central nervous system development. sdc
mutants present defects in axonal guidance associated to
alterations in Slit-Robo pathway, while Trol influences
neural stem cell proliferation through modulation of FGF
and Hhsignaling (86).
Further data obtained from other model
organisms have confirmed the role of HSPGsin the control
of development and homeostatic processes (87, 99).
Targeted deletion of genes involved in heparin / HS
biosynthesis results in embryonic / perinatal lethality in
mice. Homozygous deletion of Extl or Ext2 genes
encoding HS polymerase enzymes causes failure of
gastrulation (100, 101), while the heterozygous condition
(Ext2) is associated to development of exostoses and
multiple cartilage abnormalities (101). Mutations in two of
the four Ndst genes result in very specific phenotypes.
Ndst1 null mice present perinatal death due to respiratory
failure. The phenotype is associated to forebrain defects,
facial abnormalities and axon guidance defects (87). In the
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Ndst2 mutants the abnormalities are restricted to mastcells,
where the lack of correctly modified heparin affects the
formation of secretory granules (102, 103). Alterations of
enzymesinvolved downstream in the biosynthetic process
are also responsible for severe phenotypes, indicating the
importance ofthe fine structure of HS forits activity. HS-
C5 glucuronyl epimerase and 20ST mutants (both enzymes
havea single isoform in mouse) die perinatally and present
renal agenesis. Inactivation of one of the five genes
encoding for 30ST, Hs3stl, results in a mild phenotype
with intrauterine growth retardation (87). Transgenic mice
lacking the isoform 1 of 60ST (HS6ST1) have been
recently created (104). Homozygous mutants presentlate
embryonic lethality, impairment of placental function due
to aberrant angiogenesis and lung deformation (104).
The loss of function of single core proteins
produces milder phenotypes, probably due to a partial
overlap of function between the different isoforms and the
very modest selection pressures experienced by model
laboratory animals. The deletion of syndecan 3 gene, for
example, causes a subtle phenotype characterized by an
alteration of feeding behavior (87). Further analysis
revealed structural changes in the adult cerebral cortex of
knockout micerelated to an altered neural migration (105).
Moresevere phenotypesare caused bythe loss of the ECM
core protein perlecan. Knockout mice display embryonic or
perinatal lethality associated with aberrant brain
developmentandcartilage abnormalities (106).
These data give an extraordinary indication of the
central role of HSPGs in the control of development
processes and organ physiology. However, the complexity
of HS complicates the analysis of mutants’ phenotypes and
the understanding of underlying mechanisms. (i) Our poor
understanding of the biosynthetic machinery is a major
limitation. How the whole process is regulated, what is the
role of different enzyme isoforms, how their expression is
spatially / temporally regulated, what is the level of
redundancy betweentheiractivities are still open questions
that reduce our capabilities of interpretation. (ii) On the
core protein side, the impossibility to discriminate between
HS and core protein related effects has to be considered
together with the limits deriving from the presence of
multiple isoforms and from possible compensatory effects.
Particularly informative from this point of view is the work
of Rossi and colleagues who generate mice expressing a
mutant perlecan lacking three of the four possible HS
attachment sites (107). In this case mutants are viable,
fertile and express perlecan with a reduced level of HS
modification. The knockout mice present small eyes and
they are affected by lens degeneration after birth (107).
Interestingly, a similar phenotype has been obtained by
deletion of collagen XVIII, a related ECM core protein
(87). Further analysis revealed alterations of FGF-2
induced tumor growth and wound and tumor angiogenesis
(108). The difference with the more severe phenotype
deriving from the deletion of the whole perlecan gene
indicates the presence of functions independent from HS
chains. (iii) The limited viability of many of these mutants
impairs the study of the impact of such mutations in adult
physiology. This last issue has been overcome in some
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cases by the creation of conditional mutants (109-111).
Two related, recently published papers reported the
creation of mice bearing a targeted inactivation of the gene
Ndstl. Using the Cre-/oxP system the authors obtained
viable and fertile mutants with Ndst1 deletion restricted to
endothelial cells and leukocytes (110). The mutants
developed normally and presented an altered structure of
the endothelial HS. An impaired neutrophilinfiltration was
observed in different experimental models of inflammation.
The authors showed how the undersulfation of endothelial
HSaffected neutrophil trafficking by increasing the rolling
velocity of leukocytes and by weakening their adhesion to
endothelial cells. These phenomena are correlated to
alterations of HS binding abilities. In the first case, the
increased rolling velocity depends on a decreased binding
of L-selectin to the endothelial HS. In the second case the
weaker adhesion is due to an improper presentation of
chemokinesto the leukocite unable to sustain the activation
offirm adhesion (110). These are the first in vivo evidence
of the role of HS in leukocyte / endothelium interaction and
ofits influence on chemokine activity. In a related paper,
Fuster and colleagues used the same model to investigate
the effect of Ndstl inactivation on angiogenesis (111). The
mutants presented no alterations of physiological
angiogenesis during cutaneous wound repair. However, the
lack of Ndst1 activity reduced the growth and angiogenesis
of experimental tumors subcutaneously injected in the
mice. The authors associated these changes to altered
binding properties of undersulfated HS chains. In this case,
endothelial cells isolated from mutants mice showed a
reduced affinity for and altered signaling response to two
growth factors, FGF-2 and VEGFjo4, involved in tumor
growth and control of angiogenesis (111).
4.2. Influence on protein function
The in vivo data cited above, when considered as
a whole, give a quite strong taste of the central role of
HSPGs in many fundamental biological processes.
However, when they are evaluated in more detail, all the
complexity of the phenomena described emerges
dramatically. Its unique structural features allow HS to
interact with a vast numberofprotein partners (Table 1). Its
ability to influence their activity in a way that can be
dynamically regulated (by changes ofits structure and/or of
localization) gives to HS a central role in the regulation of
complex biological phenomena such as development. Many
mechanisms have been proposed in the past years to
describe at a molecular level the action of HS. In the next
section some of the best-characterized systems will be
summarized since they serve as our paradigmsfor the many
less well understood systems.
4.2.1. Influence on protein transport and distribution:
HS and morphogengradients
Development in metazoans represents probably
the most complex example of spatial-temporal coordination
of biological processes. The distribution of morphogensis
responsible for the transport of information during
development and it determines cell fate and pattern
formation. HSPGsplay an important role in the distribution
and activity of the main morphogensbelonging to the Wnt,
Hh, TGFbeta and FGF families. The interaction between
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Table 1. A partial heparin interactome
 
 
 
 
         
Growth factors, cytokine, chemokines and morphogens
Heparin / HS UniProtKB ID! Ref. PDB ID? Heparin / HS interacting UniprotkB ID! Ref. PDB ID?interacting protein protein
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CCL20°nineail P78556 hh Q14623 (112)
CCL21 (SLC) 000585 (235) TL2 P60568 (240)CCL22 (MDC) 000626 (241) 113 P08700 (242)CCL23 (MPIF 1) P5573 (243) TL4 POSII2 (244)CCL24 (MPIF2) 000175 (245) 1L5 POSTI3 (246)CCL25 (TECK) 015444 (238) 1L6 P05231 (247)
CCL26° Qoyv258 1L7 P13232 (248)(MIP4-alpha) ~~CCL27 (CTACK) QOY4X3 (226) TL10 P2301 (249)CCL28 (MEC) QONRIB (238) TL12 P29460 (250)CCNI (000622 (251) INF-gamma POIS79 (252)CCN2 P29279 (253) LTBP-1 P22064 (254)chordin Q9H2X0 (255) midkine P21741 (256)
CX3C (fractalkine) P78423 (224) neuregulin Q02297 (257)
GRO P09341 (126) noggin Q13253 (258)
fas P19875 (259) PDGF-A P04085 (260)
CXCL3*(MIP).beta) P19876 PDGF-B PO1127 (261)
leiotrophinCXCL4 (PF4) P02776 (126) (HB-GAM) P21246 (139)
CXCLS* (ENAT8) P42830 PIGF2 P49763 (262)CXCL6 (GPC2) P80162 (263) prolactin P01236 (264)Q2MKAT,CXCL7 (NAP2) P0275 (126) R-spondin 1-3 Q6UXX9, (265)Q9BXY4
CXCL8(IL8) P10145 (126) SFRPI Q8N474 (266)CXCL9* (MIG) Q07325 Shh Q15465 (112)CXCL10 (IP10) P02778 (267) SLIT 075093 (268)
CXCLIT 014625 SLPI P03973 (269)(I-TAC) pe7s
ere P48061 (270) 2NWG TGF-betal PO1137 (271)
CXCLI3 (BLO) 043927 (238) TGF-beta? P61812 Q71)CXCLI4(BRAK) 095715 VEGF-A P15692 (272)CXCLI6 :ames Q9H2A7 (238) VEGF-B P49765 (273)
EMBP PI3727 (Q74)_| 2BRS Watl PO4628 (113)
endostatin P39060 (51) XCLI (lymphotactin) P47992 (275)
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1AXM, 2AXM, XCL2°FGFI P5230 (276) | ogee (SCM1-beta) | Q9UBD3
Coagulation / complementcascade
Heparin / HS UniProtKB ID! Ref. PDBID? Heparin / HS interacting UniProtKB ID! Ref. PDBID?interacting protein protein
annexin-II P07355 (48) 2HYU, 2HYV factor-B P00751 (277)
annexin-V P08758 (49) 1GSN factor-D P00746 (278)
APC P04070 (279) factor-H P08603 (277)
Clinh P05155 (280) factor-I P05156 (277)
Clq a PO2746, (977) factor-P P27918 (277)
C2 P06681 (277) factor-IXa P00740 (281)
C3 P01024 (277) factor-Xa P00742 (282) 2GD4
C4 POCOL4 (277) factor-Xia P03951 (283)
C4beta-BP P04003 (284) factor-XIla P00748 (285)
C5 P01031 (277) heparin cofactorII P05546 (286) 1JMJ
C6 P13671 (277) TFPI P10646 (287)
C7 P10643 (277) thrombin P00734 @s)|
P07357, P07358, von Willebrand factorcs P07360 (277) (vWF) P04275 (188)
C9 P02748 (277)
Enzymes
Heparin / HS UniProtKB ID! Ref. PDB ID? Heparin / HS interacting UniProtKB ID! Ref. PDB ID?interacting protein protein
AChE Q9Y215 (289) HNE P08246 (290)
ADAMTS1 Q9UHI8 (291) lipoprotein lipase (LPL) P06858 (292)
ADAMTS5 Q9UNAO (293) PAI P0512] (294)ADAMTS9 Q9P2N4 (293) PCI P05S154 (295)
1AZX, —_1E03,
INQ9, 1TB6, -AT-III P01008 (134) 2BST. _ISRS. PCPE2 Q9UKZI (296)
2GD4
BACE1 P56817 (297) PEDF P36955 (298)
CAP37 P20160 (299) 1A57, [A7S PN-1 P07093 (300)cathepsin-B P07858 (301) sPLA2 P14555 (302)
cathepsin-G P08311 (303) TPA P00750 (304)
chymase P23946 (305) trypsin P07477 (306)
cyclophilin-B P23284 (307) tryptase-beta Q15661, P20231 (308)
diamine oxidase P19801 (309) urokinase P00749 (310)
EC-SOD P08294 (311) XOD P47989 (312)
hepatic lipase P11150 (313)
ECM ponents
Heparin / HS UniProtKBID! Ref. PDBID? Heparin / HS: interests. yatpentCs 1D Ref. PDB ID?interacting protein protein
collagen-I P02452, PO8123 (314) collagen-XXV Q9BXSO (315)
collagen-II P02458 (316) fibrillin1-2 P35555, P35556 (317)
collagen-IIl P02461 (318) fibrin P02675 (319)
collagen-IV P53420 (320) fibronectin P02751 (321)
collagen-IX P20849 (322) laminin P25391, P24043 (323)
collagen-V P20908 (324) PRELP P51888 (325)
collagen-XI P12107, P13942 (326) thrombospondin P07996 (327) 1ZA4
collagen-XII Q99715 (328) vitronectin P04004 (329)
collagen-XIII QSTAT6 (330) tenascin P24821 (331)
collagen-XIV Q05707 (332)
Adhesion molecules and receptors
Heparin / HS UniProtKBID! Ref. PDB ID? Heparin / HS interacting UniProtKB ID! Ref. PDBID?interacting protein protein
DCC P43 146 (333) FGFR2 P21802 (167) 1E0O
HIP P47914 (334) FGFR3 P22607 (335)
L-selectin P14151 (50) FGFR4 P22455 (336)
Mac-1 PII215 (337) neuropilin 014786 (338)
N-CAM P13592 (339) ROBO Q9Y6N7 (268)
P-selectin P16109 (340) VEGFRI P17948 (341)
AAMP Q13685 (342) VEGFR2 P35968 (343)FGFRI P11362 (147) [|1FQ9
Others
Heparin / AS UniprotKB ID! Ref. PDBID? Heparin / HS interacting (GyiprotKB ID! Ref. PDBID?interacting protein protein
APLP1-2 P51693, Q06481 (344) lactoferrin P02788 (345)
apoAs Q6Q788 (346) CSannels Q13698 (347)
apoB P04114 (348) myosin ATPase P24844 (349)
4318
 
The heparanome
 
     
apoE P02649 (350) OPG 000300 (341)
apoH P02749 (205) PDCDS5 014737 (351)
APP. P05067 (352) PrP P04156 (353)
cytochrome-C P99999 (354) SAP P02743 (355)
HMGBI P09429 (356) synuclein-alpha P37840 (357)
HRG P04196 (358) tau P10636 (359)     The UniProtKB (http://beta.uniprot.org/) identifier (UniProtKB ID) of the human homologue of the heparin / HS interacting
protein * The Protein Data Bank (http://www.rcsb.org/pdb/home/home.do) identifier (PDB ID) whena structure ofthe interactor
in complex with heparin / HSderivatives or synthetic analoguesis available 3 Indicates a protein that lacks published evidence of
interaction with heparin / HS, but presents high sequence homology with proved interactors
HS and morphogenshas been characterized in vitro (112-
115) and the results obtained in model organisms (see
above) illustrate the impact of these interactions (or of the
lack of) in vivo.
The ability of HSPGs to influence the molecular
diffusion by creating preferential diffusive paths for their
ligands was first proposed as possible mechanism to
enhance growth factor-receptor interaction (116). Similar
models have been proposed to explain the influence of
HSPGsin the movement of Wg (Drosophila ortholog of
vertebrate Wnt), Hh and Dpp (Drosophila ortholog of
vertebrate BMP2 and BMP4) (95-97). In all these cases, the
study of morphogen distribution in wing imaginal discs
revealed the inability of Wg, Hh and Dpp to move through
a line of clones with impaired HS synthesis (s/f, ttv) or
bearing mutations in core protein genes (dally, dip). The
authors proposed a model of preferential cell-to-cell
transport mediated by the glypicans dally and dlp.
According to the model, morphogens travel from the
producer cell to the target cell by sequentially binding
different HS chains. The difference in concentration would
guarantee the unidirectionality of the displacement toward
the target cell (95-97). Other authors proposed alternative
mechanisms of transport, such as direct transfer of
glypicans between neighboring cells (117, 118) and HS-
mediated transcytosis (118). Furthermore, it has been
suggested that the influence of HSPGson the shape of the
morphogen gradient resides in their ability to decrease
diffusivity through the ECM rather thanincreasingit (119).
A recent study on the dynamics of Shh signaling during
chicken embryo development showsthat a decrease of the
diffusivity of the morphogen can extendits range ofaction
(120).
A complementary example derives from the
influence of the heparin-binding activity of VEGF-A onits
control of vessel branching morphogenesis (121). Mouse
embryos have been engineered to express only the VEGF-
A isoform lacking the heparin-binding domains (HBDs)
(VEGF j29). The mutants present normal vasculogenesis and
angiogenesis able to support correct development of the
embryo, but they display abnormal capillary branching
(121). The complexity of the vascular branching is reduced
and associated with an aberrant distribution of the
endothelial cells within the growing vasculature (121). The
lack of the heparin-binding activity causes a different
localization of the secreted VEGFand a disruption ofits
concentration gradients in the ECM (121). The authors
conclude that the heparin-binding VEGF-A isoforms are
required to produce a gradient that guides endothelial cells
during the formation of branching capillary networks (121).
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4.2.2. Protein stabilization, oligomerization and
presentation to receptors: chemokines
Chemokines are a family of small secreted
proteins (8-12 kDa). More than 50 members have been
classified in four families (C, CC, CXC and CX;C) on the
basis of the arrangementof a conserved cysteine rich motif
located in the amino terminal region. Almost all the
chemokines studied to date appear to interact with HS
(122) (Table 1). Different models have been proposed to
describe the influence of HS binding in chemokines
activity. The proposed mechanismsinclude regulation of
protein localization and transport, increase of their stability
and induction / enhancementof oligomerization.
The formation of gradients of chemokines and
their presentation on the luminal surface of endothelialcells
are crucial events for the recruitment of circulating
leukocytes in sites of inflammation (123). As in the case of
morphogens, in vivo evidence supports the view of a
fundamental role of HSPGsin the distribution and transport
of their ligands (110, 124). Chemokines interact with
GAGsexpressed on the surface of endothelial cell in vitro
and in vivo (125). Their ability to bind HSis a prerequisite
for their chemotactic activity in vivo (124). Mutationsin the
GAG binding domain of MCP-1 (CCL2), MIP-Ibeta
(CCL4) and RANTES (CCLS) impairtheir ability to recruit
leukocytes in an in vivo model, whereas this activity is
unaltered in vitro assays (124). Similar results have been
obtained in mice lacking NDST-1 activity in endothelial
cells and leukocytes (see above) (110). The authors report
also that the presence of sulfated HS chains is required on
endothelial cells, but not on leukocytes and they describe a
mechanism of transcytosis of HS, which is required for the
correct presentation of the chemokines on the endothelial
lumen (124). HSPGsappearto be crucial in the transport of
chemokines from the site of production to the endothelial
cell surface and for the appropriate presentation to receptor
expressed by the leukocytes. Additionally, given the
selectivity of different chemokines for different GAGs
structures, modification of the HS chain could result in the
presentation of restricted groups of chemokines and, as a
consequence, in the recruitment of different leukocyte
subpopulations (126, 127).
Most of the chemokines tend to form dimers or
tetramers in solution using different modes of
oligomerization (122). It has been demonstrated that the
binding to heparin / HS induces or enhances the formation
of multimers in vitro (128, 129). Furthermore, multimeric
complexes of MIP-lalpha (CCL3), MIP-I beta (CCL4) and
RANTES (CCL5) associated with sulfated proteoglycans
are secreted by activated cytotoxic lymphocytes (130).
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Even though the oligomerization is not required for
receptor activation (124), mutants of MCP-1 (CCL2), MIP-
Ibeta (CCL4) and RANTES (CCL5) unable to form
oligomers, but with receptor and GAG binding activity
conserved,fail to recruit leukocytes in an in vivo model of
chemotaxis (124). The oligomerization driven by HSchains
would enhance the concentration of chemokinesat the cell
surface rendering the activation of the receptors more
probable (124). In addition, the formation of GAG /
chemokine complexes can influence the conformation of
the protein and expose or mask different epitopes on the
protein surface (122).
Finally, the interaction with heparin / HS
increases the stability of chemokines (131, 132). Heparin
binding drastically increases the plasma half-life of IFN-
gamma and decreases its inactivation by preventing the
proteolysis of its carboxy-terminal domain (131). Similarly
the interaction with HS protects SDF-1 (CXCL12) from the
inactivation mediated by the cell surface serine protease
DPP IV / CD26,in vitro (132).
4.2.3. Enhancement of activity by conformational
change
Antithrombin III (AT-III) is the prototypical
heparin interacting protein. The elucidation of its
mechanism ofactivation wasthe first example of heparin’s
influence on protein function to be described (133-136).
The binding to heparin induces a structural rearrangement
(described in detail in (137)) that results in the expulsion of
a loop containing a protease-reactive site. The
conformational change dramatically increases the inhibitor
activity of ATIII against the coagulation factors thrombin
and factor X of approximately 9000- and 17000-fold,
respectively (137). The mechanism has been finely
described and different crystal structures of ATIII
complexed with different saccharides and in ternary
complex with its substrates have been resolved (129, 137)
(Table 1).
Conformational changes induced by heparin / HS
binding have been observed also for FGF-2 by infrared
spectroscopy (138), mucus proteinase inhibitor by
fluorescence spectroscopy (138) and heparin-binding
growth associated molecule (HB-GAM) by circular
dichroism and NMR (139). However, in these cases the
conformational changes have not been characterized in
detail and no evident association with the protein function
have been demonstrated.
Evenin the absenceofstrong structural evidence,
the association between heparin binding and
conformational change can inspire speculative mechanisms
in other systems. The FGF family of growth factors
exemplifies one of these cases. Despite low sequence
homology and different chemical-physical properties, the
FGFs are characterized by a similar structure, described as
“beta-trefoil”, comprising a three-fold repeat of a four-
stranded antiparallel beta-sheet (140). With exception of
the study mentioned above, no structural changes induced
by the heparin binding have been demonstrated. However,
considerable published data argues persuasively for a
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conformational change in FGFs upon binding to the sugar.
It is known from early studies that heparin stabilizes the
conformation of FGF-1 and  FGF-2, preventing
physicochemical or enzymatic degradation (141). For FGF-
1 it has been demonstrated that the protein exists in a
partially folded state at physiological temperatures (142).
This state, defined as “molten globule”, is characterized by
the alteration of tertiary structure without loss of secondary
structure elements and it is considered an intermediate
between the native and the unfolded form; binding to
heparin induces the transition of the protein structure to the
folded form (142). A recent NMR study compared the
backbonerelaxation data of FGF-1 in free-state or bound to
a heparin-like hexasaccharide (143). The sugar binding
induces a reductionofinternal motions observedin the free
state, especially in the HBD (143). Furthermore, the crystal
structure of FGF-7 reveals the presence of just 10 well-
defined beta-strands, folded according to the beta-trefoil
motif, while strands 11 and 12 are poorly defined (144).
Interestingly, the corresponding region (strand 11) has been
described in a helix-like conformation in a NMRstudy of
FGF-2 (145). This region comprises the primary HBD and
the authors speculate that the interaction with the sugar
could induce proper formation of the beta-strand, which is
otherwise unstructured (146).
These data suggest that the induction of
conformational changes may be a mechanism more
common than expected. Our actual observations can be
biased by the lack of techniques able to capture such
structural rearrangements and the fact that protein
crystallization may favor a minority, folded structure, in
solution.
4.2.4. Assembly of active signaling complexes: the FGF
system
The FGF family of growth factors is encoded by
22 genes in the human genome and most of them possess
heparin-binding activity (115) (Table 1). Their signal
transduction is mediated by cell-surface tyrosine kinase
receptors (FGFRI1-4)also able to interact with heparin / HS
(147-149). The binding of the growth factor induces
receptor dimerization and transphosphorylation of the
cytoplasmic tyrosine kinase domains resulting in their
activation and phosphorylation of downstream signaling
mediators (149). Heparin / HS participate in the assembly
of ternary signaling complexes (FGF-HS-FGFR) and
modulate receptoractivation (150-153). Though the growth
factors are able to bind to the receptor in absence of HS
(148, 154, 155), the interaction with the sugar stabilizes the
signaling complex (148, 154) and results in sustained
receptor signaling that is required for classic biological
activities such as mitogenesis (151, 153).
Based on site-directed mutagenesis and
biophysical measurements, the first proposed model for the
assembly of the FGF-HS-FGFRis that the FGF-2 ligand is
bivalent with respect to its receptor (148, 156). The authors
proposed that the binding of the sugar to both FGF-2 and
FGFRincreased the affinity of ligand-receptor interaction
through a primary, high affinity binding site on FGF (148).
Furthermore, the presence of the heparin induces the
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formation of a quaternary complex (2:1:1 FGFR, FGF, HS)
stabilizing a further ligand-receptor interaction, mediated
by a secondary, low affinity binding site on FGF, thus
promoting the receptor dimerization required for signaling
activation (148). The disruption of the secondary binding
site by mutagenesis does not affect the primary interaction
with the receptor and the interaction with the sugar, but
leads to a significant reduction of the mitogenic activity of
FGF-2 (156). This is known as the growth hormone model
and is also supported by subsequent work with FGF-7
(157).
The almost contemporaneous publication of two
different crystal structures of the ternary complex FGF-HS-
FGFR fueled the debate about the mode of action of
heparin / HSin the activation of FGF signaling (for a recent
review see (158)), since they proposed two new different
models for the assembly of the signaling complex. The first
model (symmetric model) indicates a dimeric 2:2:2
complex of FGF-2, FGFR1 ectodomain and a heparin-
derived hexasaccharide (PDB ID: 1FQ9) (159). The second
model (asymmetric model) is also characterized by a
dimeric assembly, but with a 2:2:1 stoichiometry ratio
between FGF-1, FGFR2 and a_ heparin-derived
decasaccharide (PDB ID: 1E0O) (160). In the first case, the
sugar interacts with both ligand and receptor promoting the
assembly of a 1:1:1 complex. The dimerization of two of
these complexes is mediated by direct FGFR-FGFR
interactions, secondary interactions between ligand in one
ternary complex and receptor in the other and FGFR-FGFR
interactions mediated by the sugar (also called the “two-
end” model since the two sugar chains run in opposite
directions with their non-reducing ends facing each other)
(159). In the second case, an asymmetric heteropentameris
formed by the interaction of two 1:1 FGF-FGFR complexes
associated through the interaction with heparin. Heparin
interacts with both the ligands, but with just one of the two
receptor’s ectodomains. Therole ofthe sugaris critical for
the assembly of the heteropentamer due to the absence of
significant protein-protein interfaces (160). The two models
diverge drastically on the structural role of heparin and
imply different mechanisms of assembly. In the symmetric
model, the sugar is one of the components driving the
dimerization of the two halves of the complex, which can
occur also in the absence of the sugar through protein-
protein interactions. The assembly of the active complex
involves the formation of 1:1:1 complexes followed by
dimerization, enhancedby the presence ofthe sugar. On the
contrary, the asymmetric model requires the presence ofthe
sugar for assembly of the complex and proposes an
assembly mechanism based on the pre-formation of FGF-
FGFR binary complexes followed by dimerization induced
by heparin.
Evidence supporting the asymmetric model
derives from a biochemical characterization of the
complexes used for the crystallization. Combining size-
exclusion chromatography, analytical ultracentrifugation
and mass spectrometry data, Harmer and collegues show
that both the complexes can be obtained during sample
preparation, independently of the method used, but the
2:2:1 complex of the asymmetric model predominates over
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the 2:2:2 symmetric model (161). The authors conclude
that both the complexes can be relevant in the formation of
signaling complexes in vivo (161). However, other
biochemical and biophysical data are inconsistent with the
asymmetric model. (i) The dimerization solely dependent
on interactions established by the sugar fails to explain the
transient receptor activation induced by FGF-2 in chlorate-
treated fibroblasts, deficient in sulfated HS, and the fact
that in the same system a tetrasaccharide is sufficient to
stimulate cell proliferation (162). (ii) Site-directed
mutagenesis experiments reveal that disrupting the
secondary receptor binding site (adjacent to the primary
one, not to be confused with the low affinity second
binding site of the growth hormone model, see above) in
FGF results in an attenuation of the signaling due to
decreased dimerization (163). This binding site is required
for the secondary FGF-FGFR contacts described in the
symmetric model, but not in the asymmetric one (164).
A moreintriguing hypothesis is that HS not only
acts as co-receptor, but its structural features determine the
specificity of the FGF system, promoting the assembly of
different signaling complexes (73). Once again more than
one model has been proposed. Based on differences in the
interaction with the sugar displayed by both different FGFs
and different FGFRs, in terms of specific structural
requirements (165, 166) or kinetic parameters (167), it has
been proposed that the assembly of a specific ternary
complex is determined by the existence on the HS chain of
a domain containing optimal binding sites for the specific
growth factor and receptor involved (73). Other authors
contrast this model and propose that the specificity for the
optimal HS structure required depend on the unique
binding site determined by the association of receptors and
ligandsin the signaling complex (164).
Furthermore, the binding to HSPGscan influence
the distribution of the growth factors at the cell surface and
in the ECM (70, 73). The localization of FGFs in the ECM
mediated by the binding to matrix proteoglycan or as a
result of the shedding of cell surface HSPGs can act as a
storage mechanism.In this state the binding to the sugar
has an inhibitory effect in part because the growth factors
are unable to reach their receptors. The release of the
growth factor, mediated, for example, by enzymatic
degradation of HS chains associated with inflammation
(168) or following mechanical injury (169) induces its
immediate activation and the delivery of a strong mitogenic
signal (168, 169). HSPGsare involved in the formation of
FGF gradients during development (109). The targeted
disruption of the EXT1 (HS polymerase) gene in the mouse
embryonic brain leads to patterning defects and aberrant
axon guidance (109). The defects are associated to altered
distribution of morphogens, in particular FGF-8 (109).
5. HEPARIN — PROTEIN INTERACTION
5.1. Thermodynamicsofinteraction
The interaction between heparin / HS and
proteins is driven by electrostatic bonding (24). At
physiological pH, heparin / HS are polyanions with a
fraction of their negative charges neutralized by bound
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counterions. The binding of counterions reduces the
repulsive forces between the charged groups on the chain,
but it is entropically unfavorable, because it reduces the
disorder of the solvated ions (170).
Protein binding at this level represents an ion-
exchange process where positively charged residues of the
protein replace counter ions. The entropically favorable
release of counter ions is called the polyelectrolyte effect
and is one of the main components of the free energy
DELTAGofthe interaction of heparin / HS and proteins
(171).
The contribution of the non-ionic component has
been evaluated for the interaction between FGF-2 and
heparin by isotermal calorimetric titration (ITC). This study
showed that electrostatic interactions are responsible for
only about 30% of the binding free energy. Thus, the non-
ionic component, due to hydrogen bonding and
hydrophobic interactions, contribute the majority of the free
energy of this binding reaction (172). The analysis of
crystal structures of FGF-1 and FGF-2 complexed to
heparin-derived oligosaccharides confirmed this
hypothesis, showing the major contribution of van der
Waals contacts to the protein-sugar interaction (159, 160).
Similar studies applied to thrombin (173) and mucus
proteinase inhibitor (174) showed more substantial
contributions ofthe electrostatic component: for thrombin,
almost all of the binding free energy is due to the
polyelectrolyte effect (173).
A unique model for the interactions of proteins
and heparin / HS is probably an over-simplification: the
surfaces of different proteins can establish different
interactions with the sugar chain, resulting in binding
reactions with variable thermodynamic and_ kinetic
parameters. In addition, entropic contributions can derive
from structural rearrangements that can occur following the
initial electrostatic interaction (25). Conformational
changes have been observed both at protein (see above) and
sugar level for some interactions. The influence of AT-III
binding on the conformation of heparin-derived
oligosaccharides has been demonstrated by NMR (175,
176). Variation of glycosidic dihedral angles and IdoA ring
conformation has been observed comparing the three-
dimensionalstructures of the sugars in free and boundstate
(175, 176). Thus, such structural rearrangements can
influence the thermodynamic parameters of binding
reaction, promoting the fitting of sugar and protein surfaces
(176).
5.2. Protein binding sequences
Interactions between heparin / HS and proteins
generally depend on sulfate groups. For these reason, NS or
NA/NSdomainsare considered the protein binding motifs
of HS chains. The specific requirements, in term of
composition and minimal length of the chain, have been
investigated for a number of interactors. As usual, it is
difficult to delineate a single model for the assembly of
protein binding sites; parameters influencing different
levels of the sugar structure must be evaluated for each
case.
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The AT-III binding pentasaccharide wasthefirst
protein binding site characterized in the sugar (136). This is
the paradigmatic example of binding site containing a rare
modification of the sugar backbone. The sequence
GlcNAc6S-GlcA-GIcNS3S6S-IdoA2S-GIcNS6S contains
several unusual features. The most relevant is the rare
sulfation at position 3 of the central glucosamine, which is
absolutely essential for high affinity binding. The
pentasaccharide is sufficient for AT-III binding and forits
inhibitory activity towards factor Xa (177), while a
minimum 16 saccharide sequence is required for the
inhibition of thrombin (178). 3-O-sulfation has also been
suggested to be important for the interactions of FGF-7
(17). Another unusual feature of HS chains is the presence
of N-unsubstituted glucosamine. These rare free amino
groups are enriched in sequences able to bind L- and P-
selectin (179). Herpes simplex glycoprotein gD and
cyclophilin B require both these uncommon modifications;
their binding motif combines an unusual N-unsubstituted,
3-O sulfated glucosamine residue, though whether this
reflects a requirement for a free amine or the unusual
specificity of 30ST-3A for a free amine is not fully
understood (180, 181).
However, the majority of the binding sites are
assembled using more common modifications, arrayed in
specific patterns. For the FGF family of growth factors, for
example, the binding sites localize in sequences containing
the disaccharide IdoA2S-GIcNSwith variable degrees of 6-
O-sulfation. These sequences are common in the highly
sulfated heparin, but less frequent in HS chains, where they
localize at the center of NS domains. Members of the FGF
family show differences in the optimal sugar substitution
pattern recognized. For example, FGF-2 requires sulfation
at position 2 of the uronic acid, but not at position 6 ofthe
glucosamine, a substitution that is required for high affinity
binding of FGF-1 (165, 166). Also, in this last case longer
saccharides of 10-14 sugars in length, as well as the
presence of 6-O-sulfation are required to promote
mitogenic signal (83). However, in some cases the
stimulation of cell proliferation has been obtained with
shorter saccharides (162) even in absence of sulfate groups
(182).
The high affinity binding of some interactors
require longer sequences (20). Platelet factor 4 (PF-4) and
interleukin 8 (IL-8) are oligomeric chemokines that under
physiological condition exist as tetramer and dimer,
respectively. The oligomers form 1:1 complexes with long
sugar sequences of12-20 saccharides. It has been proposed
that sugar chains wrap around these complexes, interacting
with spatially separated binding sites exposed on their
surface (17). Similar structural arrangements have been
proposed for other proteins such as VEGF (183) INF-
gamma(184) and chemokines (122). The assembly of these
long binding sites requires short NS domains separated by
spacer region containing N-acetylated residues (SAS
domains) (20). Similar structures, where the spacing
between the sulfated regions seems to be more relevant
than the specific sequence, could be implicated also in
binding reactions involving more than one partner, as in the
case of signaling complexes (20). Importantly, this spacing
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maybe inappropriate until there is an external stimulus. For
example, it has been shown that cells (185) and tissues
(168) can express HS chains that bind FGF ligandsbutare
not able to support the assembly of a signaling complex
capable of stimulating cell proliferation. Scission of these
HS chains then liberates sulfated oligosaccharides that are
very potent co-receptors for FGF-mediated cell
proliferation (168, 185).
Finally, some binding reactions require the
presence of divalent cations. Annexin A2 and A5, serum
amyloid protein (SAP) and L- and P-selectins interact with
heparin / HS in a calcium-dependent manner. The structure
of annexin A2 and annexin A5 in complex with heparin
derived oligosaccharide have been analyzed by X-ray
crystallography (48, 49). In the annexin A2 / heparin
oligosaccharide complex two carboxyl groups of the sugar
participate in the coordination of one calcium ion together
with two oxygens of the protein main chain (48). In the
case of annexin A5 the contacts between the sugar and
calcium are indirect: the presence of cations seems to be
required to induce the protein conformation required for the
binding (49).
Thereis still an open discussion about the level
of structural requirements at the sugar level. Are protein
binding sites determined by the assembly of specific
sequences of saccharides or by a more generic distribution
of modification patterns along the chain? Probably these
two aspects are not mutually exclusive. The conformation
of the polysaccharide is determined by the local sequence,
but it is also influenced by its localization along the chain
(25). In addition, different modalities of interaction for
different proteins cannot be excluded, with variable degrees
of specificity and, as consequence, structural requirements
(20, 25).
A recent work questioned the existence of a
selectivity of FGFs for different HS structures (186).
Comparing the affinity of HS derived oligosaccharides for
different FGFs, the authors show that a very low level of
selectivity exists and that different growth factors bind with
similar affinity to identical HS epitopes (186). They
conclude that FGFs share the same binding sites on HS and
that the affinity is mainly determined by the charge density
of the sugar (186). However, it has to be noted that the
affinities have been evaluated on the basis of the salt
concentration required to elute the oligosaccharides from
immobilized growth factors, thus taking in account only the
electrostatic componentof the interaction that for FGFs has
been shownto be of minor relevance (see above) (172).
5.3. Heparin-binding domains: looking for models
The first attempt to delineate the determinants of
HBDs was made by Cardin and Weintraub and was
reported in 1989 (187). They analyzed twelve known
heparin-binding regions, in vitronectin, apoE, apoB-100
and PF-4. On the basis of the distribution of basic and
hydropathic residues they proposed two consensus
sequences: -XBBXBX- and -XBBBXXBX-, where B
represent a basic residue and X the probability of a
hydropathic residue. Molecular modeling of these
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sequences showedtheir tendency to assume conformations
facilitating the interaction between basic residue of the
protein and sulfated-groups of the sugar. The -XBBXBX-
consensustends to assumea beta-strand conformation with
basic residues aligned on one face of the sheet. In a similar
way, the -XBBBXXBX- forms an alpha helix with basic
residues aligned on one side and hydropathic amino acids
pointing back into the protein core (170, 187). A third
consensus -XBBBXXBBBXXBBX-, where B represent a
cationic residue, was proposed onthe basis of the HBD of
the von Willebrand factor (188).
Margalit and co-workers compared the three-
dimensional structures of defined heparin-binding
sequences (189). They suggested the relevance of the basic
residues arrangement for the heparin binding,
independently from the secondary structure assumed. They
observed that a distance of around 20 Angstrom between
basic residues is important for the interaction. In their
model basic amino acids are exposed on opposite sides of
secondary structures, suggesting a possible wrapping ofthe
sugar chain around the peptide backbone (189).
The general requirements for heparin and HS
binding have been investigated through affinity studies.
The importance ofspecific amino acids for the interaction
has been assessed using a library of random generated
peptides. As expected, the basic residues arginine and
lysine were essential for the binding to the highly sulfated
heparin. In contrast, their role was less determinant for the
interaction with HS, where neutral aminoacidslike glycine
and serine were surprisingly more important (190).
The role of arginine and lysine in heparin binding
was compared using homopeptides and peptides derived
from the FGF-1 HBD. Arginine containing peptides bound
heparin more tightly than the lysine analogous species.
Interestingly, a FGF-1 derived peptide having only
arginines as basic residues showed an increased affinity for
heparin, while the analogous peptide containing only
lysines boundless tightly than the native peptide (191).
Fromm and co-workers tested the role of spacing
in linear heparin-binding sequence using peptides where
two clusters of basic residues (arginines) were separated by
a variable numberof neutral amino acids (glycines) (192).
The relative affinities of two series identified by the
sequences -RRGmRR- and -RRRGmR- were compared.
The greatest affinity for heparin was achieved when the
spacer was absent (-RRRR-) and with the sequence -
RRGGGRR-.In contrast, HS bound moretightly to peptide
containing more spaced basic residues: -RRRGGGR-and-
RRRGGGGR-(192).
The overall HBDs topology was evaluated
analyzing the structural characteristics of those in FGF-1
and in FGF-2. Three turns are present in both binding sites
determining a triangular shape where basic residues are
concentrated in a small area. In order to evaluate the
relevanceof this topology, three different peptides derived
from the FGF-1 HBD were generated and their affinities
compared. These experiments confirmed the importance of
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the peptide topology. A peptide containing an unusual D-
proline residue in place of L-proline boundless tightly than
the native peptide, while locking the heparin-binding
peptide in a cyclic conformation produced an increase of
the affinity (193). Interestingly, super-secondary structure
characterized by reverse turns has been predicted in other
heparin-binding proteins. Comparing X-ray and NMR
structural data for FGF-1, FGF-2 and TGF-beta, Hileman
and co-worker proposed a heparin-binding motif described
as -TXXBXXTBXXXTBB-, where T defines a turn, B a
basic amino acid (arginine, lysine or glutamine) and X a
hydropathic residue (170).
Taken together, these studies delineate some
important aspects of the interactions between proteins and
heparin / HS. Basic residues are important for their ability
to interact with the sulfate and carboxy] groups present on
sugar chains. Their role is determinant for interaction with
heparin and, presumably, with the highly sulfated regions
within HS (NS domains) (192). Arginine residues show a
higher affinity in comparisonto lysines, probably due to the
ability of the guanidino group to establish stronger
hydrogen bonding to an oxygen of a sulfate group.
Combining arginines and lysines in HBDs could be a
mechanism to modulate the affinity of interaction (191).
For the interactions with the more heterogeneous HS,
neutral amino acids are also required. They can generate
sequence able to accommodate a widerrangeof structure,
increasingthe flexibility of the peptide backbone and acting
as spacers between basic residues (192). The role of non-
ionic interactions could be more relevant for HS binding.
Glutamine and asparagine residues seem to play an
importantrole for the interaction of FGF-2, presumably for
their ability to form hydrogen bonds with the hydroxy]
groupsof the sugar (172).
The topology of HBDsplays critical role to
orientate appropriately the residues involved in the binding
reactions and it determines specificity, affinity and kinetic
of the binding to the sugar. Despite a vast number of
interactors (hundreds) being described (Table 1), the
definition of models able to delineate general structure
characteristics of HBDsis still not possible (194). Once
again, the main responsibility can be ascribed to the
structural features of HS. The unique characteristics of
these molecules (polydispersity, different arrangement of
modification patterns, flexibility) allow them to
accommodate a variety of protein structures. Recent studies
aimed to study the interactions between proteins and
polyanionssuch as heparin,actin, tubulin and DNA give an
idea of the extent of this phenomenon (195, 196). Using
simple pull-down experiments performed on COS-7 cell
extracts and 2D gel electrophoresis, the authors show the
ability of heparin to interact with an impressive number of
proteins (944 out ofa total of 1,751), twice the numberof
actin and tubulin interactors and almost ten time higher
when compared to DNA (195). Furthermore, the structural
heterogeneity of HS chains and their ability to assume
multiple conformations make structural characterization of
protein-sugar complexes a challenge (129, 197). The
structure of protein-sugar complexes has been resolved at
atomic resolution only for few interactors (less than
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twenty), using short heparin derived oligosaccharide
(mainly tetra- hexasaccharides) or synthetic mimetics
(129). Molecular modeling has been proven to be a useful
tool for the investigation of protein-heparin interaction
when the structure at atomic resolution of the complex is
not available (194). However, also in this case, the
complexity of the interactions represents a major limit. In
order to render the modeling achievable,in fact, restrictions
have to be imposed especially to the conformational
mobility of the sugar (194, 198).
An interesting approach has been used to
elucidate the interaction between heparin and chemokines
(122). The authors analyzed the accessible surfaces of
twelve chemokines whose three-dimensional structures
have been resolved. First of all, they identified exposed
positively charged areas, more likely to interact with the
negatively charged sugars, and then they predicted areas
with high affinity for sulfate groups (122). The selected
surfaces have then been probed for the docking of heparin
fragments. In order to test different conformations of the
sugar, different conformers generated by variation of the
glycosidic linkage geometries have been applied to the
docking procedure (122). On the basis of lowest energy
models, the authors proposed four different modes of
chemokine-heparin interaction related to structural
characteristics and oligomerization of the protein (122).
Oneinteresting observation is that the oligomers selected
for different models possess important variations of their
conformation and they contact different clusters of basic
amino acids on the protein surface, giving two important
cues for a possible mechanism of GAG-chemokine
specificity (122). This study shows that when sufficient
structural data are available it is possible to generate
models of interaction, at least for a group of related
proteins, that fit with available data and that can be
extremely useful for the investigation of molecular
processes and for the design of new therapeutics.
6. CHALLENGES FOR THE FUTURE:
STRUCTURES, MODELS AND SYSTEM BIOLOGY
Since the mechanism ofactivation of ATIII by
heparin was established almost thirty years ago, an
impressive volumeofliterature on heparin / HS has been
produced. The efforts of biochemists, glycobiologists,
structural and cell biologists has completely changed our
perception of these molecules. Their structural complexity
has emerged dramatically and still represents one of the
majorchallengesof the field. Not only complex per se, the
structure of HS is also subjected to a dynamic tuning,
which involves regulation of its biosynthesis as well as
post-synthetic mechanisms. How the expression of HS on
the cell surface and the ECM / basement membrane is
coordinated in space and time is still not known. The
heterogeneity and flexibility of these moleculesallow them
to interact with a large number of partners (Table 1).
Indeed, heparin-binding activity appears nowadaysto be an
extremely widespread, though not completely universal
property of proteins that exert their activity at the cell-
matrix interface. This fact feeds a debate about the
specificity of these interactionsthatis still far from closure.
The heparanome
In the last ten years model organisms have provided the
evidence that HS really participates in the control of
biological processes in an in vivo context. Morphogenesis,
angiogenesis, inflammation and neural development are
just some examples of complex biological phenomena
whose control is influenced by HS. Also in this case, the
complexity of the observations gave rise to important
questions such as the context dependency of HS function
(98). These open questionsrepresent the main challenge for
the future.
A more detailed characterization of the solution
conformation of heparin / HS chains and how it is
influenced by substitution patterns, flanking sequences,
counterions and boundproteins is required. Improvementin
synthetic techniques can provide homogenous samples of
defined structure ready to be applied to NMR and other
spectroscopy techniques (47). The optimization of
purification and sequencing techniques is fundamental to
obtain defined pictures of the full repertoire of HS
sequences expressed by particular cells or tissues, the
heparanome(7), and possibly to follow dynamic changes of
its expression. The combination of established and new
techniques and an integration of the data set generated are
the keys for the understanding of protein-heparin
interactions. X-ray crystallography has provided almost all
the structural information nowadays available and will take
advantage in the future from the availability of more
homogenous sugar samples. NMR and new spectroscopy
techniques (199) will provide a more sophisticated level of
structural information, being able to capture
rearrangements of protein and sugar structure that
eventually occur during the interaction. Microarray
technologies could provide an additional tool to investigate
the determinants of the interaction at sugar (glycoarrays)
and protein level (peptide-arrays). Techniques such as
isotermaltitration calorimetry (ITC) and optical biosensors
are already available and they can provide reliable affinity
and kinetic data, taking in account all the energetic
components of the interactions. Finally, a systematic
investigation of heparin binding domains and protein
binding motifs, together with a rationalization of data
already available and their integration with new data set
generated (the definition of the heparin interactome), would
drastically speed up the process of modeling the
interactions between heparin and proteins, with an obvious
impact on the design of new therapeutics targeting these
interactions. The establishment of new techniques able to
track dynamically the behavior of molecules in living cells
is a strong requirement for every field of biology. The
opportunity to observe how heparin-protein molecular
complexes are assembled in the real, crowded context of
the cell surface environment and how they evolve in time in
terms of composition and location would allow us to
understand how HS carries out its function in the
coordination of molecular networks.
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Identification of Heparin-binding Sites in
Proteins by Selective Labeling*s
Alessandro Orit, Paul Free$¢, José Courty§, Mark C. Wilkinson${], and David G. Fernig#]|
Heparan sulfate proteoglycans are key regulators of com-
plex molecular networks due to the interaction of their
sugarchainswith a large numberof partner proteins, which
in humans numbermorethan 200 (Ori, A., Wilkinson, M.C.,
and Fernig, D. G. (2008) The heparanomeand regulation of
cell function: structures, functions and challenges. Front.
Biosci. 13, 4309-4338). We developed a method to selec-
tively label residues involved in heparin binding that
matches the requirements for medium/high throughput ap-
plications called the “Protect and Label” strategy. This is
based on the protection against chemical modification
given by heparin/heparansulfate to the residues located in
the heparin-binding site. Thus, analysis of fibroblast growth
factor-2 bound to heparin and incubated with N-hydroxy-
succinimide acetate showed that lysines involved in the
sugarbinding are protected against chemical modification.
Moreoverfollowing release from heparin, the protected ly-
sine side chains maybe specifically labeled with N-hydroxy-
succinimide biotin. After protein digestion, the biotinylated
peptides werereadily isolated and identified by MALDI-Q-
TOF massspectrometry. The analysis of labeled peptides
obtained from three well characterized heparin-binding
proteins with very different heparin-bindingsites,fibroblast
growthfactor-2, platelet factor-4, and pleiotrophin demon-
strates the success of this new approach, which thus pro-
vides a rapid and reliable procedure to identify heparin-
binding sites. Molecular & Cellular Proteomics 8:
2256-2265, 2009.
Heparan sulfate proteoglycans are a ubiquitous component
of the extracellular space of complex organisms(1). They are
characterized by their size and their plasticity that derives
mainly from the complex and dynamically regulated structure
of the glycosaminoglycan (GAG)' moiety.
From the ¢School of Biological Sciences and Centre for Glycobi-
ology, University of Liverpool, Liverpool L69 7ZB, United Kingdom
and §Laboratoire de Recherchesur la Croissance Cellulaire, la Rép-
aration et la Régénération Tissulaires (CRRET), CNRS UMR 7149,
Université Paris XII, 94010 Créteil Cedex, France
Received, January 21, 2009, and in revised form, June 22, 2009
Published, MCP Papers in Press, June 30, 2009, DO! 10.1074/
mcp.M900031-MCP200
' The abbreviations used are: GAG, glycosaminoglycan; HBS,he-
parin-binding site; HBP, heparin-binding protein; HS, heparan sulfate;
NHS, N-hydroxysuccinimide; TSR, thrombospondin type-1 repeat;
ATIll, antithrombin Ill; RP, reverse phase; FGF, fibroblast growth
factor; PTN, pleiotrophin; PF-4, platelet factor-4.
 
They participate in the structural organization of the extra-
cellular space (2, 3) and play an active role in molecular
networks driving complex biological phenomena suchas de-
velopment (4-6), inflammation and immune response(7,8),
and disease (9). Heparan sulfate proteoglycans exert their
functions by interacting with a vast numberof protein partners
and so regulating their activity (8, 10).
In the last decade, a numberof techniques have been used to
investigate the interaction between proteins and GAGs(for re-
views, see Refs. 11-15). However, despite the identification of
more than 200 human heparin-interacting proteins (10, 16), our
understanding of the structural features mediating the interac-
tion remains quite poor (10, 13). Some models have been pro-
posed, but they are based on thestructural features of only
restricted groupsor families of heparin-binding proteins (HBPs)
(11, 17, 18). Importantlimitations for modeling of heparin-bind-
ing sites (HBSs) are that manyinteractions are described solely
at a qualitative level and that a three-dimensional structure of
the sugar-protein complex is available for less than 10% of the
annotated interactions (10). The available data derive mainly
from x-ray crystallography (e.g. Refs. 19 and 20), NMR spec-
troscopy (e.g. Ref. 21), and quantitative biophysics with site-
directed mutagenesis (e.g. Ref. 22) or HBP-derived synthetic
peptides (e.g. Ref. 23). Although providing detailed structural
and kinetic information aboutthe interaction, all these methods
are limited to the study of single protein-sugarinteractions, and
they cannotbetranslated into a high throughput format.
In 1989 Chang (24) used a lysine-reactive chromophoric
reagentto investigate the HBS of antithrombinIII (ATIII). ATIII
was modified in the presence or absence of heparin, and the
colored peptides generated by tryptic digestion were ana-
lyzed by RP-HPLC to obtain important insights into the hep-
arin-ATIII_ interaction. N-Hydroxysuccinimide (NHS) esters
have a strong and selective reactivity toward primary amines,
in particular s-amines onlysines, and their relative stability in
neutral/weakly basic aqueous solution makes them com-
poundsof choice for the investigation of HBSs, which are
characterized by a high content of basic residues.
Wedeveloped a rapid and reliable method for the localiza-
tion of HBSs that can represent an important complement to
any structural investigation of heparin-protein interactions be-
causeof its low requirement in terms of sample quantity and
handling time. The new method,called the “protect and label”
strategy, is based on the protection against chemical modifi-
cation given by heparin/HS to residues located in the HBSs.
Thus, an acetyl NHS ester was used to protect residues
2256 Molecular & Cellular Proteomics 8.10 © 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
This paperis available on line at http:/Awww.mcponline.org
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exposed on theprotein surface but not involved in heparin
binding, and a second reagent, NHS-biotin, was used to
selectively label residues in the HBS. The identification by
mass spectrometry of the biotinylated peptides, derived from
enzymatic digestion of the HBP, provides a fingerprint of
sugar binding on the protein surface.
EXPERIMENTAL PROCEDURES
Heparin-binding Proteins
Recombinant fibroblast growth factor-2 (FGF-2) (Swiss-Prot ac-
cession number P09038) (residues 1-154) was expressed in C41
Escherichia coli cells using a pET-14b system (Novagen, Merck
Chemical Ltd., Nottingham, UK) as described previously (25).
Pleiotrophin (PTN), also knownas heparin-binding growth-associated
molecule or heparin affin regulatory peptide (Swiss-Prot accession
number P21246)(residues 33-168), was produced as described pre-
viously (26). Platelet factor-4 (PF-4) (Swiss-Prot accession number
P02776) (residues 32-101) was purchased from Athens Research and
Technology Inc. (Athens, GA).
SDS-PAGEand Western Blot
Samples were separated on 15% (w/v) polyacrylamide-SDSgels.
Gels weresilver-stained according to Heukeshoven and Dernick (27).
Samples separated by polyacrylamide-SDS gels were transferred to
Hybond™nitrocellulose membrane (GE Healthcare) using a semidry
system (Trans-Blot SD, Bio-Rad). Membranes were blocked with
PBS-BSA(8.1 mm Na,HPO,, 1.2 mm KH,PO,, 150 mm NaCl, 2.7 mu
KCl, pH 7.0 (PBS) supplemented with 5 mg/ml BSA (Sigma-Aldrich))
for 30 min at room temperature. The membraneswere then incubated
in PBST-BSA(PBS supplemented with 0.5% (v/v) Tween 20 (PBST)
and 5 mg/ml BSA) with Strep-Tactin'™-horseradish peroxidase (IBA
GmbH, Gottingen, Germany) (1:7500) for 30 min at room temperature.
After at least five washes of 5 min with PBST, the presence of
horseradish peroxidase wasrevealed with the SuperSignal West Pico
Chemiluminescent substrate (Pierce).
Peptide Map
Digested proteins were applied to an Agilent (Warrington, UK)
Zorbax Eclipse Plus C,, RP-HPLC column (100 x 2.1 mm, 3.5 wm)
equilibrated in 0.08% (v/v) TFA using a Beckman Coulter (High Wy-
combe, UK) System Gold™ HPLC system. Peptides were separated
with a 95-min gradient of O-64% (v/v) ACNin 0.08% (v/v) TFA. Elution
was monitored at 214 nm.
Desalting
Proteins were desalted with a 5-ml HiTrap™ desalting column (GE
Healthcare) using an AKTA™ HPLC system (GE Healthcare). Proteins
wereisocratically eluted with the selected buffer at a flow rate of 0.5
ml/min. Elution was monitored at 214 and 280 nm.
Protection and Labeling of HBS
AF-heparin beads (Tosoh Biosciences GmbH,Stuttgart, Germany;
binding capacity of 4 mg of ATIII/ml of resin) were preferred to others
based on polysaccharide matrix (e.g. Sepharose) to minimize poten-
tial unspecific interactions that could increase the noise level of the
method. The loading capacity for FGF-2 wasestimated at 15 mg/ml
of resin. Furthermore the sameresin has been successfully used in a
cross-linking method (28).
Step 1: Binding—A 20-l slurry of AF-heparin beads was packedin
a minicolumn consisting of a P10 tip with a plastic air filter placed at
its end to retain the resin. A 5-mlsterile syringe was used to pack the
minicolumn and dispense buffers. The heparin column was equili-
brated with 4 x 50 yl of PB 150 buffer (17.9 mm Na,HPO,, 2.1 mm
NaH.PO,, 150 mm NaCl, pH 7.8) and loaded with either 1.2 nmol of
FGF-2, 2.6 nmol of PF-4, or 1 nmol of PTN dissolved in 200 pl of PB
150 or buffer of compatible ionic strength. Loading was repeated
three times to ensure complete binding. The minicolumn was then
washed with 4 x 50 ul of PB 150.
Step 2: Acetylation of Exposed Lysines—The heparin column with
boundprotein wasfirst equilibrated by a quick wash with 20 pl of PB
150 containing 50 mm sulfo-NHS-acetate (Pierce) and then incubated
with 20 yl of PB 150 containing 50 mm sulfo-NHS-acetate for 5 min at
room temperature to ensure complete blocking (acetylation) of ex-
posed lysines. To stop the reaction, the column was extensively
washed with 4 x 50 wl of PB 150. Acetylated protein was eluted from
heparin with 40 yl of 2 m NaCl buffered with PB buffer (44.75 mm
NaHPO,, 5.25 mm NaH,PO,, pH 7.8).
Step 3: HBS Lysine Biotinylation—Eluted protein was diluted with
200 ul of PB buffer (to give a final NaCl concentration of 0.33 m) and
concentrated with a 5-kDa-molecular mass cutoff centrifugalfilter
(Sartorius Ltd., Epsom, UK). After adjusting the volumeto 37.2 jul with
PB, biotinylation was performed by the addition of 2.8 yl of 145 mm
NHS-biotin (Pierce) in DMSO(final concentration, 10 mm) and incu-
bation for 30 min at room temperature. The reaction was quenched
with 4 yl of 1 mM Tris, pH 7.5. The excess reagent was removed byfour
cycles of sequential dilution with 200 pl of 10 times diluted PB (4.48
mm Na,HPO,, 0.52 mm NaH,PO,, pH 7.8) and concentration with a
5-kDa-molecular mass cutoff centrifugal filter. The sample was then
dried by centrifugal evaporation.
Step 4: Protein Digestion—The dried sample wasdissolved with 25
pl of 8 M urea, 400 mm NH,HCO,, pH 7.8 and 2.5 yl of 45 mm DTT and
incubated for 15 min at 56 °C. Proteins were carbamidomethylated
with 2.5 yl of freshly made 0.1 m iodoacetamide for 15 min at room
temperature in the dark. Samples were diluted with 70 yl of HPLC
grade water and digested overnight at 37 °C with 1.5 ug of chymo-
trypsin (Sigma-Aldrich).
Step 5: Biotinylated Peptide Purification—A 40-l slurry of Strep-
Tactin Sepharose beads (IBA GmbH) were packedin a minicolumn
(see above), which wasequilibrated with 4 x 50 jl of 500 mm urea, 25
mm NH,HCO,. Digested protein was diluted to a final volume of 400
ul with HPLC grade water and applied to the column. Loading was
repeated three times to ensure complete binding. Unbound peptides
were removed by 3 x 50-yl washes with 0.5 m urea, 25 mm NH,HCO,
followed by 2 x 50-y!l washes with HPLC grade water. Biotinylated
peptides were eluted with two lots of 20 yl of 80% (v/v) ACN, 20%
(v/v) TFA, 5 mnbiotin.
Steps 6 and 7: Identification of Labeled Peptides—The eluate was
concentrated by rotary evaporation, desalted using a C,, ZipTip™
(Millipore Ltd., Watford, UK) according to manufacturer’s instructions
and analyzed by MALDI-Q-TOF mass spectrometry.
MALDI-Q-TOF Mass Spectrometry
Samples (1 yl) were spotted 1:1 (v/v) in 5 mg/ml a-cyano-4-hy-
droxycinnamic acid (Sigma-Aldrich) in 50% (v/v) ACN, 50% (v/v)
HPLC grade water. Data-dependent analysis was performed on the
top 10 mostintense peptides in the parent spectrum, the instrument
switching to the next peptide for MS/MS after a minimum of 100
counts had beenachieved. Collision gas was argon, laser energy was
fixed at 250, the instrument was SYNAPT™ MALDI HDMS(Waters
Corp., Manchester, UK) where CID can occurin either the trap or the
transfercollision cell. A ramp profile in the trap collision cell of 34-44
V for m/z 700-750 up to 151-161 V for m/z 3350-3400 was used.
Depending on the m/z of the peptide selected for MS/MSthe corre-
sponding energy ramp wasapplied. MS/MS spectra were processed
Molecular & Cellular Proteomics 8.10 2257
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Fic. 1. The protect and label strategy. A, the protect and label strategy consists of three main steps. Thefirst is the modification/blocking
of exposedlysines (steps 1 and 2). HBP is bound to heparin. The protein is then modified by incubation with sulfo-NHS-acetate. This results
in the acetylation of primary amines exposed onthe protein surface, the N terminus and e-aminesof lysines. The secondis the labeling of
lysines protected by heparin/HS(step 3). The protein is then dissociated from the sugarby increasing the ionic strength of the solution. The
following incubation with NHS-biotin leads to selective labeling of lysines involved in the interaction with heparin that have not been blocked
in the previous step. Thethird is the identification of labeled peptides (steps 4-7). The modified protein is enzymatically digested. Biotinylated
peptides are purified by affinity chromatography using a Strep-Tactin minicolumn. Following elution captured peptides are identified by
MALDI-Q-TOF mass spectrometry. B, the reactions of protection (acetylation) and labeling (biotinylation) mediated by NHSesters are
schematized.
using the MassLynx v4.0 software (Waters Corp.). Peak lists were
generated using the MaxEnt3 algorithm applying a 5% base peak
intensity cutoff. Data analysis was performed using the MS-tag toolof
the Protein Prospector package v.5.2.2 using the following parame-
ters: digest, chymotrypsin; maximum missed cleavages, 5; possible
modifications, acetyl (Lys), biotin (Lys), carbamidomethyl (Cys), and
carboxymethyl (Cys); parental ion tolerance, 100 ppm; fragmention
tolerance, 300 ppm; nonspecific cleavage, at one terminus. The Uni-
Prot accession numberof the protein analyzed was usedas a pre-
search parameter. All other settings were used at default values. In
the case of modified parental ions (e.g. sodium adduct ions), the
MS-producttool of the Protein Prospector packagev.5.2.2 was used
using default settings.
RESULTS
Method Development—First the kinetics of protein modifi-
cation by NHSreagents were investigated. The signal/noise
ratio of the protect and label procedure was found to depend
onthe level of modification (acetylation) of lysines exposed on
the protein surface (Fig. 1, step 2). Despite the widespread
use of NHS-derived reagents in chemistry and biochemistry,
the kinetics of reaction with biomolecules in aqueoussolution
have beenonly partially elucidated (29-31). A series of exper-
iments using two different model proteins were performed to
establish the optimal NHS reagent concentration and incuba-
tion time that ensured a high level of lysine modification
(supplemental Figs. S1 and S2).
To demonstrate the ability of heparin to selectively protect
lysines present in the HBS,a series of pilot experiments were
performed using FGF-2 as a modelprotein. FGF-2 was acety-
lated according to the conditions chosenin the absenceorin
the presence of heparin beads (under “Experimental Proce-
dures” see “Protection and Labeling of HBS” steps 1 and 2).
After buffer exchange, heparin binding activity was assessed
by application of the modified proteins to a heparin minicol-
umn. The same amount of native FGF-2 was applied to the
minicolumn as a control. A further sample, obtained by ex-
posing FGF-2 acetylated in the presence of heparin beadsto
NHS-biotin (under “Experimental Procedures” see “Protection
and Labeling of HBS”step 3), was also applied to the heparin
minicolumn. This last sample was included becauseit repre-
sented the final product of the protect and label strategy.
Lysine acetylation clearly impaired the binding of FGF-2 to
heparin (Fig. 2A, sample 2). However, when the acetylation
wasperformed in the presence of heparin beads,the protein
retained almost completely its binding activity (Fig. 2A, sam-
ple 3). This suggests a selective protection given by the sugar
2258 Molecular & Cellular Proteomics 8.10
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Fic. 2. Heparin/HS protect residues involvedin their binding against chemical modification.A,silver stain. S, standard; L, 0 of the
protein loaded onto the microcolumn; FT, ‘4o of the unbound fraction. 7, FGF-2; 2, acetylated FGF-2 (protein was incubated with 50 mm
sulfo-NHS-acetate for 5 min at room temperature); 3, FGF-2 acetylated in the presence of heparin beads (under “Experimental Procedures”
see “Protection and Labeling of HBS” steps 1 and 2); 4, FGF-2 acetylated in the presence of heparin beads (same as 3) and then biotinylated
after dissociation from the sugar with NHS-biotin at a final concentration of 10 mm for 30 min at room temperature. All samples were
buffer-exchanged to the same buffer (PB 150) by gelfiltration chromatography before application to the heparin minicolumn. The heparin
minicolumn waspacked using 20 pl of AF-heparin beads and equilibrated in PB 150. B, Western blot. /, FGF-2; /], FGF-2; lil, acetylated FGF-2
(protein was incubated with 50 mm sulfo-NHS-acetate for 5 min at room temperature); /V, FGF-2 acetylated in the presence of heparin beads
(under“Experimental Procedures” see “Protection and Labeling of HBS” steps 1 and 2). Samples were buffer-exchanged to PB 150 asin (A).
Samples I-IV were then biotinylated with NHS-biotin at a final concentration of 10 mm for 30 min at room temperature. Protein concentrations
were measuredafter the desalting step, and the same amountof protein was subjectedto biotinylation (samplesII-IV) and then SDS-PAGE.
C, biotinylated peptides from enzymatic digestion of samplesII and IV were purified with a Strep-Tactin minicolumn using 80% (v/v) ACN, 20%
(v/v) TFAas elution buffer and analyzed by RP-HPLC.Asterisks indicate peaks deriving from peptides selectively protected from acetylation
by heparin and, therefore, subsequently biotinylated. HRP, horseradish peroxidase; AU, microabsorbanceunits; w/o, without. chain to lysines involved in heparin binding. Furthermore theretained binding activity of sample 3 (acetylated in the pres-ence of heparin beads) could be abolished by further expo-sure to NHS-biotin (Fig. 2A, sample 4).After demonstrating that heparin can effectively prevent themodification of residues crucial for its binding, the next stepwas to show that those residues can beefficiently labeled(biotinylated) after dissociation of the protein from the sugar (Fig. 1, step 3). FGF-2 was acetylated in the absence orpresence of heparin beads and buffer-exchanged. Both thesamples werethen biotinylated as in step 3 of the protect andlabel strategy (see “Experimental Procedures”). Native andfully biotinylated FGF-2 (same conditions as above but with-out prior acetylation) were used as a negative and positivecontrol, respectively. Biotinylated proteins were identified byWesternblot. The acetylation condition chosen guaranteed aMolecular & Cellular Proteomics 8.10 2259 600Z‘OLJOQUISAONUOAINNTOOdN3AAIT
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TABLE|
HBSofprotect and label strategy test proteins
The HBSsand the methodsusedto identify these are given. SDM, site-directed mutagenesis; x-ray, x-ray crystallography; SP, synthetic
peptide; MM, molecular modeling. 
Swiss-Prot Molecular
 
Name secession TO. BSS pl HBS Method Ref.
Da O
FGF-2 P09038 17,253.8 9.58 HBS-1: S°KN°S, Arg®°, '*7KRTGQYKLGSKTGPGQK'** SDM,x-ray 19, 22
HBS-2: 1°°FFFERLESNNYNTYRSRKYSSWYVALKR'22 SP 36
PF-4 P02776 10,844.9 8.93 HBS-1: 77KNGR®, °?KKIIKK?” NMR, SDM, MM 18, 21
HBS-2: °'RPRH™, Lys®, Three NMR, SDM 21
PTN P21246 18,942 9.66 HBS-1: 97AECKYQFQAWGECDLNTALKTRTGSLKRALHNA'*? SP 38
high level of protection against further biotinylation (Fig. 2B,
sample Ill). However, the presence of heparin during the
acetylation step partially prevented the modification of resi-
dues that can, therefore, be biotinylated after dissociation
from the sugar (Fig. 2B, sample IV). To establish whether the
reduced protection was a generalized phenomenoninvolving
all lysines exposed on the protein surface, biotinylated pep-
tides derived from sample II (fully biotinylated FGF-2) and
sample IV (protected and labeled FGF-2) were compared by
RP-HPLC(Fig. 2C). As expected, a generally reduced recov-
ery of biotinylated peptides was observedin sample IV. Im-
portantly the difference betweentheelution profiles indicates
that the presence of heparin is selectively affecting the pro-
tection of a restricted numberof residues (Fig. 2C).
The last step of the implementation of the method was the
optimization of a high efficiency protocol for the purification
andidentification of labeled peptides derived from the enzy-
matic digestion of the product of the protect and labelstrat-
egy (Fig. 1, steps 4-7). The high affinity of the avidin-biotin
interactions allows the use of stringent conditions for the
purification of biotinylated biomolecules; however,it limits the
yield of recovery that is achievable. An array of capture sup-
ports and rationally designed elution buffers were compared
in a model experimental setting to maximize the efficiency of
recovery of biotinylated peptide and ensure compatibility with
the subsequent mass spectrometric analysis (supplemental
Fig. S3). Strep-Tactin Sepharose wasidentified as the best
affinity capture support (data not shown). Regarding the com-
position of the elution buffer, the peptide recovery was en-
hancedbyincreasing the concentration of both acid (TFA) and
solvent (ACN) up to the extreme condition where water was
excluded from the buffer composition (80% ACN, 20% TFA)
(supplemental Fig. S3B). Further improvement was achieved
by the addition of a large excess of competitor (5 mm biotin) to
the elution buffer (supplemental Fig. S3B).
Identification of HBSs by the Protect and Label Strategy—
The protect and label strategy was then evaluated for its
ability to correctly identify HBSsin well characterized heparin-
binding proteins. Labeled peptides wereidentified by MALDI-
Q-TOF mass spectrometry. The 10 mostintense ions for each
sample were automatically selected in the quadrupole, and
MS/MSdata were acquired to assign chemical modifications
introduced during the protect and label procedure (Fig. 1,
steps 6 and 7, and supplemental spectra). Furthermore frag-
mentation spectra allowed a further control on the affinity
purification of labeled peptides. A modification-specific
markerion at m/z 310.16, assigned as Lys(biotin)-NH3, was in
fact observedin all the fragmentation spectra analyzed. This
is consistent with the ion at m/z 126.1 previously described as
a markerfor lysine acetylation (biotin — acetyl = 184) (32) and
with the presence in most of the spectra of the ions m/z
227.08 and 84.08 corresponding to biotin and Lys-NHs,
respectively.
The test proteins were chosen to represent the variety of
the heparin interactors as highlighted by the heparin interac-
tome characterized so far (10). Two growth factors were se-
lected, FGF-2 and PTN. Thefirst is a prototypical member of
the FGF family of growth factors and one of the most studied
HBPs, whereas the secondis characterized by the presence
of a thrombospondin type-1 repeat (TSR) motif responsible
for the interaction with the sugar (33). PF-4 was added as an
example of a chemokine that interacts with heparin as an
oligomer and that possessesa bipartite HBS (18).
The structure of FGF-2 is described as f-trefoil, comprising
a 3-fold repeat of a four-stranded antiparallel B-sheet (34).
The main HBS of FGF-2 has been extensively characterized
by different approachesincluding site-directed mutagenesis,
synthetic peptides, x-ray crystallography, and NMRspectros-
copy (19, 22, 34-37). It consists of residues Lys*°, Asn®*°, and
the cluster of basic amino acids located in the region 128-144
(22) (Table |). These residues form an extremely basic surface
including strand |/strand Il loop (Lys®® and Asn*®), strand
X/strand XI loop, strand XI, and strand XI/XIl loop (Fig. 38).
The biotinylated peptides identified by the protect and label
strategy mappedto three areas on the protein surface (Table
Il) (Fig. 3A). These include the previously described HBS (Ta-
ble Il, peptides 1, 2, 6, 7, 9, and 10), a region located in strand
Vi/strand VII loop (Table Il, peptide 5), and the beginning of
strand | (Table II, peptides 3, 4, and 8). The loop identified by
peptide 5 is located on the same surface of the sequence
MISYRSRKYSSWY'*4 described by Baird et al. (36) and the
sequence ''’SRKYTSWYVA"*® described by Kinsella et al.
2260 Molecular & Cellular Proteomics 8.10
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Fic. 3. Labeled peptides and heparin-binding site: test proteins. A, FGF-2 (residues 25-153) is shown using overlaid schematic and
surface representations (Protein Data Bank code 1FQ9). Heparin-derived octasaccharide is shownassticks. B, FGF-2 (residues 25-153)is
shown using schematic representation only (Protein Data Bank code 1FQ9). Heparin-derived octasaccharide is shownassticks. C, primary
structure of PTN(residues 1-167). D, tetrameric PF-4 (residues 38-101) is shown using overlaid schematic and surfacerepresentations (Protein
Data Bank code 1F9Q). Previously described HBSlysines are shownin red (see Table |). Lysines labeled by the protect andlabel strategy are
shownin green (see TableIl). Yellow indicates an overlap between labeled amino acids and previously described HBSresidues. Other residues
are shownin gray. E, tetrameric PF-4 is shownasin C but in addition the HBS sequence 5'RPRH* of each monomeris highlighted in orange.
Structures are represented using PyMol.
(23) as a possible secondary HBS. No evidence has been
published to date regarding the involvement of strand | in
heparin binding. MS/MS spectra allowed the assignment of
modified residues and theidentification of peptides deriving
from unspecific cleavage (TableII, peptide 4) or other chem-
ical modifications (e.g. deamination (Table Il, peptide 1) and
sodium adduct(TableII, peptide 9)). Only in the case of the ion
at m/z 1371.71 (Table Il, peptide 5) was a double assignment
necessary. Fragment ions deriving from both the isobaric
peptides °*°LAMK(biotinJEDGRLL°* (MH*  monoisotopic
mass, 1371.7123) and ®’K(biotin)DPK(biotin)RLY*? (MH *mo-
noisotopic mass, 1371.6912) were in fact assigned in the
MS/MSspectrum (supplemental Spectrum SS).
PF-4 belongs to the CXC family of chemokines. The mono-
meric structure consists of a triple stranded antiparallel
B-sheet overlaid by a C-terminal a-helix, whereas the N-
terminal region is essentially disordered (18, 21). PF-4 exists
as a tetramer in solution. Dimerization occurs through the
antiparallel association of the first strands to form a larger
B-sheet(18). The tetramerresults from the further assemblyof
two dimers mediated by contacts between N-terminal regions
(18). The HBS has been characterized by site-directed mu-
tagenesis coupled to NMR spectroscopy (21) and by molec-
ular modeling (18). The HBS consists of a ring of positively
charged residues around the surface of the tetramer formed
by twopairs of lysines located within the C-terminal a-helix
(?KKIIKK®’), two arginines from the N terminus/strand | loop
'RPRH™), Lys’” and Arg®° from the strandII/strand III loop
("7KNGR®°), and the residues Lys® and Thr°® (18, 21) (Table
!) (Fig. 3D). Peptides including biotinylated Lys’’ (Table Il,
peptides 11-13, 15-17, and 20) and Lys®(TableIl, peptide
19) wereidentified in agreement with published data. Lys®!
was found biotinylated in five cases in association with la-
beled Lys”’ (TableII, peptides 11-13, 15, and 16) and in one
case as a single biotinylated peptide (TableII, peptide 18).
PTNis a heparin-dependent growth factor characterized by
the presence of two TSR-I| motifs. It consists of two disor-
dered basic clusters at its N and C termini and two B-sheets
containing the TSR-| motifs (N-TSR, residues 45-71; C-TSR,
residues 97-129) (33, 38). The two TSR motifs have been
Molecular & Cellular Proteomics 8.10 2261
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proposedas possible HBSs(33); however, Hamma-Kourbali
et al. (38) recently demonstrated the involvement of only the
C-TSRin heparin binding (Table I). Labeled peptides mapped
lysines located at the beginning (Table II, peptides 24-28) and
in the center (Table Il, peptide 30) of the C-TSR (Fig. 3C).
Biotinylated lysines deriving from the region between the two
TSR domains(TableIl, peptides 21-23 and 28) (Fig. 3C) were
also identified.
DISCUSSION
One of the main limitations on the study of heparin/HS-
protein interactions is the lack of rapid and reliable methods
for the identification of HBSs. A new strategy for the identifi-
cation of HBSs was developed. Reaction conditions able to
ensure a high level of protein modification by NHS reagents
were established. A high efficiency protocol for the recovery
of labeled (biotinylated) peptides was optimized. Automated
tandem mass spectrometry and partially manually curated
data interpretation allowed the assignment of labeled resi-
duesin 28 of the 30 peptides selected for the three samples
analyzed. Data obtained were usedto evaluate the ability of
the new method to correctly predict HBSsin well character-
ized heparin-binding proteins.
The results showthat(i) heparin can effectively prevent the
modification of residues in a protein that are crucial for its
binding to the polysaccharide (Fig. 2A, sample 3), (ii) further
exposure to NHS-biotin after dissociation of the protein from
the sugar can abolish the retained heparin binding activity
(Fig. 2A, sample 4), (iii) the residues that remain unmodified
during acetylation in the presence of heparin can be effec-
tively labeled (biotinylated) (Fig. 2B, sample IV), and (iv) the
labeling is not a generalized phenomenonbutis restricted to
a specific set of lysines (Fig. 2C). Thus, the application of the
protect and label strategy (steps 1-3) allows the specific
labeling of lysines crucial for heparin binding that, by defini-
tion, will represent the HBS.
The protect and label strategy allowed the correct localiza-
tion of the main HBSofall the test proteins, providing a strong
rationale for the validity of the method. Someimportant points
highlight the advantages andlimitations of the new method. In
the case of FGF-2, the canonical HBS was successfully
mappedbythe biotinylated peptides, including the loop be-
tweenstrand | and strand II @*CKNGGFF“°) even though the
contribution of the lysine to the bindingis relatively minor(22).
The second region identified, strand VlI/strand Vil loop
(®S>LAMKEDGRLL®), is adjacent to a proposed secondary
heparin-binding site (23, 36, 39) of approximately millimolar
affinity. The region including residues Lys''®, Tyr'°, and
Trp'?3 has been proposed also as a secondary receptor-
binding site (40). Thus the FGF-2 mutants K119E, Y120A, and
W123A displayed decreased mitogenic activity on Swiss 3T3
fibroblasts when comparedwith wild type FGF-2 (40). These
residues were shownto beresponsible for a secondary bind-
ing event between FGF-2 andits receptor that is dependent
on the presence of heparin (40). Residue Lys®* and residues
Arg''® and Lys''® are located in two adjacentloops (distance
of Lys®® Ca to Lys''? Ca, 9.3 A) (Fig. 3, A and B), forming a
basic patch on the protein surface that could better describe
the secondary binding site proposed with the use of synthetic
peptides. Moredifficult is the interpretation of the signal de-
riving from the N terminus of the protein. The N terminus of
FGF-2 is a highly disordered and mobile region (34, 41). Its
involvement in heparin binding has been excluded by deletion
mutagenesis (39) because mutants lacking 23 (N14 FGF-2)
and 49 (N41 FGF-2) N-terminal amino acids displayed unal-
tered affinity for heparin compared with a 146-amino acid
form (FGF-2-(11-157)) as judged by heparin affinity chroma-
tography (39). However, this analysis is qualitative, and both
the mutants werelessefficient in stimulating DNA synthesis in
BALB/c3T3 cells when compared with FGF-2-(11-157) (39),
supporting a functional role for these residues. Alternatively,
labeling of the N terminus mayarise dueto protection deriving
from a conformational change induced upon binding to
heparin.
All the lysines that are affected by major chemical shift
changesuponbinding of heparin to a tetrameric form of PF-4
(21) were successfully identified by the protect and label
strategy with the exception of the two pairs of lysine located
in the C-terminal helix. The sequence °?KKIIKK°’ wasfirst
proposedasthe center of the HBS of PF-4 and also usedfor
the development of a heparin-binding consensus sequence
by Cardin and Weintraub (17). However, investigation by NMR
spectroscopyand site-directed mutagenesis revealed a minor
contribution of this region to sugar binding (21). Side chain
resonancesof residues Arg®?, His®*, Thr°®, Lys®’, and Arg®°
were more perturbed upon heparin binding than those of
C-terminal lysines (21). Furthermore substitution of all four
lysines to alanines reduced the affinity of the mutant PF-4 for
heparin only by a factor 4 as assessed by a fluorescence
binding assay (21). In agreement with these data, the protect
and label strategy supports the AD interface of the PF-4
tetramer (Fig. 3E) as the core of the heparin-binding region
with C-terminal lysines involved in secondary and moretran-
sitory contacts, which are unable to ensure protection of
these residues against chemical modification.
Finally the selective labeling confirmed recent data (38)
indicating the C-TSR domain as the main HBSof PTN (Fig.
3C). However, the biotinylation of other residues including
Lys®", Lys®°, Lys®?, and Lys®%, located at the boundaries
between N-TSR and C-TSR, suggest a possible involvement
of this area, which has not been investigated previously, in
heparin binding.
In summary, the examples cited above indicate that the
protect and label strategy can represent a usefultool for the
localization of unknown HBSsin heparin-binding proteins.
The method displayed a great sensitivity for the detection of
heparin-binding surfaces together with a goodlevel of spec-
ificity despite the high lysine content of the protein tested (14
Molecular & Cellular Proteomics 8.10 2263
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for FGF-2, eight for PF-4, and 28 for PTN) with the possible
exception of the highly flexible N-terminal region of FGF-2.
The main limitation of the technique remains the identification
of regions involved in the sugar binding that do not contain
lysines (e.g. the °'RPRH** region of PF-4; Fig. 3E). The pro-
tect and label strategy can be considered as an in vitro
docking that, because of its low requirements in terms of
material (nanomolar range) and sample handling time (2
bench days), can find applications as a hypothesis generator
for further mutagenesis studies or as a complementary tech-
nique for structural studies, e.g. in silico docking.
In 2004 Vivés et al. (28) reported a new methodfor defin-
ing amino acid residues involved in heparin binding based
on cross-linking between HBP and heparin beads and N-
terminal sequencing of the captured peptides. This method,
recently updated to an “in-solution” version (42), shares
advantages with the protect and label strategy, such as the
low requirement of material and its rapidity, as well as
drawbacks, such as being based on NHS chemistry. How-
ever, the cross-linking reaction occurs upon binding of the
protein to a preactivated and hence modified sugar,
whereasthe protect and label strategy introduces chemical
modification on protein-heparin complexes assembled in
pseudophysiological conditions. Furthermore the combina-
tion of the selective labeling of peptides with MS/MS se-
quencing techniques allows the translation of the protect
and label strategy into a medium/high throughput format
where a semipurified mixture of HBPs are analyzed at the
same time, and their HBSs are mapped due to the unique
mass signatures deriving from the labeled peptides. The
application of the method could possibly be expanded to
other electrostatic interactions (protein-GAG, protein-pro-
tein, and protein-nucleic acid) provided thereis the involve-
mentof lysines in at least one of the binding partners. Finally
the developmentof new protein modification reagents able
to selectively target different amino acids, e.g. guanido-
specific compounds (43), could further expand the applica-
bility of protect and label strategies.
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